<SEC-DOCUMENT>0001213900-18-016080.txt : 20181116
<SEC-HEADER>0001213900-18-016080.hdr.sgml : 20181116
<ACCEPTANCE-DATETIME>20181116170041
ACCESSION NUMBER:		0001213900-18-016080
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20181218
FILED AS OF DATE:		20181116
DATE AS OF CHANGE:		20181116
EFFECTIVENESS DATE:		20181116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		181190474

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>def14a1118_actiniumpharma.htm
<DESCRIPTION>PRELIMINARY PROXY STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE 14A<BR>
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934<BR>
(Amendment No. &#8199;&#8199;)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&#9744;</TD>
    <TD STYLE="width: 95%">Preliminary Proxy Statement</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9744;</TD>
    <TD>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9746;</TD>
    <TD>Definitive Proxy Statement</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9744;</TD>
    <TD>Definitive Additional Materials</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9744;</TD>
    <TD>Soliciting Material under Rule 14a-12</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Registrant as Specified In Its
Charter)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&#9746;</TD>
    <TD COLSPAN="2">No fee required.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9744;</TD>
    <TD COLSPAN="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>1.</TD>
    <TD>Title of each class of securities to which transaction applies:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>2.</TD>
    <TD>Aggregate number of securities to which transaction applies:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>3.</TD>
    <TD>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount
    on which the filing fee is calculated and state how it was determined):</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>4.</TD>
    <TD>Proposed maximum aggregate value of transaction:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>5.</TD>
    <TD>Total fee paid:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9744;</TD>
    <TD COLSPAN="2">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9744;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-1 1(a)(2) and identify the filing
    for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form
    or Schedule and the date of its filing.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>1.</TD>
    <TD>Amount Previously Paid:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>2.</TD>
    <TD>Form, Schedule or Registration Statement No.:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>3.</TD>
    <TD>Filing Party:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>4.</TD>
    <TD>Date Filed:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
16, 2018&#9;&#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<IMG SRC="image_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Fellow Shareholders:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
has been a critical year for Actinium as your management team have developed a new strategy and focus for your company. This refocused
strategy has been driven in large part by a strengthened leadership team, valuable clinical data and a good deal of foresight.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Today,
Actinium&rsquo;s pipeline is refocused on two key areas: first, targeted conditioning prior to adoptive cell therapies such as
BMT or bone marrow transplant and CAR-T; and second, on therapeutic combinations with our ARCs or Antibody Radiation Conjugates.
We are optimistic that executing toward key milestones across a multi-asset, multi-disease pipeline will provide clinically positive
outcomes and yield positive returns for shareholders. We encourage you to read the list of Actinium&rsquo;s expected milestones
in 2019 in Appendix A that have been made possible by our many accomplishments in 2018 which we have highlighted in Appendix B.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize that the SIERRA trial has taken longer than originally expected and understand how this could create angst for our shareholders.
We share your frustration and we thank you for your continued support and greatly appreciate your patience. Without appearing
sanguine, we believe that the SIERRA trial is on solid footing under a stronger team after we have restructured and rebuilt various
aspects of the company, particularly the clinical organization. This has occurred while simultaneously forging ahead on multiple
fronts across our pipeline, which has resulted in a much stronger strategic focus for the company in 2018. Let us also take comfort
in the heartening interim feasibility and safety data from the Iomab-B SIERRA trial that has been accepted for oral presentation
at the American Society of Hematology (ASH) Annual Meeting in early December. Today, we feel confident that we have the right
team in place and that the changes we have made were necessary to deliver the positive data we look forward to presenting. Overall,
we are proud of our accomplishments in 2018 and are energized by our refocused vision and the opportunities that have been created.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2018 we were able to build the leading franchise in targeted conditioning. With our Phase 3 Iomab-B as the foundation, we added
two new programs: Iomab-ACT for lymphodepletion prior to CAR-T and near-pivotal Actimab-MDS for conditioning high-risk patients
with myelodysplastic syndrome prior to a BMT. These additions afford us a multi-asset, multi-disease pipeline that is unrivalled
in the industry. Each of these programs offers the potential to improve patient access and outcomes based on the superior ability
of our ARCs to safely and efficiently deliver the appropriate dose of radiation needed to condition the marrow or lymph system
compared to chemotherapy. Chemotherapy, which currently is used as the standard of care, has side effects as a result of being
non-targeted. These side effects limit both outcomes and eligibility of patients, especially older adults. What is most exciting
is that these new programs not only hold the potential to treat a significant unmet medical need in a broad population, but they
provide Actinium with the potential for multiple product launches and label expansion initiatives in the two to three years starting
in 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
ASH, we will demonstrate that Iomab-B feasibility and safety interim results look very promising during our high-visibility, oral
presentation for our Phase 3 SIERRA trial. There are multiple interim milestones for safety and efficacy for Iomab-B through next
year, including trial completion. In addition, we are preparing for Actimab-MDS to enter a pivotal trial after a short dose-confirmatory
Phase 1 trial planned in 2019. We also have several Iomab-ACT clinical events planned as outlined in our key milestones section
in Appendix B. These value creating events also will afford us important opportunities to engage in discussions with various constituencies
who can support our goals, including potential collaborators. We believe that the highly differentiated focus of our pipeline,
the lack of visible competition, and the high-value potential of our products presents a very real opportunity for Actinium to
play a leadership role in addressing this area of high unmet medical need.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
therapeutic combinations approach affords us yet another opportunity to use the potential of our ARCs in combination with other
chemotherapeutic or immuno-oncology-based drugs. Examples are the trials we are doing with Actimab-A and the CLAG-M regimen and
with the high-profile drug Venclexta or venetoclax. Combination approaches to oncology drug development have are increasingly
common, especially with larger companies in the immuno-oncology field. Radiation therapy is used effectively in solid tumors,
but it is not a viable option for blood cancers, which are too diffuse to be treated with external radiation that cannot be targeted.
Our ARCs have the ability to target the radiation to be delivered in a safe manner. The possibility of adding a highly-effective,
potentially synergistic modality such as radiation to immuno-oncology drugs via an ARC, as we have demonstrated pre-clinically
with Actimab-A and venetoclax, has the potential to lead to superior combinations and superior outcomes. We look forward to the
several data events from our combination trials and other CD33 program expansion trials, and to making our technology and CD33
program available to collaborators as part of our value-creating strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
new strategy has been enabled in part due to our Antibody Warhead Enabling, or AWE, platform in combination with a revitalized
research capability that we built this year at Actinium. As a result, we were able to enter into a collaboration with the Top-20
big-pharma company Astellas. Further, in a few short months, we were able to conduct validating experiments that supported the
Iomab-ACT program for CAR-T and combination trials with venetoclax, file the patents to protect these ideas, and make these programs
known publicly. As a result of these and other research activities, we will continue to strengthen our leading AWE technology
platform and we expect it to be a profit center for the company along with the Iomab-ACT program. Recent strategic activity in
the radiopharmaceutical space is contributing to growing recognition and acceptance of the value of targeted radiation among large
and medium-sized biopharma companies. Actinium is well positioned to address these needs &ldquo;in the age of Radiopharma 2.0&rdquo;.
(Please see Appendix C for a list of FAQs that we think put in perspective the rapid pace of Actinium&rsquo;s accomplishments
and the positive impact we anticipate these changes will support).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certainly,
it was no small feat to develop a new strategic focus, launch new clinical trials, advance existing trials toward clinical milestones
while simultaneously recruiting for and restructuring our small, 30-person team. Today, we have successfully reinvigorated Actinium&rsquo;s
research team. We also have made advances in securing our intellectual property and have entered into an important and validating
collaboration. We are proud that a 30-person company, with a just-in-time, personalized medicine supply chain, can support not
only an ongoing Phase 3 trial that is showing great promise, but also several phase 1/proof of concept trials, all boding well
for truly transformational results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to our efforts this year, Actinium is well-positioned for an exciting future built on strong science, positive clinical data,
and a committed and talented team. We want to reiterate that besides our differentiated focus on targeted conditioning with a
multi-asset, late-stage pipeline with visible and promising clinical data, our technological leadership extends to expertise in
alpha-radiation with the work we are doing in our Ac-225 isotope program. The scarcity value of independent companies, which is
the result of a number of acquisitions in the space, also contributes to a much more attractive profile for our company. These
factors are only just becoming apparent to investors and strategic players as we have only recently completed the refocusing and
have now begun an extensive and months-long process of educating people about the &ldquo;new Actinium.&rdquo; Taking this into
account, we are requesting your support for all of our proposals in the proxy card, some of which are being requested to enable
the company to be in the best position to protect shareholder interests in the event certain strategic actions occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are pleased to be able to report that progress has been made to set up the pipeline for success with multiple value-generating
drivers before year-end, into 2019 and beyond. We thank you for your continued support and belief in our drug candidates, technologies
and efforts, and hope you are as excited and optimistic as the team at Actinium is about the year ahead and the longer-term future
of your company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of Team Actinium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Respectfully,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh
Seth</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
and Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Appendix
A &ndash; Key Milestones for 2019</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;<IMG SRC="image_003.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><IMG SRC="image_002.jpg" ALT="">&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Appendix
B &ndash; Key Achievements in 2018</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significantly
strengthened our leadership team and capabilities bringing decades of experience to Actinium resulting in a new level of execution
across the Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Enhanced
                                         Transplant Expertise to Support Strategic Refocus</U>: Added significant bone marrow
                                         transplant expertise to our clinical development team to support our strategic focus
                                         in targeted conditioning. This has allowed us to expand and develop a franchise opportunity
                                         with three targeted conditioning programs including Iomab-ACT for CAR-T that progressed
                                         from conceptualization to launch in less than a year, near-pivotal Actimab-MDS for conditioning
                                         high-risk patients with myelodysplastic syndrome prior to a BMT and Phase 3 Iomab-B as
                                         the foundation.</FONT></TD></TR>                                                                         <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Strengthened
                                         Clinical Operations to Strengthen Trial Execution and Pipeline Expansion</U>: We have
                                         made key hires including a head of clinical operations as a new function within Actinium.
                                         The strengthened team is dedicated to the efficient, timely and cost-effective execution
                                         of our clinical trials and in a short time has developed and is implementing initiatives
                                         designed to complete enrollment of the SIERRA trial as quickly as possible. </FONT></TD></TR>                                                                                                                                      <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Established
                                         Research Team</U>: Reinvigorated our research efforts by establishing a research group.
                                         This enabled our work with Ac-225 labeled daratumumab and led to our first publication
                                         at AACR and new patent filings that extend our IP portfolio in line with our strategic
                                         vision. Our research team is working in alignment with our clinical development team
                                         resulting in highly supportive data for our Iomab-ACT program and the Actimab-A plus
                                         Venetoclax combination trials. The improved internal alignment also benefits our business
                                         development efforts. </FONT></TD></TR></TABLE>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executed
our first AWE platform partnership with Astellas Pharma, Inc., a Top 20 global biopharma company </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validates
                                         the utility of our technology platform and its potential value to large biopharma companies
                                         as well as our leadership position with the Ac-225 isotope.</FONT></TD></TR></TABLE>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Began
a combination trial with Actimab-A and CLAG-M</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                         trial studies our ARC approach with other modalities, in this case chemotherapy, where
                                         we expect to see synergies that can improve patient outcomes.</FONT></TD></TR></TABLE>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Launched
the Actimab-A MRD trial for a significant unmet need and potentially large market opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aligns
                                         our clinical development with key advancements in the field as minimal residual disease
                                         or MRD is becoming an increasingly important biomarker and emerging endpoint. Success
                                         of this trial implies a large market opportunity as frequent dosing of Actimab-A could
                                         be required to maintain a disease free or MRD negative AML state.</FONT></TD></TR></TABLE>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Initiated
our Iomab-ACT program for targeted lymphodepletion for CAR-T therapies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Builds
                                         on our targeted conditioning strategy by leveraging our clinical experience with Iomab-B
                                         to position us as a potentially universal solution for targeted lymphodepletion with
                                         improved access and outcomes. Actinium is at the forefront with this solution for the
                                         large and rapidly growing CAR-T industry.</FONT></TD></TR></TABLE>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Successfully
completed the Actimab-A Phase 2 trial as a single agent in a difficult-to-treat patient population with identification of an attractive
future development pathway</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
                                         single agent activity and minimal extramedullary toxicities in the Phase 2 Actimab-A
                                         AML trial paved the way for key opinion leaders to support our Actimab-MDS trial for
                                         targeted conditioning and our two Actimab-A plus Venetoclax combination trials. This
                                         pathway forward differentiates the asset and provides an attractive and high-value route
                                         for further development compared to a high-risk, controlled Phase 3 trial for AML patients.</FONT></TD></TR></TABLE>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Announced
two clinical trials that will study Actimab-A with Venetoclax, a targeted therapy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
                                         aligns Actinium with the most recent advancements in the AML field and with the support
                                         of thought leading physicians from MD Anderson Cancer Center and UCLA Medical Center.</FONT></TD></TR></TABLE>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Positive
outcomes from our interactions with the FDA regarding Actimab-MDS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resulted
                                         in an accelerated regulatory pathway that will now consist of a small dose finding Phase
                                         1 trial before moving to a pivotal trial for our second targeted conditioning indication.
                                         Also resulted in a broader patient population than what was proposed to FDA.</FONT></TD></TR></TABLE>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Multiple
abstracts accepted at for ASH including the acceptance of preliminary feasibility and safety results of the Iomab-B Phase 3 SIERRA
trial for oral presentation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gives
                                         Iomab-B and the ongoing SIERRA trial significant exposure at ASH, the largest blood cancer-focused
                                         medical conference in the world, where only approximately 10% of accepted abstracts are
                                         elevated to oral presentations. </FONT></TD></TR></TABLE>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Appendix
C &ndash; FAQ&rsquo;s or Frequently Asked Questions</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
has Actinium transformed itself from a year ago? What is the new focus?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>November
2017 Pipeline</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this time last year, we had 3 trials in our pipeline, 1 targeted conditioning trial and 2 single-agent therapeutic trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 66%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_004.jpg" ALT=""></TD>
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&diams;&nbsp;
        Iomab-B was our only targeted conditioning program with the Phase 3 trial in the early stages of enrollment</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&diams;&nbsp;
        Our CD33 program had just been expanded to Multiple Myeloma</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&diams;&nbsp;
        Early efforts with our AWE platform had been initiated</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>November
2018 Pipeline</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
forward to today and we are advancing 3 targeted conditioning trials (1 pivotal and 1 near-pivotal) 3 therapeutic combination
trials and 2 single-agent therapeutic trials in highly differentiated indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 66%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_005.jpg" ALT=""></TD>
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&diams;&nbsp;
        Targeted conditioning program expanded to 3 trials including Iomab-ACT for CAR-T and near pivotal Actimab-MDS</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&diams;&nbsp;
        SIERRA trial reached 25% enrollment with interim data to be presented in oral presentation at ASH</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&diams;&nbsp;
        CD33 program expanded to best in class with the largest addressable patient population and breadth of applications</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&diams;&nbsp;
        AWE platform validation via our collaboration with Astellas and expanded research efforts</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have expanded our pipeline efficiently and cost-effectively by leveraging the strengths of our ARC candidates without undertaking
significant de novo development by utilizing our AWE platform and enhanced R&amp;D capabilities to support these new initiatives.
Because our CD45 and CD33 targets are applicable to multiple diseases and indications, each of our ARCs become a pipeline within
a drug. We believe there is much more still to come. Given our ARC approach, we can utilize a high-dose to facilitate targeted
conditioning and low-dose strategy to leverage the proven modality of radiation for novel therapeutic combinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Targeted
Conditioning Related FAQs</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Why
Is Targeted Conditioning so attractive? </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
focus on targeted conditioning because it enables treatments that are potentially curative in nature, such as BMT and CAR-T, for
a significant number of patients with a range of diseases. In advance of BMT or CAR-T, patients must have their bone marrow and
immune system conditioned to make room for the new cells. This is done today with non-targeted chemotherapy and external beam
radiation. Our targeted conditioning approach delivers potent radiation to specific cells to enable more effective conditioning
while at the same time minimizing effects to normal cells with the hopes of having the strongest and healthiest patient prior
to their BMT or CAR-T. Our focus on targeted conditioning sets us apart as we believe we are the only company with a multi-disease,
multi-target, late-stage pipeline for targeted conditioning. Further, we are not aware of any other company with a focus on targeted
conditioning that is as advanced as we are in clinical trials. Our antigen targets CD45 and CD33 are widely expressed in many
hematologic indications. We believe there is an opportunity to expand the addressable patient population for our programs. For
example, CD45 is expressed on leukemia cells, lymphoma cells and multiple myeloma cells and significant data has been generated
in these indications at the Fred Hutchinson Cancer Research Center which we can use for label expansion of Iomab-B. With CD33
we are targeting high-risk MDS patients with the Actimab-MDS program. Because the addressable market for our targeted conditioning
drug candidates is limited to 50-100 medical centers that perform a majority of BMT and CAR-T procedures, we believe we have a
tremendous opportunity to create a leading, independent organization in this space that has little competition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
was accomplished via the Iomab-B and the SIERRA Trial? What can we expect in future?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have strong talent supporting the SIERRA trial. Our team includes a transplant physician who has more than 20 years of clinical
experience and a Head of Clinical Operations, a new position, who brings to Actinium more than 25 years of experience. Both of
these clinical experts are focused on the trial&rsquo;s execution and completion. In addition, a third M.D. and a nurse educator
who has significant oncology drug experience are focused on providing training and support to trial sites. Finally, we have two
clinical research associates dedicated to the operations of the SIERRA trial. Effectively, the clinical team was restructured
in April of this year and the average tenure for the team members is seven months. In this short time, this new team has positively
impacted execution of the SIERRA trial and we have great confidence in their capabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to achieve the following milestones going forward as indicated in Appendix B and below. We look forward to updating you
as each of these milestones is reached and believe the analyzed data at each point will provide many valuable insights into this
important trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrollment
                                         of the 70<SUP>th</SUP> patient &ndash; an efficacy and safety analysis may occur when
                                         the 70<SUP>th</SUP> patient reaches the primary endpoint</FONT></TD></TR>                                                                                                                  <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50%
                                         Enrollment &ndash; a DMC safety analysis will occur just like the analysis that occurred
                                         after 25% of patients were enrolled</FONT></TD></TR>                                                                                             <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrollment
                                         of the 110<SUP>th</SUP> patient &ndash; a second efficacy and safety analysis may occur
                                         when the 110<SUP>th</SUP> patient reaches the primary endpoint</FONT></TD></TR>                                                                                                                        <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75%
                                         Enrollment &ndash; the third and final safety analysis </FONT></TD></TR>                                                                                                                 <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
                                         of Enrollment &ndash; a major milestone in any trial but perhaps more so with SIERRA
                                         as it is the only trial focused on targeted conditioning for older patients with active,
                                         relapsed or refractory AML. </FONT></TD></TR></TABLE>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
is the value of the Iomab-ACT program? </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our Iomab-ACT program has the potential to offer a chemotherapy-free conditioning regimen prior to CAR-T that can effectively
achieve lymphodepletion in a single-dose and in an outpatient setting. Current approaches for lymphodepletion rely on chemotherapy,
typically the combination of fludarabine and cyclophosphamide or Fly/Cy, which is non-specific, toxic and sub-optimal. We believe
that lymphodepletion with the Iomab-ACT construct will result in superior outcomes from CAR-T including improved patient responses
and long-term outcomes, increased access to CAR-T and reduced toxicities associated with CAR-T. We believe the Iomab-ACT program
can be a universal solution for all CAR-T therapies and a potentially valuable expansion of our targeted conditioning franchise.
In addition, the Iomab-ACT program represents the new level of innovation and execution that exists within Actinium as this concept
went from ideation to existence in rapid fashion by leveraging the deep clinical experience and data of our CD45 program and the
expanded research capabilities of the company. As we have done with all of our latest initiatives, we have generated an intellectual
property portfolio which in this case currently encompasses six patents pertaining to the Iomab-ACT program. We are committed
to improving patient outcomes and generating value from our Iomab-ACT program in a rapid fashion with this being a top priority
for Actinium in 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
is Actimab-MDS expected to add? </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe it is rare for a 30-person biotech company to have the opportunity to have not just one but two pivotal trials in a field
by itself. This is the opportunity created by Actinium in 2018 by adding Actimab-MDS to our clinical pipeline. Just as we did
with the Iomab-ACT program where we leveraged our experience with CD45 and Iomab-B, with Actimab-MDS, we leveraged the extensive
experience with CD33, the isotope Ac-225 and Actimab-A to develop this exciting opportunity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
vision that brought the Actimab-MDS into a clinical trial was the result of our team and our collaborators&rsquo; ability to take
the seeming limitation of Actimab-A - namely prolonged myelosuppression - and consider the possibility that it could be a useful
attribute in a setting in which myelosuppression is not a limitation but a desired outcome. This was in the context of using highly
myelosuppressive doses of the construct to myeloablate or &ldquo;burn out&rdquo; the bone marrow prior to a bone marrow transplant.
A great deal of credit is due to Dr. Gail Roboz, Director of Leukemia at Weill-Cornell Medical Center, who conceptualized the
idea after serving as an investigator in our Actimab-A Phase 2 trial. This trial enrolled patients whose MDS had progressed to
AML. As we have reported, Actimab-A had potent myelosuppression capabilities with minimal toxicities outside of the bone marrow.
Recognizing that a bone marrow transplant is the only potentially curative treatment option for patients with high-risk MDS and
that myelosuppression can be alleviated with a bone marrow transplant, the decision to advance this trial was made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Having
been guided toward a significantly faster regulatory pathway by the FDA than we had originally expected, we plan to conduct a
pivotal trial after completing a small Phase 1 trial to confirm the myeloablative dose. Originally, we had proposed a 60-80 patient
Phase 2 trial that would then be followed by a pivotal trial. Also, we had originally proposed a patient population limited to
only those patients with a specific mutation to the TP53 gene, but the FDA guided that we should expand the addressable patient
population to intermediate and high-risk MDS patients. In 2019, we look forward to working with Dr. Roboz and her colleagues from
the MDS Clinical Research Consortium to complete the Phase 1 trial, with the goal of moving toward Actinium&rsquo;s second pivotal
trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actimab-A
AML Phase 2 Trial and CD33 Program Questions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
did the Actimab-A Phase 2 trial in AML yield? What happens next? </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are excited that the Actimab-A Phase 2 AML trial demonstrated the potent single-agent activity of the Ac-225 &ndash; lintuzumab
targeting agent. However, in the older unfit patient population enrolled in the Phase 2 trial, myelosuppression proved challenging.
Rather than move ahead into a large, lengthy and expensive Phase 3 trial in the increasingly crowded field of AML therapies, we
made the decision to follow the signals the drug candidate was giving us and move into what we believe to be more attractive opportunities
with this agent at different doses in targeted conditioning and in combination with other drugs. This decision led to our Actimab-MDS
trial giving us our second targeted conditioning asset. Actimab-MDS will utilize a high dose of the Ac-225 &ndash; lintuzumab
construct to achieve effective myeloablation for high-risk MDS patients prior to a bone marrow transplant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
a lower dose of the construct, we see the opportunity to use Actimab-A in combination with chemotherapies, targeted therapies
and immunotherapies. We have already begun executing on this strategy with our three exciting combination trials. As a result,
we have aligned Actinium with targeted therapies that will allow us to generate additional data that could prove valuable to potential
partners. We have seen increased activity in targeted radiation both in terms of company acquisitions and research publication
volume that we believe is creating a ground swell of interest for this approach amongst the industry. We believe we are solidly
positioned at this opportune time given the breadth of our pipeline, versatility of our platform and strong IP portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
is the attractiveness of combinations? Why does the industry care?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapies
based on the combination of two or more agents have long been used in the treatment of patients with cancer with the goal that
a synergistic effect would emerge and the use of combination therapies continues to grow rapidly. Our ARC drug candidates utilize
the power of radiation, which is a proven therapeutic modality that is used to treat more than half of all cancer patients. However,
we harness the powers of radiation inside the body in a targeted manner, thereby eliminating the side effects that come with delivering
radiation to cancer cells from outside the body. It has been demonstrated that radiation causes cancer cell DNA and a tumor&rsquo;s
microenvironment to work in synergy with other agents. We believe better outcomes are possible through Ac-225 &ndash; Lintuzumab
in certain cancers cells that express the CD33 antigen because it delivers radiation in a way no other drug candidate can to these
cancer cells that are radiation sensitive. This is the basis for our combination trials with Venetoclax and CLAG-M, both of which
are grounded in strong scientific rationales as well as preclinical and clinical data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
feel that demonstrating the synergy of our ARCs with other therapeutic modalities will increase their attractiveness to potential
partners. For instance, if we could demonstrate that Ac-225 can make cancer cells and or tumors &ldquo;hot,&rdquo; that is to
say more noticeable to the immune system, we believe that would be of interest to the large universe of big pharma companies that
have strong immuno-oncology franchises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
do you support your claim that you have a CD33 Program that is best in class? What can we expect from this program?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CD33 field is largely dominated by big pharma and biotech companies that are partnered with larger biopharma firms. These companies
are focused on AML and employ antibody drug conjugate, bispecific antibody and naked antibody approaches. Actinium is the only
company utilizing an antibody radiation conjugate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CD33
AML Programs</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_006.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
our ARC approach we have expanded our CD33 program from a single trial in AML to now six trials that are ongoing or planned for
2019. Our ARC technology allows us to move into indications that other CD33 program sponsors have not been able to address because
of the inherent limitations of their technological approaches. We believe our CD33 program is best in class because it not only
addresses three diseases; AML, MDS and Multiple Myeloma, which is the broadest in scope compared to competing CD33 focused programs
and provides for the largest addressable patient population or market opportunity. Further, it is the only CD33 program for patients
with Multiple Myeloma and the only CD33 program for targeted conditioning.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Actinium&rsquo;s
Multi-Disease, Multi-Indication CD33 Program</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_007.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
our extensive experience and clinical data from our CD33 program, we believe this can be leveraged to move into new indications
and start new trials in a cost-effective manner without having to fund de novo development. We will continue to identify applications
and indications for our CD33 program that build on its best-in-class profile. Given that our CD33 program is the most advanced
and has the broadest scope, companies seeking to enter this area may find our program very attractive. Further, our focus on therapeutic
combinations allows us to engage with potential partners who are interested in the radiation modality for combinations with their
therapeutic modalities, which we believe can leveraged strategically to drive value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
does the AWE Platform add value?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
AWE platform is an engine that can drive growth in our pipeline as well as collaborations and partnerships. We view the AWE platform
as an immensely valuable asset that is now being leveraged properly under the stewardship of our dedicated, talented and experienced
research team. Our AWE platform underpins our clinical programs and is supported by extensive preclinical data, clinical data
and 75 patents. We will continue to build our intellectual property portfolio to further bolster AWE&rsquo;s profile as we seek
to monetize it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe AWE can drive partnerships in numerous ways including our biobetter strategy. This strategy takes an established biologic
drug and using a radioisotope like Ac-255, we demonstrate enhanced potency, efficacy or improved administration. We demonstrated
this with our work labeling daratumumab, the blockbuster CD38 antibody therapy for multiple myeloma that is marketed as Darzalex
by Johnson &amp; Johnson. In this case, we were able to increase cell killing and demonstrate efficacy on cell lines that displayed
resistance to unlabeled daratumumab.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Another
approach is to find antibodies or other targeting agents that are no longer being pursued by their pharma or biotech sponsor and
reinvigorate them given that ARC&rsquo;s cell killing capabilities, which are not dependent on genetic factors, high antigen density,
and do not require internalization of the target. These attributes are major differentiators from other modalities like antibody
drug conjugates or ADCs. Finally, we can work with collaborators to research our radioisotope-based warhead payloads in conjunction
with novel targeting agents. We have already established a track record in this regard through our research collaboration with
Astellas that resulted in non-dilutive capital from Astellas and ongoing funding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Why
do you say the Astellas transaction was &ldquo;particularly validating&rdquo;? </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decision by Astellas to collaborate with Actinium is the first instance of corporate validation of our alpha platform technology.
We are very pleased and honored to work with a leading innovator and science-driven company like Astellas. Astellas had previously
prioritized ADC or Antibody Drug Conjugate technology with its purchase of Agensys Inc. for over $400MM. Subsequently, Astellas
appears to have disinvested in this approach and has announced a wind-down of this effort. We believe that the decision to pursue
an ARC development approach by a knowledgeable company like Astellas who certainly has considerable experience with alternative
ADC technology is a tacit acknowledgement of the inherent advantages of ARC technology as a targeting agent. Further, the selection
of Actinium by such an experienced player is a testimony to our AWE platform for sure but also our research capabilities and due
to our not being a part of a larger company. Other factors that were considerations in selection of Actinium that will be relevant
for future AWE partnerships are the clinical validation of the safety and efficacy of our linker technology and our years of experience
in handling the isotope Ac-225 and the patent portfolio surrounding it. Further, we believe that our stage-appropriate supply
chain, which has the demonstrated capability of manufacturing and supplying radiolabeled drug to top cancer centers across the
U.S. is a major point of differentiation for Actinium and will be a consideration for most partners unless they wish to invest
years and millions of dollars to acquire such a capability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
is the R back in R&amp;D at Actinium? What can we expect going forward?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the last 12 months, Actinium&rsquo;s efforts focused largely on clinical development of existing trials. In 2018, with our
renewed focus on research we have generated new IP, demonstrated the utility of our AWE platform, signed our first collaboration
with a top 20 pharma company, supported the launch of Iomab-ACT and supported our Actimab-A and Venetoclax combination trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our platform has immense potential for liquid and solid tumors with the flexibility to attenuate our dose for desired
outcomes like our high-dose myeloablation/low-dose lymphodepletion strategy with Iomab. We will continue to explore new indications
for our existing focus on CD45 and CD33 and CD38 targets, file new IP and work towards additional collaborations and partnerships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have heard the phrase &ldquo;it is the age of Radiopharma 2.0 now&rdquo; being used recently? Please explain and what does it
mean for Actinium?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the last 12 months alone, we have seen two multi-billion-dollar acquisitions of companies with radiopharmaceutical-based therapies.
The first being Advanced Accelerator Applications, Inc., acquired by Novartis for $3.9 billion and the most recent being Endocyte,
also acquired by Novartis, for $2.1 billion. These follow Algeta that was acquired by Bayer in 2013 for $2.9 billion. There are
also a growing number of publications demonstrating the utility of radiotherapy in combination with other modalities which is
creating further interest in this technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these acquisitions, there are just a few unpartnered radiopharmaceutical therapies remaining, creating a scarcity
of assets in the field. From our assessment of the landscape, we believe we have the broadest, most late-stage pipeline which
addresses a large patient population with unmet or underserved needs. Iomab-B, Actimab-MDS and the Iomab-ACT program provide Actinium
the only multi-disease, multi-target pipeline for targeted conditioning that is intended to improve access and outcomes to potentially
curative cellular therapies such as bone marrow transplant and CAR-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our targeted conditioning pipeline allows Actinium a viable pathway to commercialize these drug candidates as an
independent company and without a partner. However, we also recognize that at the right time our pipeline may be recognized as
a strategic business unit opportunity for a strategic partner. Further, our best in class CD33 therapeutics program which will
also have multiple data readouts in the 2019-2020 timeframe may further increase attractiveness as a partner for larger companies
seeking a revenue base with differentiated assets which we have in plenty along with our AWE platform which can generate further
opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="color: Red; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 93%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center; border-bottom: Black 1.5pt solid"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">General</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Questions and Answers</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Who Can Help Answer Your Questions?</TD>
    <TD STYLE="text-align: center">5</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Corporate Governance</TD>
    <TD STYLE="text-align: center">5</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Board Committees</TD>
    <TD STYLE="text-align: center">7</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Director Compensation</TD>
    <TD STYLE="text-align: center">9</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Audit Committee Report</TD>
    <TD STYLE="text-align: center">9</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Compensation Committee Report</TD>
    <TD STYLE="text-align: center">11</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Directors and Executive Officers</TD>
    <TD STYLE="text-align: center">15</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Executive Compensation</TD>
    <TD STYLE="text-align: center">20</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Principal Stockholders</TD>
    <TD STYLE="text-align: center">27</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Certain Relationships and Related Transactions</TD>
    <TD STYLE="text-align: center">29</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Proposal 1 &mdash; Election of Directors</TD>
    <TD STYLE="text-align: center">29</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Proposal 2 &mdash; Ratification of the Appointment of Marcum LLP</TD>
    <TD STYLE="text-align: center">31</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Proposal 3: To approve an amendment to the Actinium Pharmaceuticals, Inc.
    2013 Amended and Restated Stock Plan, as amended, to increase the shares of our common stock available for issuance thereunder
    by 5 million shares to support planned hiring efforts as the company grows</TD>
    <TD STYLE="text-align: center">32</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Proposal 4: To approve an amendment to our Certificate of Incorporation
    to increase the number of shares of common stock, par value $0.001 per share, the corporation is authorized to issue by 200,000,000 shares</TD>
    <TD STYLE="text-align: center">36</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Other Matters</TD>
    <TD STYLE="text-align: center">38</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Annual Report on Form 10-K</TD>
    <TD STYLE="text-align: center">38</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Householding of Proxy Materials</TD>
    <TD STYLE="text-align: center">38</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Electronic Delivery of Company Stockholder Communications</TD>
    <TD STYLE="text-align: center">38</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Important Notice Regarding the Availability of Proxy Materials for the
    Stockholders Meeting to be held on December 18, 2018</TD>
    <TD STYLE="text-align: center">39</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Proposals of Stockholders</TD>
    <TD STYLE="text-align: center">39</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Where You Can Find More Information</TD>
    <TD STYLE="text-align: center">39</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Stockholders Should Read the Entire
Proxy Statement Carefully Prior to Returning Their Proxies</I></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROXY STATEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FOR</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ANNUAL MEETING OF STOCKHOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">GENERAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The enclosed proxy is solicited on behalf of the Board of Directors
of Actinium Pharmaceuticals, Inc. for use at our annual meeting of stockholders to be held at The Garden City Hotel, 45 Seventh
St, Garden City, NY 11530 on December 18, 2018 at 9:30 a.m. Eastern Standard Time. Voting materials, including this proxy statement
and proxy card, are expected to be first delivered to all or our stockholders on or about November 8, 2018.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">QUESTIONS AND ANSWERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following are some commonly asked questions raised by our stockholders
and answers to each of those questions.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">What may I vote on at the annual meeting?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the annual meeting, stockholders will consider and vote
upon the following matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">Proposal 1: To elect Sandesh Seth
and Jeffrey W. Chell, M.D. as Class II directors to serve for a three-year term that expires at the 2021 Annual Meeting of Stockholders,
or until his successor is elected and qualified or until his earlier resignation or removal; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">Proposal 2: To ratify the appointment
of Marcum LLP as our independent registered public accounting firm; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt">Proposal 3: To approve an amendment
to our Actinium Pharmaceuticals, Inc. 2013 Amended and Restated Stock Plan, as amended, to increase the shares of our common stock
available for issuance thereunder by 5 million shares, to support planned hiring efforts as our company grows; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt">Proposal 4: To approve an amendment
to our Certificate of Incorporation to increase the number of common stock, par value $0.001 per share, we are authorized to issue
by 200,000,000 shares; and</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">To consider and act upon any other
business as may properly come before the annual meeting or any adjournments thereof.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">How does the Board of Directors recommend that
I vote on the proposals?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board unanimously recommends that the stockholders vote
&ldquo;FOR&rdquo; all proposals being put before our stockholders at the Meeting.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">How do I vote?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Whether you plan to attend the annual meeting or not, we
urge you to vote by proxy. If you vote by proxy, the individuals named on the proxy card applicable to your class of stock, or
your &ldquo;proxies,&rdquo; will vote your shares in the manner you indicate. You may specify whether your shares: should be voted
for or withheld for the nominee for director; should be voted for, against or abstained with respect to the ratification of the
appointment of the Company&rsquo;s independent registered public accounts; should be voted for, against or abstained with respect
to approving an amendment to our Actinium Pharmaceuticals, Inc. 2013 Amended and Restated Stock Plan, as amended; and should be
voted for, against or abstained with respect to approving an amendment to our Certificate of Incorporation to increase the number
of common shares we are authorized to issue to 600,000,000 shares. Voting by proxy will not affect your right to attend the annual
meeting. If your shares are registered directly in your name through our transfer agent, Action Stock Transfer Corporation, or
you have stock certificates registered in your name, you may submit a proxy to vote:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><B>By Internet or by telephone.
Follow the instructions attached to the proxy card to submit a proxy to vote by Internet or telephone.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><B>By mail. If you received one
or more proxy cards by mail, you can vote by mail by completing, signing, dating and returning the enclosed proxy card applicable
to your class of stock in the enclosed postage prepaid envelope. Your proxy will be voted in accordance with your instructions.
If you sign the proxy card but do not specify how you want your shares voted, they will be voted as recommended by our Board of
Directors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>In
person at the meeting. If you attend the annual meeting, you may deliver your completed proxy card in person or you may vote by
completing a ballot, which will be available at the annual meeting. You are required to register in advance of the annual meeting
if you plan to attend the annual meeting in person. If you wish to register in advance of the annual meeting, please contact our
investor relations office by no later than December 11, 2018, by e-mail to soloughlin@actiniumpharma.com, mail to Actinium Pharmaceuticals,
Inc., 275 Madison Avenue, 7</B></FONT><SUP>th</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Floor, New&nbsp;York,
New York 10016, or telephone at (646) 677-3875.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Telephone and Internet voting facilities for all stockholders
of record will be available 24-hours a day and will close at 11:59 p.m., Eastern Standard Time, on December 17, 2018.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If your shares are held in &ldquo;street name&rdquo; (held
in the name of a bank, broker or other nominee who is the holder of record), you must provide the bank, broker or other nominee
with instructions on how to vote your shares and can do so as follows:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><B>By Internet or by telephone.
Follow the instructions you receive from the record holder to vote by Internet or telephone.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><B>By mail. You should receive
instructions from the record holder explaining how to vote your shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><B>In person at the meeting. Contact
the broker, bank or other nominee who holds your shares to obtain a broker&rsquo;s proxy card and bring it with you to the annual
meeting. You will not be able to vote at the annual meeting unless you have a proxy card from your broker, bank or other nominee.</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">What happens if additional matters are presented
at the annual meeting?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other than the election of directors, the ratification of the
appointment of our auditor, the amendment of our stock plan to increase the number of shares that may be granted under the plan,
and approving an amendment to our certificate of incorporation to increase our authorized shares, we are not aware of any other
business to be acted upon at the annual meeting. If you grant a proxy, the person named as proxy holder, Sandesh Seth, our Chairman
and Chief Executive Officer, or CEO, will have the discretion to vote your shares on any additional matters properly presented
for a vote at the annual meeting.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">What happens if I do not give specific voting instructions?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you hold shares in your name and you sign and return a proxy
card without giving specific voting instructions, your shares will be voted as recommended by our Board of Directors, or Board,
on all matters and as the proxy holder may determine in his discretion with respect to any other matters properly presented for
a vote before the annual meeting. If you hold your shares through a stockbroker, bank or other nominee and you do not provide
instructions on how to vote, your stockbroker or other nominee may exercise their discretionary voting power with respect to certain
proposals that are considered as &ldquo;routine&rdquo; matters. For example, Proposal 2 &mdash; ratification of the appointment
of Marcum LLP as our independent registered public accounting firm, and Proposal 4 &mdash; the amendment to our certificate of
incorporation to increase our authorized shares, are considered routine matters, and thus your stockbroker, bank or other nominee
may exercise their discretionary voting power with respect to Proposals 2 and 4. <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>If
the organization that holds your shares does not receive instructions from you on how to vote your shares on a non-routine matter,
the organization that holds your shares will inform us that it does not have the authority to vote on these matters with respect
to your shares.</B></FONT> This is generally referred to as a &ldquo;broker non-vote.&rdquo; When the vote is tabulated for any
particular matter, broker non-votes will be counted for purposes of determining whether a quorum is present, but will not otherwise
be counted. In the absence of specific instructions from you, your broker does not have discretionary authority to vote your shares
with respect to Proposal 1 &mdash; the election of Sandesh Seth and Jeffrey W. Chell, M.D. as members to our Board, and Proposal
3 &mdash; the increase in shares of our stock plan. <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>We encourage you
to provide voting instructions to the organization that holds your shares by carefully following the instructions provided in
the notice.</B></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">What is the quorum requirement for the annual meeting?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 24, 2018, the Record Date for determining which
stockholders are entitled to vote, there were 114,698,044 shares of our common stock outstanding, which is our only class of
voting securities. Each share of common stock entitles the holder to one vote on matters submitted to a vote of our
stockholders. Thirty Four percent (34%) of our outstanding common shares as of the Record Date must be present at the annual
meeting (in person or represented by proxy) in order to hold the meeting and conduct business. This is called a quorum. Your
shares will be counted for purposes of determining if there is a quorum, even if you wish to abstain from voting on some or
all matters introduced at the annual meeting, if you are present and vote in person at the meeting or have properly submitted
a proxy card or voted by fax, by phone or by using the Internet.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">How can I change my vote after I return my proxy
card?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may revoke your proxy and change your vote at any time
before the final vote at the annual meeting. You may do this by signing a new proxy card with a later date, by voting on a later
date by using the Internet (only your latest Internet proxy submitted prior to the annual meeting will be counted), or by attending
the annual meeting and voting in person. However, your attendance at the annual meeting will not automatically revoke your proxy
unless you vote at the annual meeting or specifically request in writing that your prior proxy be revoked.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Is my vote confidential?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proxy instructions, ballots and voting tabulations that identify
individual stockholders are handled in a manner that protects your voting privacy. Your vote will not be disclosed either within
our company or to third parties, except:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">as necessary to meet applicable
legal requirements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">to allow for the tabulation of
votes and certification of the vote; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">to facilitate a successful proxy
solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any written comments that a stockholder might include on the
proxy card will be forwarded to our management.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where can I find the voting results of the annual
meeting?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preliminary voting results will be announced at the annual
meeting. The final voting results will be tallied by our Inspector of Elections and reported in a Current Report on Form 8-K which
we will file with the Securities and Exchange Commission, or SEC, within four business days of the date of the annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>How can I obtain a separate set of voting materials?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To reduce the expense of delivering duplicate voting materials
to our stockholders who may have more than one Actinium Pharmaceuticals, Inc. stock account, we are delivering only one Notice
to certain stockholders who share an address, unless otherwise requested. If you share an address with another stockholder and
have received only one Notice, you may write or call us to request to receive a separate Notice. Similarly, if you share an address
with another stockholder and have received multiple copies of the Notice, you may write or call us at the address and phone number
below to request delivery of a single copy of this Notice. For future annual meetings, you may request separate Notices, or request
that we send only one Notice to you if you are receiving multiple copies, by writing or calling us at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Actinium Pharmaceuticals, Inc.<BR>
Attention: Steve O&rsquo;Loughlin, Principal Financial Officer<BR>
275 Madison Avenue, 7<SUP>th</SUP> Floor<BR>
New York, New York 10016<BR>
Tel: (646) 677-3875</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Who pays for the cost of this proxy solicitation?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay the costs of the solicitation of proxies. We may
also reimburse brokerage firms and other persons representing beneficial owners of shares for expenses incurred in forwarding
the voting materials to their customers who are beneficial owners and obtaining their voting instructions. In addition to soliciting
proxies by mail, our board members, officers and employees may solicit proxies on our behalf, without additional compensation,
personally, electronically or by telephone.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">How can I obtain a copy of Actinium Pharmaceuticals,
Inc.&rsquo;s 2017 Annual Report on Form 10-K?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proxy statement and our 2017 annual report to stockholders
are available for viewing, printing and downloading at <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>www.proxyvote.com.
</I></FONT>To view these materials, please have your 12-digit control number(s) available that appears on your Notice or proxy
card. On this website, you can also elect to receive future distributions of our proxy statements and annual reports to stockholders
by electronic delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, you can find a copy of our Annual Report on Form
10-K, which includes our financial statements, for the fiscal year ended December 31, 2017 on the website of the SEC, at <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>www.sec.gov</I></FONT>,
or in the &ldquo;All SEC Filings&rdquo; section of the &ldquo;Investors&rdquo; section of our website at <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>www.actiniumpharma.com.
</I></FONT>You may also obtain a printed copy of our Annual Report on Form 10-K including our financial statements, free of charge,
from us by sending a written request to: Actinium Pharmaceuticals, Inc., 275 Madison Avenue, 7<SUP>th</SUP> Floor, New York, NY
10016, attention: Principal Financial Officer.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">What is the voting requirement to elect directors?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Directors are elected by a plurality of the votes cast in person
or by proxy at the annual meeting and entitled to vote on the election of directors. &ldquo;Plurality&rdquo; means that the nominees
receiving the greatest number of affirmative votes will be elected as directors, up to the number of directors to be chosen at
the meeting. Broker non-votes will not affect the outcome of the election of directors because brokers do not have discretion
to cast votes on this proposal without instruction from the beneficial owner of the shares.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">What is the voting requirement to approve the other
three proposals?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The proposal to ratify the appointment of Marcum LLP as our
independent registered public accounting firm will be approved if there is a quorum and the votes cast &ldquo;FOR&rdquo; the proposal
exceeds those cast against the proposal. The proposal to approve an amendment to our 2013 stock plan to increase the shares authorized
under the plan will be approved if there is a quorum and the votes cast &ldquo;FOR&rdquo; the proposal exceeds those cast against
the proposal. The proposal to amend the charter to increase the authorized shares of the company will be approved if at least
50% of the issued and outstanding shares votes &ldquo;FOR&rdquo; the proposal and this exceeds those cast against the proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abstentions and broker non-votes will be treated as shares
that are present, or represented and entitled to vote for purposes of determining the presence of a quorum at the annual meeting.
Abstentions will not be counted in determining the number of votes cast in connection with any matter presented at the annual
meeting. Broker non-votes will not be counted as a vote cast on any matter presented at the annual meeting.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Do I Have Dissenters&rsquo; (Appraisal) Rights?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Appraisal rights are not available to our shareholders with
any of the proposals described above to be brought before the annual meeting of shareholders.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">How can I communicate with the non-employee directors
on the Actinium Pharmaceuticals, Inc. Board of Directors?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board encourages stockholders who are interested in communicating
directly with the non-employee directors as a group to do so by writing to the non-employee directors in care of our Chairman
and CEO. Stockholders can send communications by mail to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Sandesh Seth, Chairman and Chief Executive
Officer<BR>
Actinium Pharmaceuticals, Inc.<BR>
275 Madison Avenue, 7<SUP>th</SUP> Floor<BR>
New York, New York 10016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Correspondence received that is addressed to the non-employee
directors will be reviewed by our Chairman of the Board or his designee, who will regularly forward to the non-employee directors
a summary of all such correspondence and copies of all correspondence that, in the opinion of our chairman, deals with the functions
of our Board or committees thereof or that our chairman otherwise determines requires their attention. Directors may at any time
review a log of all correspondence received by us that is addressed to the non-employee members of our Board and request copies
of any such correspondence.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WHO CAN HELP ANSWER YOUR QUESTIONS?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may seek answers to your questions by writing, calling
or emailing us at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Steve O&rsquo;Loughlin<BR>
Principal Financial Officer<BR>
Actinium Pharmaceuticals, Inc.<BR>
275 Madison Avenue, 7<SUP>th</SUP> Floor<BR>
New York, NY 10016<BR>
Email: <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>soloughlin@actiniumpharma.com</I></FONT><BR>
Tel: 646-677-3875</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CORPORATE GOVERNANCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors oversees our business affairs and monitors
the performance of management. In accordance with our corporate governance principles, our Board does not involve itself in day-to-day
operations. The directors keep themselves informed through discussions with the Chairman and CEO, other key executives, and by
reading the reports and other materials that we send them and by participating in Board and committee meetings. Our directors
hold office until their successors have been elected and duly qualified unless the director resigns or by reason of death or other
cause is unable to serve in the capacity of director. Biographical information about our directors is provided in &ldquo;Election
of Directors &mdash; Proposal No. 1&rdquo; on&nbsp;page 29.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Term of Office</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our directors are divided into three classes, designated Class
I, Class II and Class III. Class I shall consists of two directors, Class II shall consists of two directors, and Class III consists
of one director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The term of each director is set forth below or until their
successors are duly elected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 30%; border-bottom: Black 1.5pt solid; font-weight: bold"><B>Director</B></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 23%; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><B>Class</B></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 45%; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><B>Term
    (from 2018 Annual Meeting, if elected)</B></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom">David Nicholson</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Class I</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">2 years</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom">Richard I Steinhart</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Class I</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">2 years</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom">Sandesh Seth</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Class II</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">3 years</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom">Jeffrey W. Chell</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Class II</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">3 years</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom">Ajit S. Shetty</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Class III</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">1 year</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notwithstanding the foregoing, each director shall serve until
his successor is duly elected and qualified, or until his retirement, death, resignation or removal. In order to implement a classified
board of directors, Class I serves a two year term from the date of the 2018 Annual Shareholders Meeting; Class II serves a three
year term from the date of the 2018 Annual Shareholders Meeting; and Class III serves a one year term from the date the date of
the 2018 Annual Shareholders Meeting. Directors elected at each annual meeting are elected for a three&nbsp;year&nbsp;term.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director Independence</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We use the definition of &ldquo;independence&rdquo; of the
NYSE American stock exchange to make this determination. We are listed on the NYSE American under the symbol &ldquo;ATNM&rdquo;.
NYSE MKT corporate governance rule Sec. 803(A)(2) provides that an &ldquo;independent director&rdquo; means a person other than
an executive officer or employee of the company. No director qualifies as independent unless the issuer&rsquo;s board of directors
affirmatively determines that the director does not have a relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director. The following is a non-exclusive list of persons who shall not be
considered independent under NYSE American rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">a director who is, or during the
past three years was, employed by the company, other than prior employment as an interim executive officer (provided the interim
employment did not last longer than one year);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">a director who accepted or has
an immediate family member who accepted any compensation from the company in excess of $120,000 during any period of twelve consecutive
months within the three years preceding the determination of independence, other than the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 24pt">(i)</TD><TD>compensation for board or board committee service;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 24pt">(ii)</TD><TD>compensation paid to an immediate family member who is an employee
                                         (other than an executive officer) of the company,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 24pt">(iii)</TD><TD>compensation received for former service as an interim executive
                                         officer (provided the interim employment did not last longer than one year); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48pt"></TD><TD STYLE="width: 24pt">(iv)</TD><TD>benefits under a tax-qualified retirement plan, or non-discretionary
                                         compensation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">a director who is an immediate
family member of an individual who is, or at any time during the past three years was, employed by the company as an executive
officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">a director who is, or has an immediate
family member who is, a partner in, or a controlling shareholder or an executive officer of, any organization to which the company
made, or from which the company received, payments (other than those arising solely from investments in the company&rsquo;s securities
or payments under non-discretionary charitable contribution matching programs) that exceed 5% of the organization&rsquo;s consolidated
gross revenues for that year, or $200,000, whichever is more, in any of the most recent three fiscal years;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">a director who is, or has an immediate
family member who is, employed as an executive officer of another entity where at any time during the most recent three fiscal
years any of the issuer&rsquo;s executive officers serve on the compensation committee of such other entity; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">a director who is, or has an immediate
family member who is, a current partner of the company&rsquo;s outside auditor, or was a partner or employee of the company&rsquo;s
outside auditor who worked on the company&rsquo;s audit at any time during any of the past three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the above-mentioned NYSE American director independence
rules, Jeffrey W. Chell, David Nicholson, Ajit S. Shetty, and Richard I. Steinhart are independent directors of the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board Leadership Structure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2013, Sandesh Seth was appointed Chairman of our
Board of Directors and in June 2017 Mr. Seth was named Chief Executive Officer of the Company. In September 2017, David Nicholson
was appointed lead independent director of our board of directors (&ldquo;Lead Independent Director&rdquo;). Our Lead Independent
Director chairs the executive sessions of our board of director meetings; provides feedback to the Chairman and CEO; if appropriate,
and in coordination with executive management, be available for consultation and direct communication with major shareholders;
and leads the board&rsquo;s evaluation of the Chairman and CEO. We have a separate chair for each committee of our board of directors,
all of whom are independent directors. The chairs of each committee report on the activities of their committees in fulfilling
their responsibilities at the meetings of our board of directors.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors Meetings and Attendance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the fiscal year 2017, our Board held 15 meetings. No
director attended fewer than 93% of the total number of meetings of our Board and of any committees of which he was a member during
the year ended December&nbsp;31, 2017. It is our policy that directors should make every effort to attend the annual meeting of
stockholders, and each of our directors attended the annual meeting of stockholders in&nbsp;2017.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Code of Business Conduct and Ethics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We adopted a Code of Business Conduct and Ethics that applies
to all of our directors, officers and employees, including our principal executive officer and principal financial and accounting
officer. A copy of the Code of Business Conduct and Ethics is available on the Investor section of our website at <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>www.actiniumpharma.com</I></FONT>.
We will post on our website any amendment to our Code of Business Conduct and Ethics or waivers of our Code of Business Conduct
and Ethics for directors and executive officers.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Complaints Regarding Accounting Matters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Audit Committee has established procedures for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">the receipt, retention and treatment
of complaints regarding accounting, internal accounting controls, or auditing matters; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">the confidential, anonymous submission
by our employees of concerns regarding questionable accounting or auditing matters.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Communications with Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors has approved procedures for stockholders
to send communications to individual directors or the non-employee directors as a group. Written correspondence should be addressed
to the director or directors in care of Sandesh Seth, Chairman and CEO of Actinium Pharmaceuticals, Inc., 275 Madison Avenue,
7<SUP>th</SUP> Floor, New&nbsp;York, NY 10016. Correspondence received that is addressed to the non-employee directors will be
reviewed by our Chairman and CEO or his designee, who will regularly forward to the non-employee directors a summary of all such
correspondence and copies of all correspondence that, deals with the functions of our Board of Directors or committees thereof
or that he otherwise determines requires their attention. Directors may at any time review a log of all correspondence received
by us that is addressed to the non-employee members of our Board of Directors and request copies of any such correspondence. You
may also contact individual directors by calling our principal executive offices at (646) 677-3875.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Legal Proceedings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are no legal proceedings to which any director, director
nominee or officer of our company, any owner of record or beneficially of more than 5% of common stock, or any associate of any
such director, director nominee, officer of our company or major security holder is a party in legal proceedings adverse to our
company or has a material interest adverse to us.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Compliance With Section 16(a) of the Exchange Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based solely upon a review of copies of such forms filed on
Forms 3, 4, and 5, and amendments thereto furnished to us we believe that as of the date of this proxy, our executive officers,
directors and greater than 10 percent beneficial owners have complied on a timely basis with all Section 16(a) filing requirements,
with the exception of a Form 4 filed by Dr. Berger on March 19, 2018 for a transaction on March 6, 2018.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BOARD COMMITTEES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Committees of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors has formed three standing committees:
audit, compensation and corporate governance. Actions taken by our committees are reported to the full board. Each of our committees
has a charter and each charter is posted on our website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: Black 1.5pt solid; font-weight: bold">Audit Committee</TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Compensation
    Committee</TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Corporate
    Governance Committee</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Richard I. Steinhart*</TD>
    <TD>&nbsp;</TD>
    <TD>David Nicholson*</TD>
    <TD>&nbsp;</TD>
    <TD>Ajit S. Shetty*</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Jeffrey W. Chell</TD>
    <TD>&nbsp;</TD>
    <TD>Jeffrey W. Chell</TD>
    <TD>&nbsp;</TD>
    <TD>David Nicholson</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Ajit S. Shetty</TD>
    <TD>&nbsp;</TD>
    <TD>Ajit S. Shetty</TD>
    <TD>&nbsp;</TD>
    <TD>Richard I. Steinhart</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>*</B></FONT></TD><TD>Indicates
                                         committee chair</TD></TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audit Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit committee, which currently consists of three directors,
provides assistance to our board in fulfilling its legal and fiduciary obligations with respect to matters involving the accounting,
financial reporting, internal control and compliance functions of the company. Our audit committee employs an independent registered
public accounting firm to audit the financial statements of the company and perform other assigned duties. Further, our audit
committee provides general oversight with respect to the accounting principles employed in financial reporting and the adequacy
of our internal controls. In discharging its responsibilities, our audit committee may rely on the reports, findings and representations
of the company&rsquo;s auditors, legal counsel, and responsible officers. Our board has determined that all members of the audit
committee are financially literate within the meaning of SEC rules and under the current listing standards of the NYSE MKT. Richard
I. Steinhart is the chairman of the audit committee. Our audit committee met four&nbsp;times during the year ended December&nbsp;31,
2017.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Compensation Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compensation committee, which currently consists of three
directors, establishes executive compensation policies consistent with the company&rsquo;s objectives and stockholder interests.
Our compensation committee also reviews the performance of our executive officers and establishes, adjusts and awards compensation,
including incentive-based compensation, as more fully discussed below. Our compensation committee met two&nbsp;times during the
year ended December&nbsp;31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, our compensation committee generally is responsible
for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">establishing and periodically
reviewing our compensation philosophy and the adequacy of compensation plans and programs for our directors, executive officers
and other employees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">overseeing our compensation plans,
including the establishment of performance goals under the company&rsquo;s incentive compensation arrangements and the review
of performance against those goals in determining incentive award payouts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">overseeing our executive employment
contracts, special retirement benefits, severance, change in control arrangements and/or similar plans;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">acting as administrator of any
company stock option plans; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">overseeing the outside consultant,
if any, engaged by the compensation committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compensation committee periodically reviews the compensation
paid to our non-employee directors and the principles upon which their compensation is determined. The compensation committee
also periodically reports to the board on how our non-employee director compensation practices compare with those of other similarly
situated public corporations and, if the compensation committee deems it appropriate, recommends changes to our director compensation
practices to our board for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Outside consulting firms retained by our compensation committee
and management also will, if requested, provide assistance to the compensation committee in making its compensation-related decisions.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Corporate Governance Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our corporate governance committee, which currently consists
of three directors, monitors our corporate governance system. Our corporate governance committee met two&nbsp;times during the
year ended December&nbsp;31, 2017.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nomination of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Director nominations are selected, or recommended
for our Board&rsquo;s selection, by a majority of the independent directors.&nbsp;Our independent directors include Jeffrey W.
Chell, David Nicholson, Ajit S. Shetty and Richard I. Steinhart. These directors are charged with the responsibility of proposing
potential director nominees to the board of directors for consideration. All of our independent directors are independent directors
as defined by the rules of the NYSE MKT. Our independent directors use criteria by which they will seek to evaluate candidates
to serve on our Board. The evaluation methodology includes items such as experience in the biotechnology sector, experience with
public companies, executive managerial experience, operations and commercial experience, fundraising experience and contacts in
the investment banking industry, personal and skill set compatibility with current board members, industry reputation, knowledge
of our company generally, and independence.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">DIRECTOR COMPENSATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth the compensation
of our non-employee directors for the 2017 fiscal year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees Earned or <BR> Paid in
    Cash</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<BR> Awards</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option</B><BR>
                                         <B>Awards</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(1)</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other <BR> Compensation</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">David Nicholson (2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">59,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">73,430</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">132,430</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Ajit J. Shetty (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,694</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">122,597</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Richard Steinhart</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">63,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,430</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">136,430</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Sergio Traversa (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">58,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,430</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">131,930</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the end of fiscal
    year 2017, the aggregate number of option awards outstanding for each director was as follows: (i) for Dr. Nicholson, 274,900,
    (ii) for Dr. Shetty, 75,000, (iii) for Mr. Steinhart, 224,950, and (iv) for Mr. Traversa, 172,950. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Nicholson was
    named Lead Director in September 2017 and receives an additional $10,000 per year for his role as Lead Director.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Shetty was appointed
    a director on March 28, 2017. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Traversa resigned
    from the company on June 6, 2017.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In accordance with
SEC rules, the amounts shown reflect the aggregate grant date fair value of option awards granted to Non-Employee Directors during
2017, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our non-employee directors
are paid an annual fee of $40,000 and receive annual option grants. Board committee members will receive the following compensation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">BOD Committee</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Chairman</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Member</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Audit</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Corporate Governance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AUDIT COMMITTEE REPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Report of the Audit Committee of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Audit Committee provides assistance to the Board of Directors
in fulfilling its oversight responsibilities relating to our corporate accounting and reporting practices toward assurance of
the quality and integrity of our consolidated financial statements. The purpose of the Audit Committee is to serve as an independent
and objective party to monitor our financial reporting process and internal control system; oversee, review and appraise the audit
activities of our independent registered public accounting firm and internal auditing function, maintain complete, objective and
open communication between the Board of Directors, the independent accountants, financial management and the internal audit function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our independent registered public accounting firm reports directly
to the Audit Committee and the Audit Committee is solely responsible to appoint or replace our independent registered public accounting
firm and to assure its independence and to provide oversight and supervision thereof. The Audit Committee determines compensation
of the independent registered public accounting firm and has established a policy for approval of non-audit related engagements
awarded to the independent registered public accounting firm. Such engagements must not impair the independence of the registered
public accounting firm with respect to our company as prescribed by the Sarbanes-Oxley Act of 2002; thus payment amounts are limited
and non-audit related engagements must be approved in advance by the Audit Committee. The Audit Committee determines the extent
of funding that we must provide to the Audit Committee to carry out its duties and has determined that such amounts were sufficient
in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With respect to the fiscal year ended December 31, 2017, in
addition to its other work, the Audit Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">Reviewed and discussed with management
our audited consolidated financial statements as of December 31, 2017 and for the year then ended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">Discussed with GBH CPAs, PC the
matters required to be discussed by Statement on Auditing Standards No. 61, &ldquo;Communication with Audit Committees,&rdquo;
as amended, with respect to its review of the findings of the independent registered public accounting firm during its examination
of our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Audit Committee recommended, based on the review and discussion
summarized above, that the Board of Directors include the 2017 audited consolidated financial statements in the 2017 Form 10-K
for the fiscal year ended December 31, 2017 for filing with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Audit Committee of the Board of Directors of Actinium Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Richard I. Steinhart, Chairman</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeffrey W. Chell</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ajit S. Shetty</P></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information About Our Auditors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Audit Committee of our Board appointed GBH CPAs, PC as
the independent registered public accounting firm to conduct the audit of our consolidated financial statements for the 2017 fiscal
year and to report on our consolidated balance sheets, statements of income and other related statements. GBH CPAs, PC served
as our independent registered public accounting firm since December 2012. In August 2018, we appointed Marcum LLP as our independent
registered public accounting firm due to a merger between GBH CPAs, PC and Marcum LLP. The Audit Committee Charter includes the
procedures for pre-approval of all fees charged by our independent registered public accounting firm. Under the procedure, our
Audit Committee approves the engagement letter with respect to audit and review services. Other fees are subject to pre-approval
by our Audit Committee. The audit and audit-related fees paid to the auditors with respect to the 2017 fiscal year were pre-approved
by our Audit Committee.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fees and Services</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The aggregate fees billed for the fiscal
years ended December 31, 2017 and 2016, respectively, for professional services rendered by GBH CPAs, PC for the audits of the
Company&rsquo;s annual financial statements included in Form 10-K, or Audit Fees,&nbsp;tax compliance, advice, and planning, or
Tax Fees, and all other fees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December&nbsp;31,<BR>
    2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December&nbsp;31,<BR>
    2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Audit Fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">116,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">123,168</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Audit &ndash; Related Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">All Other Fees</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">177,300</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">146,918</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-Approval Policy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In 2015, the Audit Committee adopted policies
and procedures for the pre-approval of audit and non-audit services performed by the independent registered public accountants
pursuant to which the Audit Committee generally is required to pre-approve the audit and permissible non-audit services performed
by the independent registered public accountants in order to ensure that the provision of such services does not impair the registered
accountants&rsquo; independence.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Compensation
Committee Report*</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Compensation Committee has reviewed and discussed with
management the Compensation Discussion and Analysis (&ldquo;CD&amp;A&rdquo;) included in this proxy statement. Based on that review
and discussion, the Compensation Committee has recommended to our Board that the CD&amp;A be included in the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Submitted by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Compensation Committee of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ David Nicholson, Chairman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Jeffrey W. Chell</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Ajit S. Shetty</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt">*</TD><TD STYLE="text-align: left">The information contained in this Compensation
                                         Committee Report shall not be deemed to be &ldquo;soliciting material&rdquo; or &ldquo;filed&rdquo;
                                         or incorporated by reference in future filings with the SEC, or subject to the liabilities
                                         of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
                                         Act&rdquo;), except to the extent that we specifically request that the information be
                                         treated as soliciting material or specifically incorporate it by reference into a document
                                         filed under the Securities Act of 1933, as amended, or the Exchange Act.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Compensation Discussion and Analysis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Compensation Committee of our Board of Directors has the
responsibility to review, determine and approve the compensation for our executive officers. Further, our Compensation Committee
oversees our overall compensation strategy, including compensation policies, plans and programs that cover all employees. In 2016,
our Stockholders voted on an advisory basis with respect to our compensation program for named executive officers. Of the votes
cast (excluding abstentions and broker non-votes), 69.0% were cast in support of the program. In light of this, in reviewing the
executive compensation program for 2016, our Compensation Committee decided to retain the general overall program design, which
ties a significant portion of the executives&rsquo; pay closely with our performance. In the future, our Compensation Committee
will continue to consider the executive compensation program in light of changing circumstances and stockholder feedback.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently employ six executive officers, each of whom serves
as a &ldquo;Named Executive Officer&rdquo; (or NEO) for purposes of SEC reporting: (1) Sandesh Seth, our Chairman and Chief Executive
Officer (who we refer to in this Compensation Discussion and Analysis as our CEO); (2) Steve O&rsquo;Loughlin, our Principal Financial
Officer, (3) Mark Berger, our Chief Medical Officer; (4) Nitya Ray, our Executive Vice-President, Head of Product Development,
Manufacturing and Supply Chain; (5) Anil Kapur, our Chief Commercial Officer; and (6) Dale Ludwig, our Chief Scientific Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Compensation Discussion and Analysis sets forth a discussion
of the compensation for our NEOs as well as a discussion of our philosophies underlying the compensation for our NEOs and our
employees generally.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Objectives of Our Compensation Program</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Compensation Committee&rsquo;s philosophy seeks to align
the interests of our stockholders, officers and employees by tying compensation to individual and company performance, both directly
in the form of salary or annual cash incentive payments, and indirectly in the form of equity awards. The objectives of our compensation
program enhance our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">attract and retain qualified and
talented individuals; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">provide reasonable and appropriate
incentives and rewards to our team for building long-term value within our company, in each case in a manner comparable to companies
similar to ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we strive to be competitive with other similarly
situated companies in our industry. The process of developing pharmaceutical products and bringing those products to market is
a long-term proposition and outcomes may not be measurable for several years. Therefore, in order to build long-term value for
our company and its stockholders, and in order to achieve our business objectives, we believe that we must compensate our officers
and employees in a competitive and fair manner that reflects current company activities, but also reflects contributions to building
long-term value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We utilize the services of StreeterWyatt Governance LLC to
review compensation programs of peer companies in order to assist the Compensation Committee in determining the compensation levels
for our NEOs, as well as for other employees of our company. StreeterWyatt is a recognized independent consulting company and
services clients throughout the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The companies that comprise our peer group are selected and
reviewed no less frequently than biennially.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elements of Our Compensation Program and Why We Chose
Each</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Main Compensation Components</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our company-wide compensation program, including for our NEOs,
is broken down into three main components: base salary, performance cash bonuses and potential long-term compensation in the form
of stock options or restricted stock awards. We believe these three components constitute the minimum essential elements of a
competitive compensation package in our industry.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Salary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Base salary is used to recognize the experience, skills, knowledge
and responsibilities required of our NEOs as well as recognizing the competitive nature of the biopharmaceutical industry. This
is determined partially by evaluating our peer companies as well as the degree of responsibility and experience levels of our
NEOs and their overall contributions to our company. Base salary is one component of the compensation package for NEOs; the other
components being cash bonuses, annual equity grants, and company benefit programs. Base salary is determined in advance whereas
the other components of compensation are awarded in varying degrees following an assessment of the performance of a NEO. This
approach to compensation reflects the philosophy of our Board and its Compensation Committee to emphasize and reward, on an annual
basis, performance levels achieved by our NEOs.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Performance Bonus Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have a performance bonus plan under which bonuses are paid
to our NEOs based on achievement of company performance goals and objectives established by the Compensation Committee and/or
our Board as well as on individual performance. The bonus program is discretionary and is intended to: (i) strengthen the connection
between individual compensation and our company&rsquo;s achievements; (ii) encourage teamwork among all disciplines within our
company; (iii) reinforce our pay-for-performance philosophy by awarding higher bonuses to higher performing employees; and (iv)
help ensure that our cash compensation is competitive. Depending on the cash position of the company, the Compensation Committee
and our Board have the discretion to not pay cash bonuses in order that we may conserve cash and support ongoing development programs
and commercialization efforts. Regardless of our cash position, we consistently grant annual merit-based stock options to continue
incentivizing both our senior management and our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on their employment agreements, each NEO is assigned
a target payout under the performance bonus plan, expressed as a percentage of base salary for the year. Actual payouts under
the performance bonus plan are based on the achievement of corporate performance goals and an assessment of individual performance,
each of which is separately weighted as a component of such officer&rsquo;s target payout. For the NEOs, the corporate goals receive
the highest weighting in order to ensure that the bonus system for our management team is closely tied to our corporate performance.
Each employee also has specific individual goals and objectives as well that are tied to the overall corporate goals. For employees,
mid-year and end-of-year progress is reviewed with the employees&rsquo; managers.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Equity Incentive Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We view long-term compensation, currently in the form of stock
options and restricted stock generally vesting in annual increments over four years, as a tool to align the interests of our NEOs
and employees generally with the creation of stockholder value, to motivate our employees to achieve and exceed corporate and
individual objectives and to encourage them to remain employed by the company. While cash compensation is a significant component
of employees&rsquo; overall compensation, the Compensation Committee and our Board (as well as our NEOs) believe that the driving
force of any employee working in a small biotechnology company should be strong equity participation. We believe that this not
only creates the potential for substantial longer term corporate value but also serves to motivate employees and retain their
loyalty and commitment with appropriate personal compensation.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Other Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the main components of compensation outlined
above, we also provide contractual severance and/or change in control benefits to our Chairman and CEO. The change in control
benefits for all applicable persons have a &ldquo;double trigger.&rdquo; A double trigger means that the executive officers will
receive the change in control benefits described in the agreements only if there is both (1) a Change in Control of our company
(as defined in the agreements) and (2) a termination by us of the applicable person&rsquo;s employment &ldquo;without cause&rdquo;
or a resignation by the applicable persons for &ldquo;good reason&rdquo; (as defined in the agreements) within a specified time
period prior to or following the Change in Control. We believe this double trigger requirement creates the potential to maximize
stockholder value because it prevents an unintended windfall to management, as no benefits are triggered solely in the event of
a Change in Control, while providing appropriate incentives to act in furtherance of a change in control that may be in the best
interests of the stockholders. We believe these severance or change in control benefits are important elements of our compensation
program that assist us in retaining talented individuals at the executive and senior managerial levels and that these arrangements
help to promote stability and continuity of our executives and senior management team. Further, we believe that the interests
of our stockholders will be best served if the interests of these members of our management are aligned with theirs. We believe
that providing change in control benefits lessens or eliminates any potential reluctance of members of our management to pursue
potential change in control transactions that may be in the best interests of the stockholders. We also believe that it is important
to provide severance benefits to members of our management, to promote stability and focus on the job at hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also provide benefits to the executive officers that are
generally available to all regular full-time employees of our company, including our medical and dental insurance, and a 401(k)
plan. At this time, we do not provide any perquisites to any of our NEOs. Further, we do not have deferred compensation plans,
pension arrangements or post-retirement health coverage for our executive officers or employees. All of our employees not specifically
under contract are &ldquo;at-will&rdquo; employees, which means that their employment can be terminated at any time for any reason
by either us or the employee. Our Chairman and CEO has an employment agreement that provides lump sum compensation in the event
of his termination without cause or, under certain circumstances, upon a Change of&nbsp;Control.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Determination of Compensation Amounts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A number of factors impact the determination of compensation
amounts for our NEOs, including the individual&rsquo;s role in the company and individual performance, length of service with
the company, competition for talent, individual compensation package, assessments of internal pay equity and industry data. Stock
price performance has generally not been a factor in determining annual compensation because the price of our common stock is
subject to a variety of factors outside of our control.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Industry Survey Data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In collaboration with StreeterWyatt, we establish and maintain
a list of peer companies to best assure ourselves that we are compensating our executives on a fair and reasonable basis, as set
forth above under the heading &ldquo;Objectives of our Compensation Program.&rdquo; We also utilize StreetWyatt-prepared data
for below-executive level personnel, which data focuses on similarly-sized bio-tech companies. The availability of peer data is
used by the Compensation Committee strictly as a guide in determining compensation levels with regard to salaries, cash bonuses
and performance-related annual equity grants to all employees. However, the availability of this data does not imply that the
Compensation Committee is under any obligation to exactly follow peer companies in compensation matters.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Determination of Base Salaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a guideline for NEO base salary, we perform formal benchmarks
against respective comparable positions in our established peer group. We adjust salaries based on our assessment of our NEOs&rsquo;
levels of responsibility, experience, overall compensation structure and individual performance. The Compensation Committee is
not obliged to raise salaries purely on the availability of data. Merit-based increases to salaries of executive officers are
based on our assessment of individual performance and the relationship to applicable salary ranges. Cost of living adjustments
may also be a part of that assessment.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Performance Bonus Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concurrently with the beginning of each calendar year, preliminary
corporate goals that reflect our business priorities for the coming year are prepared by the CEO with input from the other executive
officers. These goals are weighted by relative importance. The draft goals and proposed weightings are presented to the Compensation
Committee and the Board and discussed, revised as necessary, and then approved by our Board. The Compensation Committee then reviews
the final goals and their weightings to determine and confirm their appropriateness for use as performance measurements for purposes
of the bonus program. The goals and/or weightings may be re-visited during the year and potentially restated in the event of significant
changes in corporate strategy or the occurrence of significant corporate events. Following the agreement of our Board on the corporate
objectives, the goals are then shared with all employees in a formal meeting(s), and are reviewed periodically throughout the
year.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Determination of Equity Incentive Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To assist us in assessing the reasonableness of our equity
grant amounts, we have reviewed StreeterWyatt supplied information. Such information included equity data from a cross-section
of similar companies in our industry.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Equity Grant Practices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All stock options and/or restricted stock granted to the NEOs
and other executives are approved by the Compensation Committee. Exercise prices for options are set at the closing price of our
common stock on the date of grant. Grants are generally made: (i) on the employee&rsquo;s start date and (ii) at our Board meetings
held each February and following annual performance reviews. However, grants have been made at other times during the year. The
size of year-end grants for each NEO is assessed against our internal equity guidelines. Current market conditions for grants
for comparable positions and internal equity may also be assessed. Also, grants may be made in connection with promotions or job-related
changes in responsibilities. In addition, on occasion, the Compensation Committee may make additional special awards for extraordinary
individual or company performance.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Compensation Setting Process</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the February meetings of our Board and the Compensation
Committee, overall corporate performance and relative achievement of the corporate goals for the prior year are assessed. The
relative achievement of each goal is assessed and quantified and the summation of the individual components results in a corporate
goal rating, expressed as percentages. The Compensation Committee then approves the final disbursement of salary increases, cash
bonuses and option or restricted stock grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Compensation Committee looks to the CEO&rsquo;s performance
assessments of the other NEOs and his recommendations regarding a performance rating for each, as well as input from the other
members of our Board. These recommendations may be adjusted by the Compensation Committee prior to finalization. For the CEO,
the Compensation Committee evaluates his performance, taking into consideration input from the other members of our Board, and
considers the achievement of overall corporate objectives by both the CEO specifically and the company generally. The CEO is not
present during the Compensation Committee&rsquo;s deliberations regarding his compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Compensation Committee has the authority to directly engage,
at our company&rsquo;s expense, any compensation consultants or other advisors (such as StreeterWyatt) that it deems necessary
to determine the amount and form of employee, executive and director compensation. In determining the amount and form of employee,
executive and director compensation, the Compensation Committee has reviewed and discussed historical salary information as well
as salaries for similar positions at comparable companies. However the availability of this data does not imply that the Compensation
Committee is under any obligation to exactly follow peer companies&rsquo; compensation practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We paid consultant fees to StreeterWyatt of $10,000. NEOs may
have indirect input in the compensation results for other executive officers by virtue of their participation in the performance
review and feedback process for the other executive officers.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DIRECTORS AND EXECUTIVE OFFICERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Directors And Executive Officers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The names, positions and ages of our directors and executive
officers as of October 24, 2018, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; border-bottom: black 1.5pt solid; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 61%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark S. Berger, MD</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Medical Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitya Ray, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President, Head of Product Development,
    Manufacturing and Supply Chain</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anil Kapur</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Commercial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dale L. Ludwig, Ph. D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Scientific Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer (Principal Financial
    and Accounting Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell. M.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson, Ph. D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lead Independent Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Subject to the classified board provisions
of our charter, all directors hold office until the next annual meeting of stockholders and the election and qualification of
their successors. Officers are elected annually by our Board and serve at the discretion of our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">There are no arrangements or understanding
between any of our directors and any other persons pursuant to which they were selected as a director.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Background of Executive Officers and
Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The principal occupations for the past five
years (and, in some instances, for prior years) of each of our directors and executive officers are as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Sandesh Seth, MS, MBA, Chairman and
CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Mr. Sandesh Seth has been our Chief Executive
Officer since June 2017. Mr. Seth has been a Director since March 2012, our Chairman of the Board since October 2013, and served
as Executive Chairman from August 2014 to June 2017. Mr. Seth was affiliated with Laidlaw &amp; Co. (UK) Ltd., a healthcare focused,
investment banking and wealth management firm where he was Head of Healthcare Investment Banking. Mr. Seth is the Chairman of
the Board of Relmada Therapeutics, Inc., a publicly listed, specialty pharmaceuticals company focused on pain therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Mr. Seth has 25+ years of experience in investment
banking (Cowen &amp; Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharma industry (Pfizer, Warner-Lambert,
SmithKline in strategic planning, business development and R&amp;D project management). Mr. Seth has an MBA in Finance from New
York University; an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry
from Bombay University. He has published several scientific articles and was awarded the University Regents Award for Research
Excellence at the University of Oklahoma. Mr. Seth was designated as Regulatory Affairs Certified (R.A.C.) by the Regulatory Affairs
Professionals Society which signifies proficiency with U.S. FDA regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">That Mr. Seth has served in various business
executive-level positions over the course of his career, has significant investment banking experience, has developed significant
management and leadership skills and is well accustomed to interfacing with investors, analysts, auditors, C-level executives,
and outside advisors, led us to conclude that Mr. Seth should serve as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Steve O&rsquo;Loughlin, BS, Principal Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steve O&rsquo;Loughlin has been our Principal Financial Officer
since May 2017. Mr. O&rsquo;Loughlin joined Actinium in October 2015 as Vice President, Finance and Corporate Development, with
almost a decade of life sciences industry experience gained from previous positions in investment banking and publicly traded
life sciences companies. Prior to Actinium, from June 2015 to October 2015, Mr. O&rsquo;Loughlin worked at J. Streicher LLC as
an investment banker, from August 2012 to June 2015 Mr. O&rsquo;Loughlin held the position of Vice President, Corporate Finance
and Development and was a corporate officer at Protea Biosciences, Inc., a publicly traded life sciences tools company. Previously,
From June 2010 to June 2012, Mr. O&rsquo;Loughlin held corporate development positions with Caliber I.D., a publicly traded diagnostics
company. Mr. O&rsquo;Loughlin previously worked in investment banking at Jesup &amp; Lamont where he focused on the biotechnology
and life sciences industries. Mr. O&rsquo;Loughlin has a B.S. in Business Administration with a concentration in finance from
Ramapo College of New Jersey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mark S. Berger, MD, Chief Medical Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Berger has been our Chief Medical Officer since January
2017. From September 2013 to January 2017 Dr.&nbsp;Berger worked for Kadmon Corporation where he was Senior Vice President, Clinical
Research. In this role he was responsible for all clinical aspects of new drug development including designing and managing clinical
trials in oncology indications (non-small cell lung cancer and glioblastoma) and non-oncology indications (chronic graft versus
host disease and polycystic kidney disease). Dr. Berger joined Kadmon after serving as Chief Medical Officer of Deciphera Pharmaceuticals
from June 2011 to September 2013. Prior to Deciphera, Dr. Berger was Vice President for Clinical Development at Gemin X Pharmaceuticals
where he led the clinical strategy, design and management of clinical trials for two novel oncology agents including obatoclax,
a pan Bcl-2 inhibitor. Based on the results of a randomized Phase 2 clinical trial of obatoclax, Gemin X was acquired by Cephalon
in March of 2011 for a total consideration of $525 million including $225 million in an upfront cash payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Before his work with biotechnology companies, Dr. Berger held
key positions in two global pharmaceutical companies. Dr. Berger previously served as Group Director, Medicine Development Centre-Oncology
for GlaxoSmithKline. In this position Dr. Berger managed the development of Tykerb (lapatinib) in lung and breast cancer where
he designed and led two Phase 2 clinical trials before planning and leading a 399 patient pivotal Phase 3 trial that resulted
in the FDA approval of Tykerb in breast cancer. In addition, he managed the Lapatinib Expanded Access Program (LEAP) that enrolled
over 4000 patients on a global basis. Dr. Berger began his career in drug development at Wyeth Research where he led the planning
and execution of the pivotal Phase 2 trial for Mylotarg, which was the first antibody targeted chemotherapy agent and targeted
CD33, similar to Actimab-A. He presented the Mylotarg clinical data at the FDA&rsquo;s Oncology Drug Advisory Committee meeting,
after which Mylotarg received accelerated FDA approval for patients with relapsed AML.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Berger has a B.A. in biology from Wesleyan University and
received his M.D. from the University of Virginia School of Medicine. He did his Hematology-Oncology fellowship at the University
of Pennsylvania where he was an Assistant Professor of Medicine, and also was a Research Fellow&nbsp;at the Ludwig Institute for
Cancer Research and the Imperial Cancer Research Fund, both in London. Dr. Berger is board certified in internal medicine, hematology
and medical oncology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nitya Ray, PhD, Executive Vice-President, Head of Product
Development, Manufacturing and Supply Chain</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Nitya Ray has been our Executive Vice-President, Head of
Product Development, Manufacturing and Supply Chain since June 2017. Dr. Ray joins the Company from CytoDyn, Inc. where he was
Sr. Vice President of Manufacturing and CMC Team Leader. At CytoDyn Dr. Ray developed robust and cost effective manufacturing
processes for an antibody therapeutic drug candidate, currently in two Phase 3 clinical studies intended to treat and prevent
HIV infection. Dr. Ray led a successful regulatory meetings with the FDA while simultaneously developing strategies for process
development, scale-up, validation, commercial manufacturing, and supply chain to support potential commercialization of the CytoDyn&rsquo;s
HIV therapeutic drug candidate. Prior to CytoDyn, Dr. Ray spent 15 years at Progenics Pharmaceuticals, Inc., a radiopharmaceutical
therapeutic and diagnostic company, most recently as Senior Vice President, Manufacturing. At Progenics, Dr. Ray led the development
of scalable manufacturing processes and achieved order-of-magnitude cost reduction through improved productivity and scale. In
addition, Dr. Ray built process and product development teams for Progenics&rsquo; small molecule, biologics, and radiopharmaceuticals
that developed innovative processes for various phases of clinical development and commercial manufacturing. Dr. Ray supported
in-house cGMP biologics manufacturing for Phase 1&ndash;3 clinical development and managed relationships with Contract Development
and manufacturing Organizations (CDMO&rsquo;s) on a global basis. Dr. Ray also worked at Hoffman-La Roche with a focus on biopharmaceuticals
and Verax Corporation in roles of increasing responsibility. Dr. Ray has a Ph.D. in Biochemical Engineering and an M.S. in Chemical
and Biochemical Engineering from Rutgers University and a B.S. in Chemical Engineering from Jadavpur University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B>Anil
Kapur, Chief Commercial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Mr. Kapur joined Actinium in February 2018
from Bristol-Myers Squibb, where he was the Vice President, Head of Early Assets, Biomarkers &amp; External Innovation within
the Worldwide Oncology Commercialization organization and helped advance the company&rsquo;s leading Immuno-Oncology portfolio.
Prior to this position, he was the Vice President &amp; Global Head, Oncology Commercial Portfolio &amp; Product Strategy at Baxalta
and a member of the Oncology Leadership Team. In this role, Mr. Kapur also led the Joint Strategic Committees responsible for
advancing the early Immuno-Oncology partnerships with Symphogen and the allogeneic CAR-T partnership with Precision Bio-Sciences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Mr. Kapur built a distinguished career spanning
15 years at Johnson &amp; Johnson where in his last role, he served as the Vice President, Commercial Leader for the Hematology
Franchise with responsibility for the development and execution of global commercial strategy and launch plans for all Hematology
in-market, late-stage development, and early pipeline assets. He is credited with significantly shaping the clinical development
plans and successful launch and growth of multiple Oncology blockbuster products including IMBRUVICA<B>&reg;</B>, DARZALEX<B>&reg;</B>,
and VELCADE<B>&reg;</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">At J&amp;J, he led the IMBRUVICA&reg; Joint
Commercial Committee (JCC), established between J&amp;J and Pharmacyclics, and built and led the global team that launched DARZALEX&reg;,
the first biologic for Multiple Myeloma. Anil also held leadership roles of increasing complexity and responsibility in US Marketing,
US Regional Sales, and within the Asia-Pacific Regional Oncology organization covering 14 markets including Japan, China, Australia
and Korea.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Mr. Kapur has an MBA from the Fuqua School
of Business at Duke University, a MS in Industrial Engineering from Louisiana Tech University, and a Bachelor of Engineering from
the Birla Institute of Technology, India.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Dale L. Ludwig, Ph.D., Chief Scientific
Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Dr. Ludwig joined Actinium in January 2018.
Dr. Ludwig has worked for 20 years in oncology antibody drug discovery and development at Eli Lilly and Company and at ImClone
Systems, Inc., until its acquisition by Eli Lilly where he supported the development and successful launch of several biologic
oncology drugs including Erbitux&reg;, Cyramza<SUP>TM</SUP>, Portrazza&reg;, and Lartruvo<SUP>TM&nbsp;</SUP>as well as the clinical
advancement of 10 additional therapeutic antibodies. Most recently, Dr. Ludwig served Chief Scientific Officer/Vice President
of Oncology Discovery Research - Biologics Technology. In this role he was responsible for directing antibody discovery and development
for oncology biologics and contributed to key strategic and project advancement efforts. Dr. Ludwig was a member of the Oncology
Research Senior Leadership Team and directed the empowered antibody drug discovery programs that included collaborations with
Immunogen and Zymeworks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Prior to the acquisition of Imclone by Eli
Lilly and Company, Dr. Ludwig served as Head of Molecular &amp; Cellular Engineering at IMClone Systems Incorporated. In this
capacity, Dr. Ludwig served as core team leader for several IND filings and phase 1 advancements for novel antibodies. In addition,
he directed and oversaw the full spectrum of drug development including antibody discovery, screening, selection, engineering,
optimization, cloning and expression. He was also tasked with establishing meaningful preclinical collaborations with key academic
investigators and industry leaders. Post-acquisition he was the research representative to the ImClone-Lilly Transition Team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Before his work in the biotechnology industry,
Dr. Ludwig trained as a postdoctoral associate in the DNA Damage and Repair Group of the Los Alamos National Laboratory and as
a postdoctoral fellow in the Department of Molecular Genetics, Biochemistry and Microbiology at the University of Cincinnati College
of Medicine. Dr. Ludwig has a B.S. in biology with a concentration in microbiology from James Madison University and received
his Ph.D. in Microbiology from East Carolina University.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeffrey W. Chell, MD, Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Dr. Chell has been a director of the Company
since April 2018. Dr. Chell is also a member of our Audit Committee and Compensation Committee. He has been the Chief Executive
Officer Emeritus of the National Marrow Donor Program (NMDP) since 2017 having served as its CEO since 2000. Dr. Chell has led
the NMDP through transformational growth as its Be The Match Registry tripled to more than 12 million donors, the number of transplants
facilitated has grown five fold to over 6,400 annually, and revenue more than tripled to nearly $400 million per year. He is also
the co-founder and has served as Executive Director of the Center For International Blood &amp; Marrow Transplant Research since
2004, a leading research program in the field contributing over 70 research publications per year in peer-reviewed journals. &nbsp;Dr.
Chell also currently serves as chair of CLR Insurance, a captive insurance company domiciled in the Cayman Islands. From 2014
to 2016, Dr. Chell served as co-chair of Bone Marrow Donors Worldwide (BMDW) during its IT transformation project, improving revenues
and reducing costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Prior to joining the NMDP, he served as President,
Allina Medical Clinics, a 450 physician multi-specialty medical group from 1994 to 1999. Prior to that he practiced Internal Medicine
in Minneapolis and in the U.S. Air Force Medical Corps.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: left">Dr. Chell received his M.D. from
the University of Minnesota and his training in Internal Medicine at the University of Wisconsin, Madison. Dr. Chell is a diplomate
of the American Board of Internal Medicine, a member of the American Society of Hematology and a member of the American Society
of Blood and Marrow Transplantation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">He has received multiple honors including
the 2018 Public Service award of the American Society For Blood and Marrow Transplantation, 2017 Most Admired CEO by the Minneapolis/St.
Paul Business Journal, 2010 Healthcare Executive of the Year by the Minneapolis/St, Paul Business Journal, and the 2017 Bone Marrow
Foundation Service Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">That Dr. Chell has over 25 years of leadership
and executive experience in healthcare, that he has significant knowledge in the blood and marrow transplantation field and that
he has experience conducting business in the health sector, led us to conclude that Dr. Chell should serve as a director.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">David Nicholson, PhD, Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">David Nicholson has been a Director of the
Company since 2008. Dr. Nicholson is also a member of our Compensation Committee and Corporate Governance Committee. In August
2014, Dr. Nicholson joined Actavis plc and Forest Laboratories, Inc. as Senior Vice President, Actavis Global Brands R&amp;D.
From March 2012 to August 2014, Dr. Nicholson was on the Executive Committee of Bayer CropScience as Head of Research &amp; Development
responsible for the integration of the company&rsquo;s R&amp;D activities into one global organization. Dr.&nbsp;Nicholson graduated
in pharmacology, earning his B.Sc. from the University of Manchester (1975) and his Ph.D. from the University of Wales (1980).
Between 1978 and 1988, Dr. Nicholson worked in the pharmaceutical industry for the British company Beecham-W&uuml;lfing in Gronau,
Germany. The main emphasis of his activities as group leader in a multidisciplinary project group was the development of cardiovascular
drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">From 1988-2007, Dr. Nicholson held various
positions of increasing seniority in the UK, the Netherlands and the USA with Organon, a Business Unit of Akzo Nobel. Ultimately,
he became Executive Vice President, Research&nbsp;&amp;&nbsp;Development, and member of the Organon Executive Management Committee.
He implemented change programs, leading to maximizing effectiveness in research &amp; development, ensuring customer focus and
the establishment of a competitive pipeline of innovative drugs. In 2007, Dr. Nicholson transferred to Schering-Plough, Kenilworth,
New Jersey as Senior Vice President, responsible for Global Project Management and Drug Safety. From 2009 to December 2011, he
was Vice President Licensing and Knowledge Management at Merck in Rahway, New Jersey, reporting to the President of Merck R&amp;D.
As an integration team member, Dr. Nicholson played a role in the strategic mergers of Organon BioSciences, the human and animal
health business of Dutch chemical giant Akzo-Nobel, and Schering-Plough in 2007 as well as of Schering-Plough and Merck in 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">That Dr. Nicholson brings over 25 years of
pharmaceutical experience to our Board, having served in various pharmaceutical research and development executive-level positions
over the course of his career, and that Dr.&nbsp;Nicholson has developed significant management and leadership skills relating
to the pharmaceutical industry. and is well accustomed to interfacing with investors, analysts, auditors, outside advisors and
governmental officials, led us to conclude that Dr. Nicholson should serve as a director.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ajit S. Shetty, PhD, Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Shetty has been a Director of the Company since March,
2017. Dr. Shetty is also a member of our, Audit Committee, Compensation Committee, and Chairman of our Corporate Governance Committee.
Dr. Shetty joined Janssen Pharmaceutica, Inc. in 1976 ultimately rising to the position of President in 1986 where he led the
establishment of Janssen&rsquo;s business in the U.S. From 1999 to 2008 he was Managing Director of Janssen Pharmaceutica, during
this time the Janssen Group of companies&rsquo; global sales grew from $1 billion to $8 billion, and from 2004 until 2012 he was
Chairman of the Board of Directors. In Dr. Shetty&rsquo;s most recent role at Johnson &amp; Johnson he was head of Enterprise
Supply Chain, where he reported to the CEO and was responsible for the transformation and optimization of Johnson &amp; Johnson&rsquo;s
supply chain. Dr. Shetty earned a Ph.D. in Metallurgy and B.A. Natural Sciences from Trinity College, Cambridge University and
a Master of Business Administration from Carnegie Mellon University. Dr.&nbsp;Shetty has served as a member of Agile Therapeutics,
Inc.&rsquo;s board of directors since February 2016. In 2007, Dr. Shetty was bestowed the title of Baron by King Albert II of
Belgium for his exceptional merits. He is a member of the Board of Trustees of Carnegie Mellon University, serves on the Board
of Governors for GS1 (Global Standards) in Belgium and formerly served on the Corporate Advisory Board of the John Hopkins Carey
Business School. In 2016, Dr. Shetty was named as Chairperson of the Vlaams Instituut voor Biotechnologie (VIB), a Belgium based
life sciences research institute focused on translating scientific results into pharmaceutical, agricultural and industrial applications.
In addition, he was elected&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Manager of the Year&nbsp;</I></FONT>in
2004 in Flanders and received a Life-Time Achievement Award in India in 2010. We believe Dr.&nbsp;Shetty&rsquo;s qualifications
to sit on our Board include his extensive pharmaceutical experience leading commercial and supply chain operations and his significant
education background.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">That Dr. Shetty has 37 years of leadership and executive experience
in the pharmaceutical industry, that he has significant supply chain knowledge and that he has experience conducting business
in the U.S. and Europe, led us to conclude that Dr. Shetty should serve as a director.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Richard I. Steinhart, MBA, Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Steinhart has served as our Director and Chairman of the
Audit Committee since November 2013. Mr. Steinhart is also a member of our Corporate Governance Committee. Since October 2017
Mr. Steinhart has been the Chief Financial Officer of BioXcel Therapeutics, Inc. Since March 2014, Mr. Steinhart has been a Member
of the Board of Directors of Atossa Genetics, Inc. where he is Chairman of the Audit Committee and a member of the Compensation
Committee. Form October 2015 to April 2017, Mr. Steinhart was Vice President and CFO at Remedy Pharmaceuticals, a privately-held,
clinical stage pharmaceutical company. From January 2014 through September 2015 Mr. Steinhart had been a financial and strategic
consultant to the biotechnology and medical device industries. From April 2006 through December 2013, Mr. Steinhart was employed
by MELA Sciences, Inc., as their Vice President, Finance and Chief Financial Officer, Treasurer and Secretary. In April 2012,
Mr. Steinhart received a promotion to Sr. Vice President, Finance and Chief Financial Officer. From May 1992 until joining MELA
Sciences, Mr. Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture
capital, and management consulting firm focused on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures,
he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr. Steinhart&rsquo;s other experience includes
seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he
was a General Partner and Chief Financial Officer. Mr. Steinhart began his career at Price Waterhouse, now known as PricewaterhouseCoopers.
He holds BBA and MBA degrees from Pace University and is a Certified Public Accountant (inactive).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">That Mr. Steinhart brings nearly 30 years of financial experience
to our Board, having served in various financial executive-level positions over the course of his career, and that Mr. Steinhart
is a certified public accountant led us to conclude that Mr. Steinhart should serve as a director and chair the audit committee.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXECUTIVE COMPENSATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>The following discussion provides compensation
information pursuant to SEC rules and may contain statements regarding future individual and Company performance targets and goals.
These targets and goals are disclosed in the limited context of the Company&rsquo;s compensation programs and should not be understood
to be statements of management&rsquo;s expectations or estimates of results or other guidance. We specifically caution stockholders
not to apply these statements to other contexts.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Chief Executive Officer&rsquo;s Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In August 2018, we amended and restated Mr.
Seth&rsquo;s, our Chief Executive Officer, August 6, 2015 Executive Chairman Agreement (the &ldquo;Prior Agreement&rdquo;), as
amended. This new agreement (the &ldquo;Agreement&rdquo;) sets forth the terms related to his position as Chief Executive Officer
and Chairman of the Board of the Company while retaining and adapting material provisions of the Prior Agreement to that of his
role of Chief Executive Officer. Mr. Seth is currently paid an annual salary of $545,000. The Board reviews the amount of his
base salary and performance bonus, and determines the appropriate adjustments to each component of his compensation each calendar
year, and he may be entitled to a cash bonus in an amount to be determined by the board with a target of 50% of the base salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Chairman and CEO shall also be awarded
stock option and/or restricted stock grants at our Board&rsquo;s discretion. Mr. Seth&rsquo;s agreement includes severance benefits,
including in the event of a change of control of the Company, and to provide for immediate vesting of options in accordance with
our Amended and Restated 2013 Stock Plan. The term of the agreement is until February 21, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If the Company terminates the consulting
arrangement other than for cause or if Mr. Seth resigns for good reason, Mr. Seth shall be entitled to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt; text-align: left"></TD><TD STYLE="width: 24pt; text-align: left">(i)</TD><TD STYLE="text-align: left">a
                                         single lump sum payment equal to twenty-four (24) months of Mr. Seth&rsquo;s compensation
                                         (at the rate in effect as of the date of termination);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt; text-align: left"></TD><TD STYLE="width: 24pt; text-align: left">(ii)</TD><TD STYLE="text-align: left">continued
                                         health benefits for the 24-month period beginning on the date of termination; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt; text-align: left"></TD><TD STYLE="width: 24pt; text-align: left">(iii)</TD><TD STYLE="text-align: left">All
                                         outstanding equity awards granted to Mr. Seth under the Company&rsquo;s equity compensation
                                         plans shall become immediately vested and exercisable (as applicable) as of the date
                                         of such termination and the performance goals with respect to such outstanding performance
                                         awards, if any, will deemed satisfied at &ldquo;target&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If the Company terminates Mr. Seth&rsquo;s
consulting arrangement other than for cause or if Mr. Seth resigns for good reason, in any case during the 12-month period beginning
on the date of a change in control, Mr. Seth shall be entitled to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt; text-align: left"></TD><TD STYLE="width: 24pt; text-align: left">(i)</TD><TD STYLE="text-align: left">a
                                         single lump sum payment equal to thirty (30) months of Mr. Seth&rsquo;s compensation
                                         (at the rate in effect as of the date of termination);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt; text-align: left"></TD><TD STYLE="width: 24pt; text-align: left">(ii)</TD><TD STYLE="text-align: left">continued
                                         health benefits for the 30-month period beginning on the date of termination; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt; text-align: left"></TD><TD STYLE="width: 24pt; text-align: left">(iii)</TD><TD STYLE="text-align: left">All
                                         outstanding equity awards granted to Mr. Seth under the Company&rsquo;s equity compensation
                                         plans shall become immediately vested and exercisable (as applicable) as of the date
                                         of such termination and the performance goals with respect to such outstanding performance
                                         awards, if any, will deemed satisfied at &ldquo;target&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">Mr. Seth
is eligible to receive all standard benefits that Company employees are eligible to receive, including 20 vacation days and 5
sick days each year. The Company will provide Mr. Seth with standard business reimbursements (including mileage, supplies, long
distance calls), subject to Company policies and procedures and with appropriate receipts. &nbsp;In addition, he will receive
any other statutory benefits required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company also entered in a standard Company
indemnification agreement with Mr. Seth where the Company agreed to indemnify him in certain situations for his role as a Company
officer.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Principal Financial Officer Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In August 2018, we amended and restated Mr.
O&rsquo;Loughlin&rsquo;s, our Principal Financial Officer, September 17, 2015 Employment Agreement (the &ldquo;Prior Agreement&rdquo;),
as amended. This new agreement (the &ldquo;Employment Agreement&rdquo;) sets forth the terms related to his position as Principal
Financial Officer of the Company while retaining and adapting material provisions of the Prior Agreement to that of his role of
Principal Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Mr. O&rsquo;Loughlin&rsquo;s employment with
the Company is on an &ldquo;at will&rdquo; basis, meaning that either Mr. O&rsquo;Loughlin or the Company may terminate his employment
at any time for any reason or no reason, without further obligation or liability, except as provided in his Employment Agreement.
Pursuant to the Employment Agreement, Mr. O&rsquo;Loughlin is entitled to the following compensation and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left"><U>Salary and Bonus</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Board shall review the amount of his base salary and performance bonus, and shall determine the appropriate adjustments to each
component of his compensation each calendar year.&nbsp;&nbsp;Mr. O&rsquo;Loughlin&rsquo;s is entitled to participate in an executive
bonus program pursuant to which the Board may award him bonuses, based upon the achievement of written individual and corporate
objectives such as the Board shall determine. Upon the attainment of such performance objectives, in addition to base salary,
he shall be entitled to a cash bonus in an amount to be determined by the board with a target of 30% of the base salary. </FONT>Mr.
O&rsquo;Loughlin&rsquo;s current annual base salary is $285,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left"><U>Options</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">From time to
time the Board may grant him options or restricted stock to purchase common shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left"><U>Non-Solicitation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">Mr. O&rsquo;Loughlin
agreed that during the term of his employment with the Company, and for a period of 24 months following the cessation of employment
with the Company for any reason or no reason, he shall not directly or indirectly solicit, induce, recruit or encourage any of
our employees or consultants to terminate their relationship with us, or attempt any of the foregoing. For a period of 24 months
following cessation of employment with us for any reason or no reason, he shall not attempt to negatively influence any of our
clients or customers from purchasing our products or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left"><U>Benefits</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">Mr. O&rsquo;Loughlin
is eligible to receive all standard benefits that Company employees are eligible to receive, including 20 vacation days and 5
sick days each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt; text-align: left"></TD><TD STYLE="width: 24pt; text-align: left"><U>Indemnification</U></TD><TD STYLE="text-align: left"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: left">The Company also entered in a standard
Company indemnification agreement with Mr. OLoughlin, where the Company agreed to indemnify him in certain situations for his
role as a Company officer.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Chief Medical Officer Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In December 2016, the Company and Dr. Mark
S. Berger entered into an agreement (the &ldquo;Berger Employment Agreement&rdquo;), to employ Dr. Berger as our Chief Medical
Officer. <FONT STYLE="font-family: Times New Roman, Times, Serif">Dr. Berger&rsquo;s employment with the Company is on an &ldquo;at
will&rdquo; basis, meaning that either Dr,. Berger or the Company may terminate his employment at any time for any reason or no
reason, without further obligation or liability, except as provided in his Employment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to the Berger Employment Agreement,
Dr. Berger is entitled to the following compensation and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">Dr. Berger&rsquo;s
current annual base salary is $400,000 per year. Dr. Berger may be entitled to a cash bonus in an amount to be determined by the
Board with a target of 30% of the base salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">From time to
time the Board may grant him options or restricted stock to purchase common shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">Dr. Berger
is also eligible to participate in the Company&rsquo;s benefit plans that are generally provided for executive employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">Non-Competition. During
the term and for a period of two years thereafter, Dr. Berger shall not, either directly or indirectly, engage (as principal,
partner, employee, consultant, owner, independent contractor, advisor or otherwise, with or without compensation) in any business
that directly or indirectly is developing, or plans to develop, radioimmunotherapies for cancer or any therapy related to bone
marrow transplant (the &ldquo;Competing Business&rdquo;). Notwithstanding the foregoing, this does not prevent Dr. Berger from
being engaged or employed with business that has a Competing Business as part of its business, so long as he is not engaged or
involved in any way in the Competing Business at such business or enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: left">Non-Solicitation. The employment
agreement also contains a non-solicitation provision that provides that during the term of employment and for a period of 24 months
following the cessation of employment with the company shall not directly or indirectly solicit, induce, recruit or encourage
any of our employees or consultants to terminate their relationship with us, or attempt any of the foregoing, either for himself
or any other person or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: left">The Company also entered in a standard
Company indemnification agreement with Dr. Berger where the Company agreed to indemnify him in certain situations for his role
as a Company officer.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Executive Vice-President, Head of Product
Development, Manufacturing and Supply Chain Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In May 2017 the Company and Dr. Nitya Ray
entered into an Offer Letter (the &ldquo;Employment Agreement&rdquo;) pursuant to which Dr. Ray is the Company&rsquo;s Executive
Vice President, Head of Product Development, Manufacturing and Supply Chain. <FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.
Ray&rsquo;s employment with the Company is on an &ldquo;at will&rdquo; basis, meaning that either Dr. Ray or the Company may terminate
his employment at any time for any reason or no reason, without further obligation or liability, except as provided in his Employment
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to the Employment Agreement, Dr.
Ray is entitled to the following compensation and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">Dr. Ray&rsquo;s
current annual base salary is $330,850 per year, and Dr. Ray may be entitled to a cash bonus in an amount to be determined by
the Board with a target of 30% of the base salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">From time to
time the Board may grant him options or restricted stock to purchase common shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; text-align: left">Dr. Ray is also
eligible to participate in our benefit plans that are generally provided for executive employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0in; text-align: left">Non-Competition.
During the term and for a period of three years thereafter, Dr. Ray shall not, either directly or indirectly, engage (as principal,
partner, employee, consultant, owner, independent contractor, advisor or otherwise, with or without compensation) in any business
that directly or indirectly is developing, or plans to develop, radioimmunotherapies for cancer or any therapy related to bone
marrow transplant (the &ldquo;Competing Business&rdquo;). Notwithstanding the foregoing, this does not prevent Dr. Ray from being
engaged or employed with business that has a Competing Business as part of its business, so long as he is not engaged or involved
in any way in the Competing Business at such business or enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: left">Non-Solicitation. The Employment
Agreement also contains a non-solicitation provision that provides that during the term of employment and for a period of 24 months
following the cessation of employment with the company shall not directly or indirectly solicit, induce, recruit or encourage
any of the Company&rsquo;s employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing,
either for himself or any other person or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: left">The Company also entered in a standard
Company indemnification agreement with Dr. Ray where the Company agreed to indemnify him in certain situations for his role as
a Company officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Chief Scientific Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company and Dr. Dale Ludwig, effective
January 2018, entered into an Offer Letter (the &ldquo;Employment Agreement&rdquo;) pursuant to which Dr. Ludwig is the Company&rsquo;s
Chief Scientific Officer.&nbsp; Dr. Ludwig&rsquo;s employment with the Company is on an &ldquo;at will&rdquo; basis, meaning that
either Dr. Ludwig or the Company may terminate his employment at any time for any reason or no reason, without further obligation
or liability, except as provided in his Employment Agreement. Pursuant to the Employment Agreement. Dr. Ludwig is entitled to
the following compensation and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dr. Ludwig&rsquo;s
    current annual base salary is $325,000 per year, and Dr. Ludwig may be entitled to a cash bonus in an amount to be determined
    by the Board with a target of 30% of the base salary.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board granted to
    Dr. Ludwig an option to purchase 200,000 common shares of the Company at an exercise price equal to the closing price of the
    Company&rsquo;s common stock on January 8, 2018.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting Schedule. Twenty-eight
    percent (28%) of the initial options granted shall vest twelve months after the date of grant and two percent (2%) of the
    remainder shall vest each month thereafter until fully vested. The term of all options granted under this Agreement will be
    for 10 years from the date of grant, subject to Dr. Ludwig&rsquo; continuing service with the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Ludwig is also
    eligible to participate in the Company&rsquo;s benefit plans that are generally provided for executive employees.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 24px">&#9679;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Competition. During
    the term and for a period of three (3) years thereafter, he shall not, either directly or indirectly, engage (as principal,
    partner, employee, consultant, owner, independent contractor, advisor or otherwise, with or without compensation) in any business
    that directly or indirectly competes with the Company (the &ldquo;Competing Business&rdquo;). Notwithstanding the foregoing,
    this does not prevent Dr. Ludwig from being engaged or employed with a business that has a Competing Business as part of its
    business, so long as he is not engaged or involved in any way in the Competing Business at such business or enterprise.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">Non-Solicitation. The employment
agreement also contains a non-solicitation provision that provides that during the term of employment and for a period of 24 months
following the cessation of employment with the company Dr. Ludwig shall not directly or indirectly solicit, induce, recruit or
encourage any of the Company&rsquo;s employees or consultants to terminate their relationship with the Company, or attempt any
of the foregoing, either for himself or any other person or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px; text-align: left"></TD><TD STYLE="width: 24px; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification.
                                         The Company also entered in a standard Company indemnification agreement with Mr. Ludwig
                                         where the Company agreed to indemnify him in certain situations for his role as a Company
                                         officer.</FONT></TD>
</TR></TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Chief Commercial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">In January
2018 the Company and Anil Kapur entered into an Offer Letter (the &ldquo;Employment Agreement&rdquo;) pursuant to which Mr. Kapur
is the Company&rsquo;s Chief Commercial Officer.&nbsp;</FONT>Mr. Kapur<FONT STYLE="font-size: 10pt">&rsquo;s employment with the
Company is on an &ldquo;at will&rdquo; basis, me</FONT>aning that either Dr. Kapur <FONT STYLE="font-size: 10pt">or the Company
may terminate his employment at any time for any reason or no reason, without further obligation or liability, except as provided
in his Employment Agreement. Pursu</FONT>ant to the Employment Agreement. <FONT STYLE="font-size: 10pt">Pursuant to the Employment
Agreement, Mr. Kapur is entitled to the following compensation and benefits:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px; text-align: left">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                         Kapur&rsquo;s current annual base salary is $325,000 per year, and he may be entitled
                                         to a cash bonus in an amount to be determined by the board with a target of 35% of the
                                         base salary.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px; text-align: left">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         board granted to Mr. Kapur an option to purchase 475,000 common shares of the Company
                                         at an exercise price equal to the closing price of the Company&rsquo;s common stock on
                                         February 6, 2018.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px; text-align: left">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting
                                         Schedule. Twenty-eight percent (28%) of the initial options granted shall vest twelve
                                         months after the date of grant and two percent (2%) of the remainder shall vest each
                                         month thereafter until fully vested. The term of all options granted under this Agreement
                                         will be for 10 years from the date of grant, subject to Mr. Kapur&rsquo;s continuing
                                         service with the Company.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px; text-align: left">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                         Kapur is also eligible to participate in the Company&rsquo;s benefit plans that are generally
                                         provided for executive employees.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px; text-align: left">&#9679;</TD><TD>Non-Competition. During the term and for
                                         a period of three (3) years thereafter, Mr. Kapur shall not, either directly or indirectly,
                                         engage (as principal, partner, employee, consultant, owner, independent contractor, advisor
                                         or otherwise, with or without compensation) in any business that directly or indirectly
                                         is developing, or plans to develop, radioimmunotherapies for cancer or any therapy related
                                         to bone marrow transplant (the &ldquo;Competing Business&rdquo;). Notwithstanding the
                                         foregoing, this does not prevent him from being engaged or employed with a business that
                                         has a Competing Business as part of its business, so long as he is not engaged or involved
                                         in any way in the Competing Business at such business or enterprise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">Non-Solicitation. The employment
agreement also contains a non-solicitation provision that, among other things, provides that during the term of employment and
for a period of 24 months following the cessation of employment with the Company he shall not directly or indirectly solicit,
induce, recruit or encourage any of the Company&rsquo;s employees or consultants to terminate their relationship with the Company,
or attempt any of the foregoing, either for himself or any other person or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px; text-align: left">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification.
                                         The Company also entered in a standard Company indemnification agreement with Mr. Kapur
                                         where the Company agreed to indemnify him in certain situations for his role as a Company
                                         officer.</FONT></TD>
</TR></TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Summary Compensation Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following table provides information
regarding the compensation earned during the fiscal years ended December 31, 2017 and 2016 for our named executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name/Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus (1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option Awards</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other Compensation</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">Sandesh Seth (2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">306,250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">306,250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Kaushik J. Dave,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">577,942</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">110,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">244,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">932,708</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Former CEO (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">405,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">105,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">571,150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">98,593</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,179,743</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Mark Berger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">343,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">234,695</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">578,445</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dragan Cicic,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">389,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">45,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">73,430</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">507,555</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Former COO (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">280,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">71,394</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">391,894</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Nitya Ray</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">177,273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">198,896</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">376,169</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Steve O&rsquo;Loughlin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">235,152</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">97,907</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">383,059</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">192,610</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">71,394</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">274,004</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(1)&nbsp;The bonus disclosed in this column
relates to performance in the prior year, but was contingent upon board approval, and was paid in the year disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(2)&nbsp;Mr. Seth was appointed Chief
Executive Officer on June 5, 2017. Prior to this, Mr. Seth was Executive Chairman and was paid an annual consulting fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(3) Dr. Dave resigned from the company
on May 12, 2017. His 2017 salary includes a severance of $410,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(4) Dr. Cicic resigned from the company
on May 12, 2017. His 2017 salary includes a severance of $283,000.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As an &ldquo;emerging
growth company&rdquo; we are not required to provide information relating to the ratio of total compensation of our Chief Executive
Officer to the median of the annual total compensation of all of our employees, as required by the Investor Protection and Securities
Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Outstanding Equity Awards at Fiscal Year-End Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OUTSTANDING EQUITY AWARDS AT FISCAL
YEAR-END - 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table
sets forth all unexercised options and unvested restricted stock that have been awarded to our named executives by the Company
and were outstanding as of December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -4.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="16" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option Awards</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock Awards</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Name <BR> (a)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <BR> Securities
    <BR> Underlying <BR> Unexercised <BR> Options <BR> (#) <BR> (Exercisable) (b)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <BR> Securities
    <BR> Underlying <BR> Unexercised <BR> Options <BR> (#) <BR> (Unexercisable) (c)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity <BR> Incentive <BR>
    Plan <BR> Awards: <BR> Number of <BR> Securities <BR> Underlying <BR> Unexercised Unearned <BR> Options <BR> (#) <BR> (d)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option <BR> Exercise <BR>
    Price <BR> ($) <BR> (e)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option <BR> Expiration Date<BR> (f)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <BR> Shares or <BR>
    Units of <BR> Stock That <BR> Have Not <BR> Vested <BR> (#) <BR> (g)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Market <BR> Value of <BR>
    Shares <BR> or Units <BR> of Stock <BR> That <BR> Have Not <BR> Vested <BR> ($) <BR> (h)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity <BR> Incentive <BR>
    Plan <BR> Awards: <BR> Number <BR> of <BR> Unearned <BR> Shares, <BR> Units or <BR> Other <BR> Rights <BR> That <BR> Have
    Not <BR> Vested <BR> (#) <BR> (i)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity <BR> Incentive <BR>
    Plan <BR> Awards: <BR> Market or <BR> Payout <BR> Value of <BR> Unearned <BR> Shares, <BR> Units or <BR> Other <BR> Rights
    <BR> That <BR> Have Not <BR> Vested <BR> ($) <BR> (j)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 12%">Sandesh Seth</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">24,975</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">1.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center">8/30/2022</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,975</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/19/2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/23/2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2/15/2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4/15/2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">217,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">533,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3/14/2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Mark Berger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.04</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1/17/2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Nitya Ray</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6/13/2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Steve O&rsquo;Loughlin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/28/2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4/15/2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3/14/2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pension Benefits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the present time, we do not sponsor a qualified or non-qualified
defined benefit. Our Compensation Committee may elect to adopt qualified or non-qualified benefit plans in the future if it determines
that doing so is in our best interest.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Potential Payments Under Severance/Change in Control Arrangements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below sets forth potential payments payable to our
Chief Executive Officer in the event of a termination of employment or consulting arrangement, as applicable, under various circumstances.
For purposes of calculating the potential payments set forth in the table below, we have assumed that (i) the date of termination
was September 28, 2018 and (ii) the stock price was $0.7415, which was the closing market price of our common stock on September
28, 2018, the last business day of the third quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Termination of Employment
    Other Than for Cause or Resignation for Good Reason (Not in Connection with a Change in Control).<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Termination Following a Change
    in Control without Cause or Executive Resigns with Good Reason<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Sandesh Seth</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt; padding-bottom: 1.5pt">Cash Payment</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 1.5pt solid">1,650,000</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 1.5pt solid">2,062,500</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total Cash and
    Benefits</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,650,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,062,500</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The term &ldquo;change of control&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt">(i)</TD><TD>the direct or indirect sale, transfer, conveyance or other disposition
                                         (other than by way of merger or consolidation), in one or a series of related transactions,
                                         of all or substantially all of the properties or assets of the Company and its subsidiaries,
                                         taken as a whole, to any &ldquo;Person&rdquo; (as that term is used in Section 13(d)(3)
                                         of the Exchange Act) that is not an Affiliate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt">(ii)</TD><TD>the &ldquo;Incumbent Directors&rdquo; (meaning those individuals
                                         who, on date the Plan was adopted by the Board (the &ldquo;Effective Date&rdquo;), constitute
                                         the Board, provided that any individual becoming a Director subsequent to the Effective
                                         Date whose election or nomination for election to the Board was approved by a vote of
                                         at least two-thirds of the Incumbent Directors then on the Board (either by a specific
                                         vote or by approval of the proxy statement of the Company in which such person is named
                                         as a nominee for Director without objection to such nomination) shall be an Incumbent
                                         Director, and further provided that no individual initially elected or nominated as a
                                         director of the Company as a result of an actual or threatened election contest with
                                         respect to Directors or as a result of any other actual or threatened solicitation of
                                         proxies by or on behalf of any person other than the Board shall be an Incumbent Director)
                                         cease for any reason to constitute at least a majority of the Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt">(iii)</TD><TD>the date which is 10 business days prior to the consummation
                                         of a complete liquidation or dissolution of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt">(iv)</TD><TD>the acquisition by any Person of &ldquo;Beneficial Ownership&rdquo;
                                         (within the meaning of Rule 13d-3 and Rule&nbsp;13d-5 under the Exchange Act, except
                                         that in calculating the Beneficial Ownership of any particular Person, such Person shall
                                         be deemed to have beneficial ownership of all securities that such Person has the right
                                         to acquire by conversion or exercise of other securities, whether such right is currently
                                         exercisable or is exercisable only after the passage of time) of 50% or more (on a fully
                                         diluted basis) of either (A) the then outstanding shares of Common Stock of the Company,
                                         taking into account as outstanding for this purpose such Common Stock issuable upon the
                                         exercise of options or warrants, the conversion of convertible stock or debt, and the
                                         exercise of any similar right to acquire such Common Stock (the &ldquo;Outstanding Company
                                         Common Stock&rdquo;) or (B) the combined voting power of the then outstanding voting
                                         securities of the Company entitled to vote generally in the election of directors (the
                                         &ldquo;Outstanding Company Voting Securities&rdquo;); provided, however, that for purposes
                                         of this Plan, the following acquisitions shall not constitute a Change of Control: (I)
                                         any acquisition by the Company or any Affiliate, (II) any acquisition by any employee
                                         benefit plan sponsored or maintained by the Company or any Affiliate, (III) any acquisition
                                         which complies with clauses, (A), (B) and (C) of subsection (v)&nbsp;of this definition,
                                         or (IV) in respect of an Award held by a particular Participant, any acquisition by the
                                         Participant or any group of persons including the Participant (or any entity controlled
                                         by the Participant or any group of persons including the Participant); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt">(v)</TD><TD>the consummation of a reorganization, merger, consolidation,
                                         statutory share exchange or similar form of corporate transaction involving the Company
                                         that requires the approval of the Company&rsquo;s shareholders, whether for such transaction
                                         or the issuance of securities in the transaction (a &ldquo;Business Combination&rdquo;),
                                         unless immediately following such Business Combination: (A) more than 50% of the total
                                         voting power of (I) the entity resulting from such Business Combination (the &ldquo;Surviving
                                         Company&rdquo;), or (II) if applicable, the ultimate parent entity that directly or indirectly
                                         has beneficial ownership of sufficient voting securities eligible to elect a majority
                                         of the members of the board of directors (or the analogous governing body) of the Surviving
                                         Company (the &ldquo;Parent Company&rdquo;), is represented by the Outstanding Company
                                         Voting Securities that were outstanding immediately prior to such Business Combination
                                         (or, if applicable, is represented by shares into which the Outstanding Company Voting
                                         Securities were converted pursuant to such Business Combination), and such voting power
                                         among the holders thereof is in substantially the same proportion as the voting power
                                         of the Outstanding Company Voting Securities among the holders thereof immediately prior
                                         to the Business Combination; (B) no Person (other than any employee benefit plan sponsored
                                         or maintained by the Surviving Company or the Parent Company) is or becomes the Beneficial
                                         Owner, directly or indirectly, of 50% or more of the total voting power of the outstanding
                                         voting securities eligible to elect members of the board of directors of the Parent Company
                                         (or the analogous governing body) (or, if there is no Parent Company, the Surviving Company);
                                         and (C) at least a majority of the members of the board of directors (or the analogous
                                         governing body) of the Parent Company (or, if there is no Parent Company, the Surviving
                                         Company) following the consummation of the Business Combination were Board members at
                                         the time of the Board&rsquo;s approval of the execution of the initial agreement providing
                                         for such Business Combination</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The cash component (as opposed to option accelerations) of
any change of control payment would be structured as a one-time cash severance payment.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PRINCIPAL STOCKHOLDERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table shows the beneficial ownership of our Common
Stock as of October 23, 2018 held by (i) each person known to us to be the beneficial owner of more than five percent (5%) of
any class of our shares; (ii) each director; (iii) each executive officer; and (iv) all directors and executive officers as a
group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficial ownership is determined in accordance with the
rules of the SEC, and generally includes voting power and/or investment power with respect to the securities held. Shares of
Common Stock subject to options and warrants currently exercisable or which may become exercisable within 60 days of October
23, 2018, are deemed outstanding and beneficially owned by the person holding such options or warrants for purposes of
computing the number of shares and percentage beneficially owned by such person, but are not deemed outstanding for purposes
of computing the percentage beneficially owned by any other person. Except as indicated in the footnotes to this table, the
persons or entities named have sole voting and investment power with respect to all shares of our Common Stock shown as
beneficially owned by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise indicated, the principal address of each of
the persons below is c/o Actinium Pharmaceuticals, Inc., 275 Madison Ave, 7<SUP>th</SUP> floor, New York, NY 10016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Executive Officers and Directors</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Number of Shares of Common
    Stock and Preferred Stock Beneficially Owned</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><P STYLE="border-bottom: Black 0.5pt solid; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Percentage
                                         of Ownership<SUP>(a)</SUP></P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Sandesh Seth</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">1,611,147</TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">1.4</TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Steve O&rsquo;Loughlin</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">230,500</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><SUP>(2)</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">*</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Mark Berger, M.D.</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">220,500</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><SUP>(3)</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">*</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Nitya G. Ray, Ph.D.</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">137,500</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><SUP>(4)</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">*</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Anil Kapur</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">40,000</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><SUP>(5)</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">*</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Dale Ludwig, Ph.D.</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">-</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><SUP>(6)</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">*</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Jeffrey W. Chell, M.D.</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">7,500</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><SUP>(7)</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">*</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">David Nicholson, Ph.D.</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">219,900</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><SUP>(8)</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">*</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Ajit S. Shetty, Ph.D.</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">64,730</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><SUP>(9)</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">*</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Richard I. Steinhart</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">179,447</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><SUP>(10)</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">*</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">All Directors and Officers as a Group
    (10 persons)</TD><TD STYLE="font-weight: bold; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; font-family: Times New Roman, Times, Serif">2,711,224</TD><TD STYLE="font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></TD><TD STYLE="font-weight: bold; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; font-family: Times New Roman, Times, Serif">2.3</TD><TD STYLE="font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">All other 5% holders</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">Anson Funds Management LP, Anson Management GP LLC, Mr.&nbsp;Bruce&nbsp;R. Winson, Anson Advisors
    Inc., Mr.&nbsp;Amin Nathoo and Mr.&nbsp;Moez Kassam <BR>5950 Berkshire Lane, Suite 210 <BR>Dallas, Texas 75225</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">6,000,000</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">5.5</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">%</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt">*</TD><TD>less than 1%</TD></TR></TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based&nbsp;on 114,698,044 shares of Common Stock outstanding as of October 23, 2018</FONT></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
                                         to purchase an aggregate of 64,747 shares of Common Stock of the Company at an exercise
                                         price of $0.784 per share, exercisable on a cashless basis, warrants to purchase an aggregate
                                         of 99,617 of Common Stock of the Company at an exercise price of $0.784 per share, exercisable
                                         on a cashless basis issued to Amrosan, LLC, a partnership in which the majority member
                                         interest is owned by the family of Mr. Seth, and warrants to purchase 57,212 shares of
                                         Common Stock at an exercise price of $2.34 per share. Excludes warrants to purchase an
                                         aggregate of 375,556 shares of Common Stock of the Company at par value per share, exercisable
                                         on a cashless basis issued to Amrosan, LLC as the warrants are not exercisable upon less
                                         than 90 days&rsquo; notice. The holder may waive the 90-day exercise notice requirement
                                         by giving 65 days prior notice of such waiver. Excludes 353,023 warrants issued to Carnegie
                                         Hill Asset Partners and irrevocable trust linked to Mr. Seth&rsquo;s family and 721,068
                                         warrants issued to Bioche Asset Management, LLC, a partnership in which the majority
                                         member interest is owned by the family of Mr. Seth whose terms are the same as those
                                         issued to Amrosan LLC. On August 30, 2012 and December 12, 2012, Mr. Seth was granted
                                         options to purchase an aggregate of 49,950 shares of Common Stock at an exercise price
                                         of $1.50 per share. On September 13, 2014, Mr. Seth was granted an option to purchase
                                         280,000 shares with an exercise price of $6.13 per share. On February 18, 2015, Mr. Seth
                                         was granted an option to purchase 150,000 shares with an exercise price of $3.58 per
                                         share. On April 15, 2016, Mr. Seth was granted an option to purchase 500,000 shares at
                                         an exercise price of $1.99 per share. On March 14, 2017, Mr. Seth was granted options
                                         to purchase an aggregate of 750,000 shares of&nbsp;Common Stock at an exercise price
                                         of $1.39 per share. On July 13, 2018, Mr. Seth was granted an option to purchase 1,000,000
                                         shares at an exercise price of $0.7829 per share. All options are subject to vesting.
                                         Within 60 days of October 23, 2018, 1,260,950 options will have vested. Includes 133,333
                                         shares of Common Stock, 13,125 March 2018 Series A Warrants and 39,375 March 2018 Series
                                         B Warrants.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         October 1, 2015, Mr. O&rsquo;Loughlin was granted an option to purchase 100,000 shares
                                         with an exercise price of $1.79&nbsp;per&nbsp;share. On April 14, 2016, Mr. O&rsquo;Loughlin
                                         was granted an option to purchase 50,000 shares at an exercise price of $1.99 per share.
                                         On March 14, 2017, Mr. O&rsquo;Loughlin was granted options to purchase an aggregate
                                         of 100,000 shares at an exercise price of $1.39 per share. On July 13, 2018, Mr. O&rsquo;Loughlin
                                         was granted an option to purchase 265,000 shares at an exercise price of $0.7829 per
                                         share. All options are subject to vesting. Within 60&nbsp;days of October 23, 2018, 195,000
                                         options will have vested. Includes 25,500 shares of Common Stock, 2,500 March 2018 Series
                                         A Warrants and 7,500 March 2018 Series B Warrants.</FONT></TD>
</TR></TABLE>






<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         January 17, 2017, Dr. Berger was granted an option to purchase 325,000 shares with an
                                         exercise price of $1.04 per share. On July 13, 2018, Dr. Berger was granted an option
                                         to purchase 250,000 shares at an exercise price of $0.7829. All options are subject to
                                         vesting. Within 60 days of October 23, 2018, 187,500 shares will have vested. Includes
                                         19,000 shares of Common Stock, 3,500 March 2018 Series A Warrants and 10,500 March 2018
                                         Series B Warrants.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         June 15, 2017, Dr. Ray was granted an option to purchase 250,000 shares with an exercise
                                         price of $1.15 per share. On July 13, 2018, Dr. Ray was granted an option to purchase
                                         75,000 shares with an exercise price of $0.7829 per share. All options are subject to
                                         vesting. Within 60 days of October 23, 2018, 107,500 shares will have vested. Includes
                                         20,000 shares of Common Stock, 2,500 March 2018 Series A Warrants and 7,500 March 2018
                                         Series B Warrants.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         February 6, 2018, Mr. Kapur was granted an option to purchase 475,000 shares of Common
                                         Stock at an exercise price of $0.64 per share. It is not exercisable with 60 days of
                                         October 23, 2018. Includes 40,000 shares of Common Stock.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         January 8, 2018, Dr. Ludwig was granted an option to purchase 200,000 shares of Common
                                         Stock at an exercise price of $0.72 per share. It is not exercisable within 60 days of
                                         October 23, 2018.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         April 27, 2018, Dr. Chell was granted an option to purchase 75,000 shares of Common Stock
                                         at an exercise price of $0.347 per share. On July 13, 2018, Dr. Chell was granted an
                                         option to purchase 75,000 shares at an exercise price of $0.7829 per share. Within 60
                                         days of October 23, 2018, 7,500 shares will have vested.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         February 12, 2012, Dr. Nicholson was granted an option to purchase 49,950 shares of Common
                                         Stock at an exercise price of $0.784 per share and on August 12, 2012 and December 19,
                                         2012, Dr.&nbsp;Nicholson was granted options to purchase an aggregate of 49,950 shares
                                         at an exercise price of $1.50 per share. On February 18, 2015, Dr. Nicholson was granted
                                         an option to purchase 25,000 shares with an exercise price of $3.58 per share. On April
                                         15, 2016, Dr. Nicholson was granted an option to purchase 75,000 shares at an exercise
                                         price of $1.99 per share. On March 14, 2017, Dr. Nicholson was granted an option to purchase
                                         75,000 shares at an exercise price of $1.39 per share. On July 13, 2018, Dr. Nicholson
                                         was granted an option to purchase 75,000 shares at an exercise price of $0.7829 per share.
                                         All options are subject to vesting. Within 60 days of October 23, 2018, 209,900 options
                                         will have vested. Includes 10,000 shares of Common Stock.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         March 28, 2017, Dr. Shetty was granted an option to purchase 75,000 shares of Common
                                         Stock with an exercise price of $1.58 per share. On July 13, 2018, Dr. Shetty was granted
                                         an option to purchase 75,000 shares at an exercise price of $0.7829 per share. Within
                                         60 days of October 23, 2018, 42,000 shares will have vested. Includes 22,730 shares of
                                         Common Stock.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10)</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         December 16, 2013 Mr. Steinhart was granted an option to purchase 49,950 shares of Common
                                         Stock at an exercise price of $6.70 per share. On February 18, 2015, Mr. Steinhart was
                                         granted an option to purchase 25,000 shares at an exercise price of $3.58 per share.
                                         On April 15, 2016, Mr. Steinhart was granted an option to purchase 75,000 shares at an
                                         exercise price of $1.99 per share. On March 14, 2017, Mr. Steinhart was granted an option
                                         to purchase 75,000 shares at an exercise price of $1.39 per share. On July 13, 2018,
                                         Mr Steinhart was granted an option to purchase 75,000 shares at an exercise price of
                                         $0.7829 per share. All options are subject to vesting. Within 60 days of October 23,
                                         2018, 162,947 options will have vested. Includes 9,500 shares of Common Stock, 1,750
                                         March 2018 Series A Warrants and 5,250 March 2018 Series B Warrants.</FONT></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following sets forth a summary of transactions, or any
currently proposed transaction, in which the Company was to be a participant and the amount involved exceeded or exceeds $120,000
and in which any related person had or will have a direct or indirect material interest (other than compensation described under
&ldquo;Executive Compensation&rdquo;). We believe the terms obtained or consideration that we paid or received, as applicable,
in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received,
as applicable, in arm&rsquo;s-length transactions.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Transactions with Related Persons</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 11, 2015, the Company completed a public offering
of common shares and warrants, representing gross proceeds of approximately $20.0 million and a net amount of approximately $18.5
million after deducting the underwriting discount and the other offering expenses. Laidlaw &amp; Company (UK) Ltd., of which Mr.
Seth, Chairman and CEO was the former Head of Healthcare Investment Banking, acted as sole book-running manager for the offering.
The offering was made pursuant to a shelf registration statement (File No. 333-194768) previously filed with and declared effective
by the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In an agreement dated March 11, 2015 and effective August 11,
2014, Mr. Seth entered into a consulting agreement with the Company to serve as Executive Chairman of the Company. The agreement
was amended and restated on August 6, 2015. This agreement was later amended and restated in August 2018, to take in account Mr.
Seth&rsquo;s position as Chairman and CEO of the Company. Mr. Seth is also entitled to participate in a Company bonus program,
which shall be established by the Board pursuant to which the Board shall award bonuses to the consultant, based upon the achievement
of written individual and corporate objectives such as the Board shall determine..</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-Competition Agreements and Indemnity Agreements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our executive officers have signed non-competition agreements,
which provide that all inventions become the immediate property of our Company and require invention assignments. The agreements
provide that the executive officers will hold proprietary information in the strictest confidence and not use the confidential
information for any purpose not expressly authorized by us. Our executive officers and directors have also entered into indemnity
agreements with us.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">MATTERS TO BE CONSIDERED AT THE ANNUAL
MEETING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROPOSAL 1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ELECTION OF DIRECTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nominee for the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s Certificate of Incorporation (the &ldquo;Charter&rdquo;)
established a classified Board of Directors with three classes of directors. Currently there are four directors divided into three
classes designated Class I, Class II, and Class III. The term of office for each Class I director expires at the 2020 Annual Meeting;
the term of office for each Class II director expires at the 2018 annual meeting of shareholders; and the term of office for each
Class III director expires at the 2019 annual meeting of shareholders. Pursuant to the Charter, the directors due for election
at the 2018 Annual meeting are Jeffrey W. Chell and Sandesh Seth (Class II).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors proposes the election of the following
individuals to serve on its Board of Directors for a term that continues pursuant to the director terms outlined below or until
his successor is duly elected. The nominees are current board members Dr. Chell and Mr. Seth. In the event the nominee is unable
or unwilling to serve as a director, the individual named as proxy on the proxy card will vote the shares that he represents for
election of such other person or persons as the Board of Directors may recommend. The Board of Directors has no reason to believe
that the nominee will be unable or unwilling to serve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is information about the nominee, including biographical
data for at least the last five years. Should the nominees become unavailable to accept nomination or election as a director,
the individual named as proxy on the enclosed proxy card will vote the shares that he represents for the election of such other
person as the Board of Directors may recommend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors is responsible for supervision of the
overall affairs of the company. Following the annual meeting, the Board of Directors will consist of four directors. The term
of each director is set forth below or until their successors are duly elected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 30%; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Director</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 23%; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Class</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 45%; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Term
    (from 2018 Annual Meeting, if elected)</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: center">David Nicholson</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Class I</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">2 years</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: center">Richard I Steinhart</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Class I</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">2 years</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: center">Jeffrey W. Chell</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Class II</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">3 years</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: center">Sandesh Seth</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Class II</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">3 years</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: center">Ajit S. Shetty</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">Class III</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">1 years</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Directors elected at each annual meeting shall be elected for
a 3-year term. The name of the nominee for our Board of Directors and information about him is set forth below. There are no family
relationships between any of the executive officers and directors.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeffrey W. Chell, MD, Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Dr. Chell has been a director of the Company
since April 2018. Dr. Chell is also a member of our Audit Committee and Compensation Committee. He has been the Chief Executive
Officer Emeritus of the National Marrow Donor Program (NMDP) since 2017, having served as its CEO since 2000. Dr. Chell has led
the NMDP through transformational growth as its Be The Match Registry tripled to more than 12 million donors, the number of transplants
facilitated has grown fivefold to over 6,400 annually, and revenue more than tripled to nearly $400 million per year. He is also
the co-founder and has served as Executive Director of the Center For International Blood &amp; Marrow Transplant Research since
2004, a leading research program in the field, contributing over 70 research publications per year in peer-reviewed journals.
Dr. Chell also currently serves as chair of CLR Insurance, a captive insurance company domiciled in the Cayman Islands. From 2014
to 2016, Dr. Chell served as co-chair of Bone Marrow Donors Worldwide (BMDW) during its IT transformation project, improving revenues
and reducing costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Prior to joining the NMDP, he served as
President, Allina Medical Clinics, a 450 physician multi-specialty medical group from 1994 to 1999. Prior to that he practiced
Internal Medicine in Minneapolis and in the U.S. Air Force Medical Corps.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: left">Dr. Chell received his M.D.
from the University of Minnesota and his training in Internal Medicine at the University of Wisconsin, Madison. Dr. Chell is a
diplomate of the American Board of Internal Medicine, a member of the American Society of Hematology and a member of the American
Society of Blood and Marrow Transplantation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">He has received multiple honors including
the 2018 Public Service award of the American Society For Blood and Marrow Transplantation, 2017 Most Admired CEO by the Minneapolis/St.
Paul Business Journal, 2010 Healthcare Executive of the Year by the Minneapolis/St, Paul Business Journal, and the 2017 Bone Marrow
Foundation Service Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">That Dr. Chell has over 25 years of leadership
and executive experience in healthcare, that he has significant knowledge in the blood and marrow transplantation field and that
he has experience conducting business in the health sector, led us to conclude that Dr. Chell should serve as a director.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sandesh Seth, MS, MBA, Chairman and CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Sandesh Seth has been our Chief Executive Officer since
June 2017. Mr. Seth has been a Director since March 2012, our Chairman of the Board since October 2013, and served as Executive
Chairman from August 2014 to June 2017. Mr. Seth was affiliated with Laidlaw &amp; Co. (UK) Ltd., a healthcare focused, investment
banking and wealth management firm where he was Head of Healthcare Investment Banking. Mr. Seth is the Chairman of the Board of
Relmada Therapeutics, Inc., a publicly listed, specialty pharmaceuticals company focused on pain therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Seth has over 25 years of experience in investment banking
(Cowen &amp; Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharma industry (Pfizer, Warner-Lambert,
SmithKline in strategic planning, business development and R&amp;D project management). Mr. Seth has an MBA in Finance from New
York University; an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry
from Bombay University. He has published several scientific articles and was awarded the University Regents Award for Research
Excellence at the University of Oklahoma. Mr. Seth was designated as Regulatory Affairs Certified (R.A.C.) by the Regulatory Affairs
Professionals Society which signifies proficiency with U.S. FDA regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">That Mr. Seth has served in various business executive-level
positions over the course of his career, has significant investment banking experience, has developed significant management and
leadership skills and is well accustomed to interfacing with investors, analysts, auditors, C-level executives, and outside advisors,
led us to conclude that Mr. Seth should serve as a director.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vote Required</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Directors are elected by a plurality of the votes cast in person
or by proxy at the annual meeting and entitled to vote on the election of directors. &ldquo;Plurality&rdquo; means that the nominees
receiving the greatest number of affirmative votes will be elected as directors, up to the number of directors to be chosen at
the meeting. Broker non-votes will not affect the outcome of the election of directors because brokers do not have discretion
to cast votes on this proposal without instruction from the beneficial owner of the shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>THE BOARD OF DIRECTORS RECOMMENDS
A VOTE &ldquo;FOR&rdquo; ELECTION OF</I><BR>
<I>THE DIRECTOR NOMINEES</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROPOSAL 2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RATIFICATION OF THE APPOINTMENT OF
MARCUM LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The audit committee has appointed Marcum LLP as our independent
registered public accounting firm to audit the consolidated financial statements of Actinium Pharmaceuticals, Inc. and its subsidiaries
for the fiscal year ending December 31, 2018. Representatives of Marcum LLP will be present at the annual meeting and will have
an opportunity to make a statement or to respond to appropriate questions from stockholders. Although stockholder ratification
of the appointment of our independent auditor is not required by our Bylaws or otherwise, we are submitting the selection of Marcum
LLP to our stockholders for ratification to permit stockholders to participate in this important corporate decision. If not ratified,
the audit committee will reconsider the selection, although the audit committee will not be required to select a different independent
auditor for our company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vote Required</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ratification of the appointment of Marcum LLP as our independent
registered public accounting firm will be approved if there is a quorum and the votes cast &ldquo;FOR&rdquo; the proposal exceeds
those cast against the proposal.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>THE BOARD OF DIRECTORS RECOMMENDS
A VOTE &ldquo;FOR&rdquo; RATIFICATION OF MARCUM LLP AS THE INDEPENDENT REGISTERED ACCOUNTING FIRM OF ACTINIUM PHARMACEUTICALS,
INC.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>PROPOSAL 3</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APPROVAL OF AMENDMENT OF THE 2013
AMENDED AND RESTATED STOCK PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE
PLAN BY 5 MILLION SHARES FROM 17,750,000 TO 22,750,000 TO SUPPORT PLANNED HIRING EFFORTS AS THE COMPANY GROWS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Description of Proposed Amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 28, 2018, the Board unanimously approved an amendment
(the &ldquo;Plan Amendment&rdquo;) to the Company&rsquo;s 2013 Amended and Restated Stock Plan, as amended (the &ldquo;Plan&rdquo;),
subject to stockholder approval, to increase the number of shares of Common Stock authorized for issuance under the Plan by 5
million shares from 17,750,000 to 22,750,000 to support planned hiring efforts as the company grows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The full text of the proposed Plan Amendment is set out in
<U>Annex A</U> to this Proxy Statement. The text of the proposed Plan Amendment is subject to modification to include such changes
as the Board deems necessary and advisable to affect the increase in the number of shares of Common Stock reserved and available
for issuance under the Plan. Stockholders are being asked to approve the Plan Amendment.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vote Required and Recommendation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The approval of the Plan Amendment will be made upon the affirmative
vote of the majority of shares cast on the proposal. Abstentions and broker non-votes will have no direct effect on the outcome
of this proposal. If the proposal is not approved by the stockholders, the Plan Amendment will not be effective and the proposal
will not be implemented.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reasons for the Plan Amendment</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Existing Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Plan is currently comprised of 17,750,000 shares of Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The purpose of the Plan is to provide a means through which
we may attract and retain key personnel and to provide a means whereby directors, officers, managers, employees, consultants and
advisors (and prospective directors, officers, managers, employees, consultants and advisors) can acquire and maintain an equity
interest in our Company, or be paid incentive compensation, which may (but need not) be measured by reference to the value of
common shares, thereby strengthening their commitment to the welfare of our Company and aligning their interests with those of
our stockholders.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">Increase in Size of Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of September 30, 2018, outstanding awards (consisting of
options to purchase shares of common stock) issued under the Plan totaled 7,667,271 shares of common stock, leaving 9,481,065
shares available for issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board determined to increase the number of shares of common
stock reserved and available for issuance under the Plan by 5 million shares because it believes that the current number is insufficient
for the purposes of the Plan for future issuances. The market for quality personnel is competitive, and the ability to obtain
and retain competent personnel is of great importance to our business operations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effects of the Plan Amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the Plan Amendment, there will be an increase
in the total number of shares of common stock reserved for issuance under the Plan. This will provide us with the ability to grant
more awards than are currently available under the Plan to eligible recipients including employees, directors, consultants and
advisors. The issuance in the future of awards under the Plan consisting of full value awards and options to purchase shares of
common stock may have the effect of diluting the earnings per share and book value per share, as well as the stock ownership and
voting rights, of the holders of the currently outstanding shares of common stock. The effective increase in the number of authorized
but unissued shares of common stock which may be issued as awards under the Plan may be construed as having an anti-takeover effect
by permitting the issuance of shares to purchasers who might oppose a hostile takeover bid or oppose any efforts to amend or repeal
certain provisions of our Certificate of Incorporation or Bylaws. Holders of our common stock have no preemptive or other subscription
rights. There are no other material differences to the Plan as a result of the Plan Amendment.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Material Terms of the Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>Purpose<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></I> The
purposes of the 2013 Stock Plan, as amended, are to attract and retain the best available personnel for positions of substantial
responsibility, to provide additional incentive to employees, directors and consultants and to promote the success of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Administration.</I></FONT> The
Plan shall be administered by our Board or a committee, or a combination thereof, as determined by our Board. The Plan may be
administered by different administrative bodies with respect to different classes of participants and, if permitted by the applicable
laws, the board may authorize one or more officers to make awards under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Powers
of the Administrator.</I></FONT> The specific duties delegated by our Board to the committee, the administrator shall have
the authority, in its discretion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">to determine the fair market value
of the common stock, provided that such determination shall be applied consistently with respect to participants under the Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">to select the employees, directors
and consultants to whom Plan awards may from time to time be granted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">to determine whether and to what
extent Plan awards are granted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">to determine the number of shares
of common stock to be covered by each award granted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">to approve the form(s) of agreement(s)
used under the Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">to determine the terms and conditions,
not inconsistent with the terms of the Plan, of any award granted hereunder, which terms and conditions include but are not limited
to the exercise or purchase price, the time or times when awards may be exercised (which may be based on performance criteria),
any vesting acceleration or waiver of forfeiture restrictions, any pro-rata adjustment to vesting as a result of a Participant&rsquo;s
transitioning from full-to part-time services (or vice versa), and any restriction or limitation regarding any option, optioned
stock, stock purchase right or restricted stock, based in each case on such factors as the Administrator, in its sole discretion,
shall determine;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">to adjust the vesting of an option
held by an employee, director or consultant as a result of a change in the terms or conditions under which such person is providing
services to us;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">to construe and interpret the
terms of the Plan and awards granted under the Plan, which constructions, interpretations and decisions shall be final and binding
on all participants; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">in order to fulfill the purposes
of the Plan and without amending the Plan, to modify grants of options or stock purchase rights to participants who are foreign
nationals or employed outside of the United States in order to recognize differences in local law, tax policies or customs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Eligibility.</I></FONT> Nonstatutory
Stock Options and Stock Purchase Rights may be granted to employees, directors and consultants. Incentive Stock Options may be
granted only to employees, provided that employees of affiliates shall not be eligible to receive Incentive Stock Options. Each
option shall be designated in the option agreement as either an Incentive Stock Option or a Nonstatutory Stock Option. To the
extent that the aggregate fair market value of shares with respect to which options designated as Incentive Stock Options are
exercisable for the first time by any optionee during any calendar year exceeds $100,000, such excess options shall be treated
as Nonstatutory Stock Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Term
of Plan.</I></FONT> The Plan shall become effective upon its adoption by our Board. It shall continue in effect for a term
of ten (10) years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Term
of Option.</I></FONT> The term of each option shall be the term stated in the option agreement; provided that the term shall
be no more than ten years from the date of grant thereof or such shorter term as may be provided in the option agreement and provided
further that, in the case of an incentive stock option granted to a person who at the time of such grant is a holder of ten percent
or more of our outstanding shares, the term of the option shall be five years from the date of grant thereof or such shorter term
as may be provided in the option agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Option
Exercise Price and Consideration.</I></FONT> The per share exercise price for the shares to be issued pursuant to exercise
of an option shall be such price as is determined by the administrator and set forth in the option agreement, but shall be subject
to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the case of an Incentive Stock Option</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt">(A)</TD><TD>granted to an employee who at the time of grant is a holder of
                                         ten percent or more of our outstanding shares, the per share exercise price shall be
                                         no less than 110% of the fair market value per share on the date of grant; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt">(B)</TD><TD>granted to any other employee, the per share exercise price shall
                                         be no less than 100% of the fair market value per share on the date of grant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In the case of a Nonstatutory Stock Option,
the per share exercise price shall be such price as determined by the administrator provided that for any Nonstatutory Stock Option
granted on any date on which the common stock is a listed security to an eligible person who is, at the time of the grant of such
option, a named executive of the Company, the per share exercise price shall be no less than 100% of the fair market value on
the date of grant if such option is intended to qualify as performance-based compensation under Section 162(m) of the Internal
Revenue&nbsp;Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Exercise
of Option.</I></FONT> Any option granted hereunder shall be exercisable at such times and under such conditions as determined
by the administrator, consistent with the term of the Plan and reflected in the option agreement, including vesting requirements
and/or performance criteria with respect to the Company and/or the optionee. The administrator shall have the discretion to determine
whether and to what extent the vesting of options shall be tolled during any unpaid leave of absence; provided however that in
the absence of such determination, vesting of options shall be tolled during any such leave (unless otherwise required by the
Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Until the issuance of the shares (as evidenced
by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote
or receive dividends or any other rights as a stockholder shall exist with respect to the optioned stock, notwithstanding the
exercise of the option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Termination
of Employment or Consulting Relationship.</I></FONT> Except as otherwise set forth in the plan the administrator shall establish
and set forth in the applicable option agreement the terms and conditions upon which an option shall remain exercisable, if at
all, following termination of an optionee&rsquo;s continuous service status, which provisions may be waived or modified by the
administrator at any time in the Administrator&rsquo;s sole discretion. Unless otherwise provided in the option agreement, to
the extent that the optionee is not vested in the optioned stock on the date of termination of his or her continuous service status,
or if the optionee (or other person entitled to exercise the option) does not exercise the option to the extent so entitled within
the time specified in the option agreement or below (as applicable), the option shall terminate and the optioned stock underlying
the unexercised portion of the option shall revert to the Plan. In no event may any option be exercised after the expiration of
the option term as set forth in the option agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The following provisions (1) shall apply
to the extent an option agreement does not specify the terms and conditions upon which an option shall terminate upon termination
of an optionee&rsquo;s continuous service status, and (2)&nbsp;establish the minimum post-termination exercise periods that may
be set forth in an option agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Termination
other than Upon Disability or Death.</I><B> </B></FONT>In the event of termination of an optionee&rsquo;s continuous service
status, such optionee may exercise an option for 30 days following such termination to the extent the optionee was vested in the
optioned stock as of the date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Disability
of Optionee.</I><B> </B></FONT>In the event of termination of an optionee&rsquo;s continuous service status as a result of
his or her disability (including a disability within the meaning of Section 22(e)(3) of the Internal Revenue Code), such optionee
may exercise an option at any time within twelve months following such termination to the extent the optionee was vested in the
optioned stock as of the date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Death
of Optionee</I><B>.</B></FONT> In the event of the death of an optionee during the period of continuous service status since
the date of grant of the option, or within thirty days following termination of optionee&rsquo;s continuous service, the option
may be exercised by optionee&rsquo;s estate or by a person who acquired the right to exercise the option by bequest or inheritance
at any time within twelve months following the date of death, but only to the extent the optionee was vested in the optioned stock
as of the date of death or, if earlier, the date the optionee&rsquo;s continuous service status terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Buyout
Provisions.</I></FONT> The administrator may at any time offer to buy out for a payment in cash or shares an option previously
granted under the Plan based on such terms and conditions as the administrator shall establish and communicate to the optionee
at the time that such offer is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Stock
Purchase Rights.</I></FONT> When the administrator determines that it will offer stock purchase rights under the Plan, it
shall advise the offeree in writing of the terms, conditions and restrictions related to the offer, including the number of shares
that such person shall be entitled to purchase, the price to be paid, and the time within which such person must accept such offer.
The offer to purchase shares subject to stock purchase rights shall be accepted by execution of a restricted stock purchase agreement
in the form determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless the administrator determines otherwise, the restricted
stock purchase agreement shall grant the Company a repurchase option exercisable upon the voluntary or involuntary termination
of the purchaser&rsquo;s employment with the Company for any reason (including death or disability). The purchase price for shares
repurchased pursuant to the restricted stock purchase agreement shall be the original purchase price paid by the purchaser and
may be paid by cancellation of any indebtedness of the purchaser to the Company. The repurchase option shall lapse at such rate
as the administrator may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Taxes.</I></FONT>
As a condition of the exercise of an option or stock purchase right granted under the Plan, the participant (or in the case
of the participant&rsquo;s death, the person exercising the option or stock purchase right) shall make such arrangements as
the administrator may require for the satisfaction of any applicable federal, state, local or foreign withholding tax
obligations that may arise in connection with the exercise of the option or stock purchase right and the issuance of shares.
The Company shall not be required to issue any shares under the Plan until such obligations are satisfied. If permitted by
the administrator, in its discretion, a participant may satisfy his or her tax withholding obligations upon exercise of an
option or stock purchase right by surrendering to the Company shares that have a fair market value determined as of the
applicable tax date equal to the amount required to be withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Non-Transferability
of Options and Stock Purchase Rights</I></FONT>. Except as set forth in the Plan, options and stock purchase rights may not
be sold, pledged, assigned, hypothecated, transferred or disposed of in any manner other than by will or by the laws of descent
or distribution. Notwithstanding anything else, prior to the date, if any, on which the common stock becomes a listed security,
the administrator may in its discretion grant nonstatutory stock options that may be transferred by instrument to an inter vivos
or testamentary trust in which the options are to be passed to beneficiaries upon the death of the trustor (settlor) or by gift
to &ldquo;Immediate Family&rdquo; (as defined below), on such terms and conditions as the administrator deems appropriate. Following
the date, if any, on which the common stock becomes a listed security, the administrator may in its discretion grant transferable
nonstatutory stock options pursuant to option agreements specifying the manner in which such nonstatutory stock options are transferable.
&ldquo;<U>Immediate Family</U>&rdquo; means any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, and shall include adoptive relationships.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Adjustments Upon Changes in Capitalization,
Merger or Certain Other Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Change
of Control. </I></FONT>In the event of a Change of Control, (i) each outstanding option shall become immediately vested
and exercisable, and (ii) any outstanding restricted stock shall become immediately vested and any repurchase option with
respect to such restricted stock shall immediately lapse, in each case effective immediately prior to the Change of
Control.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Changes
in Capitalization. </I></FONT>Subject to any required action by the stockholders of the Company, the number of shares of common
stock covered by each outstanding option or stock purchase right, the number of shares and the number of shares of common stock
that have been authorized for issuance under the Plan but as to which no options or stock purchase rights have yet been granted
or that have been returned to the Plan upon cancellation or expiration of an option or stock purchase right, as well as the price
per share of common stock covered by each such outstanding option or stock purchase right, shall be proportionately adjusted for
any increase or decrease in the number of issued shares of common stock resulting from a stock split, reverse stock split, stock
dividend, combination, recapitalization or reclassification of the common stock, or any other increase or decrease in the number
of issued shares of common stock effected without receipt of consideration by the Company; provided, however, that conversion
of any convertible securities of the Company shall not be deemed to have been &ldquo;effected without receipt of consideration.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Dissolution
or Liquidation.</I></FONT> In the event of the dissolution or liquidation of our Company, each option and stock purchase
right will terminate immediately prior to the consummation of such action, unless otherwise determined by the administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Corporate
Transaction.</I></FONT> In the event of a Corporate Transaction, each outstanding option or stock purchase right shall be
assumed or an equivalent option or right shall be substituted by such successor corporation or a parent or subsidiary of such
successor corporation (the &ldquo;<U>Successor Corporation</U>&rdquo;), unless the Successor Corporation does not agree to assume
the award or to substitute an equivalent option or right, in which case such option or stock purchase right shall terminate upon
the consummation of the transaction in consideration for a cash payment to the participant (on the date of the Corporate Transaction),
with respect to each such option, equal to the excess, if any, of the fair market value of the Common Stock subject to such option
over the exercise price of such option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Amendment
and Termination of the Plan.</I></FONT> The board may at any time amend, alter, suspend or discontinue the Plan, but no amendment,
alteration, suspension or discontinuation shall be made that would materially and adversely affect the rights of any optionee
or holder of stock purchase rights under any outstanding grant, without his or her consent. No amendment or termination of the
Plan shall materially and adversely affect options or stock purchase rights already granted, unless mutually agreed otherwise
between the optionee or holder of the stock purchase rights and the administrator, which agreement must be in writing and signed
by the optionee or holder and the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities Authorized for Issuance Under Equity Compensation
Plans As of September 30, 2018</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Plan category</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of securities to be
    issued upon exercise of outstanding options, warrants and rights</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted- average exercise
    price of outstanding options, warrants and rights</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of securities remaining
    available for future<BR> issuance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(a)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(b)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(c)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Equity compensation plans approved by security
    holders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7,667,271</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.70</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9,481,065</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Equity compensation plans not
    approved by security holders</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,667,271</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.70</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,481,065</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recommendation of the Board of Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE BOARD RECOMMENDS THAT THE STOCKHOLDERS
VOTE &ldquo;FOR&rdquo; TO APPROVE AN AMENDMENT TO THE COMPANY&rsquo;S 2013 AMENDED AND RESTATED STOCK PLAN, AS AMENDED, TO INCREASE
THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE PLAN FROM 17,750,000 TO 22,750,000.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROPOSAL 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO APPROVE AN AMENDMENT TO OUR CERTIFICATE
OF INCORPORATION TO INCREASE THE NUMBER OF SHARES THE CORPORATION IS AUTHORIZED TO ISSUE TO 600,000,000 SHARES OF COMMON STOCK,
PAR VALUE $0.001 PER SHARE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shareholders are being asked to approve an amendment to the
Company&rsquo;s Certificate of Incorporation (the &ldquo;Certificate&rdquo;) to increase the number of authorized shares of Company
common stock from four hundred million shares (400,000,000)&nbsp;to six hundred million shares (600,000,000). At its meeting held
on September 28, 2018, the Board of Directors approved this amendment, subject to shareholder approval, and directed that this
amendment be submitted to a vote of the Company&rsquo;s shareholders at this Annual Meeting of Shareholders. The Board has determined
that this amendment is in the best interests of the Company and its shareholders and recommends approval by the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Certificate currently authorizes the issuance of (i) up
to 400,000,000 shares of Company common stock, each with a par value of $0.001 per share, and (ii) up to 50,000,000 shares of Company
preferred stock, each with a par value of $0.001 per share. As of the close of business on November 5, 2018, 114,698,044 shares
of common stock were outstanding and no shares of preferred stock were outstanding. In addition, as of the close of business on
November 5, 2018, the Company had 7,667,271 shares of common stock subject to outstanding stock options and 9,481,065 shares reserved
for issuance pursuant to future grants under the Company&rsquo;s current stock incentive plans. The Company also had 43,534 shares
reserved subject to the vesting of restricted stock. The Company also had 55,822,622 shares reserved subject to the exercise of
outstanding warrants. This means that as of November 5, 2018, the Company had just 212,287,464 shares of common stock available
for corporate purposes, including, among other things, the issuance of shares for potential financings.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Purpose of Amendment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board believes it is in the best interest of our Company
to increase the number of authorized shares of common stock in order to give us greater flexibility in considering and planning
for future potential business needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no current plan, commitment, arrangement, understanding
or agreement regarding the issuance of the additional shares of common stock resulting from the proposed increase in authorized
shares. The additional shares of common stock will be available for issuance by our Board for various corporate purposes, including
but not limited to, stock splits, stock dividends, grants under employee stock plans, financings, potential strategic transactions,
including mergers, acquisitions, strategic partnerships, joint ventures, divestitures, and business combinations, as well as other
general corporate transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Having this additional authorized common stock available for
future use will allow us to issue additional shares of common stock without the expense and delay of arranging a special meeting
of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Possible Effects of the Amendment and Additional Anti-takeover
Consideration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the amendment to the Certificate is approved, the additional
authorized shares would be available for issuance at the discretion of our Board and without further shareholder approval, except
as may be required by law. The additional shares of authorized common stock would have the same rights and privileges as the shares
of common stock currently issued and outstanding. There are currently no shares of preferred stock outstanding. The adoption of
the amendment would not have any immediate dilutive effect on the proportionate voting power or other rights of existing shareholders.
Shares of common stock issued otherwise than for a stock split may decrease existing shareholders&rsquo; percentage equity ownership
and, depending on the price at which they are issued, could be dilutive to the voting rights of existing shareholders and have
a negative effect on the market price of the common stock. Current shareholders have no preemptive or similar rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We cannot provide assurances that any such transactions will
be consummated on favorable terms or at all, that they will enhance shareholder value or that they will not adversely affect our
business or the trading price of our stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not proposed the increase in the number of authorized
shares of common stock with the intention of using the additional authorized shares for anti-takeover purposes, but we would be
able to use the additional shares to oppose a hostile takeover attempt or delay or prevent changes in control or management. For
example, without further shareholder approval, our Board could sell shares of common stock in a private transaction to purchasers
who would oppose a takeover or favor our current Board. Although this proposal to increase the authorized number of shares of
common stock has been prompted by business and financial considerations and not by the threat of any known or threatened hostile
takeover attempt, shareholders should be aware that approval of this proposal could facilitate future efforts by us to oppose
changes in control of our Company and perpetuate our management, including transactions in which the shareholders might otherwise
receive a premium for their shares over then current market prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If our shareholders approve the increase in the number of authorized
shares of common stock to 400,000,000, the Board will have authority to file with the Secretary of State of Delaware an amendment
to our Certificate, effectively increasing our authorized shares by an additional 200,000,000 shares of common stock. Upon approval
and following such filing with the Secretary of State of the State of Delaware, the amendment will become effective on the date
it is filed. The amendment proposed by us to the Article FOURTH of our Certificate is attached to this proxy statement as <U>Appendix
B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neither Delaware law, our Certificate, nor our by-laws provides
for appraisal or other similar rights for dissenting shareholders in connection with this proposal. Accordingly, our shareholders
will have no right to dissent and obtain payment for their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>THE BOARD OF DIRECTORS UNANIMOUSLY
RECOMMENDS A VOTE FOR THE AMENDMENT OF THE COMPANY&rsquo;S CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES.</I></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OTHER MATTERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of the date hereof, there are no other matters that we intend
to present, or have reason to believe others will present, at the annual meeting. If, however, other matters properly come before
the annual meeting, the accompanying proxy authorizes the person named as proxy or his substitute to vote on such matters as he
determines appropriate.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ANNUAL REPORT ON FORM 10-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As required, we filed our 2017 Form 10-K, as amended, with
the SEC. Stockholders may obtain, free of charge, a copy of the 2017 Form 10-K by writing to us at Actinium Pharmaceuticals, Inc.,
275 Madison Avenue, 7<SUP>th</SUP> Floor, New York NY 10016, Attention: Corporate Secretary, or from our website, <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>www.actiniumpharma.com
</I></FONT>under the heading &ldquo;Investor Relations&rdquo; and the subheading &ldquo;Company Financial Reports.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">HOUSEHOLDING OF PROXY MATERIALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SEC rules concerning the delivery of annual disclosure documents
allow us or your broker to send a single Notice or, if applicable, a single set of our proxy materials to any household at which
two or more of our stockholders reside, if we or your broker believe that the stockholders are members of the same family. This
practice, referred to as &ldquo;householding,&rdquo; benefits both you and us. It reduces the volume of duplicate information
received at your household and helps us to reduce our expenses. The rule applies to our Notices, annual reports, proxy statements
and information statements. Once you receive notice from your broker or from us that communications to your address will be &ldquo;householded,&rdquo;
the practice will continue until you are otherwise notified or until you revoke your consent to the practice. Stockholders who
participate in householding will continue to have access to and utilize separate proxy voting instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If your household received a single Notice or, if applicable, a
single set of proxy materials this year, but you would prefer to receive your own copy, please contact Alliance Advisors, by calling
their toll free number, 1-877-777-2857.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If you do not wish to participate in &ldquo;householding&rdquo;
and would like to receive your own Notice or, if applicable, set of our annual disclosure documents in future years, follow the
instructions described below. Conversely, if you share an address with another holder of our Common Stock or Preferred Stock and
together both of you would like to receive only a single Notice or, if applicable, set of our annual disclosure documents, follow
these instructions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt">If your shares are registered in your
own name, please contact Alliance Advisors, and inform them of your request by calling them at 1-877-777-2857 or writing them at
200 Broadacres Drive, 3rd Fl., Bloomfield, NJ 07003</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt">If a broker, bank or other nominee
holds your shares, please contact the broker, bank or other nominee directly and inform them of your request. Be sure to include
your name, the name of your brokerage firm and your account number.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Electronic
Delivery of Company Stockholder Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Most stockholders can elect to view future proxy statements
and annual reports over the Internet instead of receiving paper copies in the mail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You can choose this option and save the cost of producing and
mailing these documents by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">following the instructions provided
on your Notice or proxy card;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">following the instructions provided
when you submit a proxy to vote over the Internet; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-indent: -24pt">going to <I>www.AALvote.com/atnm.com
</I>and following the instructions provided.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IMPORTANT NOTICE REGARDING THE AVAILABILITY
OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON DECEMBER 20, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This proxy statement and our 2017 Form 10-K to stockholders are
available for viewing, printing and downloading at http://www.viewproxy.com/actinium pharma/2018 or by email at: requests@viewproxy.com. To view these materials, please
have your control number available that appears on your Notice or proxy card. On this website, you can also elect to receive future
distributions of our proxy statements and annual reports to stockholders by electronic delivery.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, you can find a copy of our Annual Report on Form
10-K, which includes our financial statements, for the fiscal year ended December 31, 2017 on the website of the Securities and
Exchange Commission, or the SEC, at <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>www.sec.gov</I></FONT>, or in
the &ldquo;SEC Filings&rdquo; section of the &ldquo;Investors &amp; Media&rdquo; section of our website at <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>ww</I></FONT>w.ac<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>tiniumpharma.com.
</I></FONT>You may also obtain a printed copy of our Annual Report on Form 10-K, including our financial statements, free of charge,
from us by sending a written request to: Actinium Pharmaceuticals, Inc., 275&nbsp;Madison Avenue, 7<SUP>th</SUP> Floor, New York,
NY 10016, attention: Principal Financial Officer. Exhibits will be provided upon written request and payment of an appropriate
processing fee.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROPOSALS OF STOCKHOLDERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stockholders may present proposals intended for inclusion in
our proxy statement for our 2019 Annual Meeting of Stockholders provided that such proposals are received by the Secretary of
the Company in accordance with the time schedules set forth in, and otherwise in compliance with, applicable SEC regulations,
and the Company&rsquo;s Amended and Restated Bylaws, as applicable. Proposals submitted not in accordance with such regulations
will be deemed untimely or otherwise deficient; however, the Company will have discretionary authority to include such proposals
in the 2018 Proxy Statement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WHERE YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proxy statement refers to certain documents that are not
presented herein or delivered herewith. Such documents are available to any person, including any beneficial owner of our shares,
to whom this proxy statement is delivered upon oral or written request, without charge. Requests for such documents should be
directed to Principal Financial Officer, Actinium Pharmaceuticals, Inc., 275 Madison Avenue, 7<SUP>th</SUP> Floor, New York, NY
10016, (646) 677-3875. Please note that additional information can be obtained from our website at <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>www.actiniumpharma.com</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We file annual and special reports and other information with
the SEC. Certain of our SEC filings are available over the Internet at the SEC&rsquo;s web site at <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>http://www.sec.gov</I></FONT>.
You may also read and copy any document we file with the SEC at its public reference facilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Public Reference Room Office 100 F Street,
N.E.<BR>
Room 1580<BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may also obtain copies of the documents at prescribed rates
by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Callers in the
United States can also call 1-202-551-8090 for further information on the operations of the public reference facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Annex A</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDMENT NO. 6<BR>
TO<BR>
ACTINIUM PHARMACEUTICALS, INC. 2013 AMENDED AND RESTATED STOCK PLAN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to Section 14 of the 2013 Amended and Restated Stock
Plan, as amended (the &ldquo;Plan&rdquo;) of Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;), the Board of Directors
of the Company has duly adopted a resolution, conditioned upon approval by the stockholders of the Company, approving this Amendment
No. 6 to the Plan to increase the total number of shares of common stock, par value $.001 per share, of the Company (the &ldquo;Common
Stock&rdquo;) reserved and available for issuance under the Plan as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt">1.</TD><TD>Section 3 of the Plan is hereby amended to read in its entirety
                                         as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: 0in">&ldquo;Subject to the provisions
of Section 14 of the Plan, the maximum aggregate number of Shares reserved for issuance to Participants under the Plan is 22,750,000,
and the maximum aggregate number of Shares that may be granted in the form of Incentive Stock Options is 22,750,000. The Shares
may be authorized, but unissued, or reacquired Common Stock. If an award should expire or become unexercisable for any reason
without having been exercised in full, or is surrendered pursuant to an Option Exchange Program, the unpurchased Shares that were
subject thereto shall, unless the Plan shall have been terminated, become available for future grant under the Plan. In addition,
any Shares of Common Stock which are retained by the Company upon exercise of an award in order to satisfy the exercise or purchase
price for such award or any withholding taxes due with respect to such exercise or purchase shall be treated as not issued and
shall continue to be available under the Plan. Shares issued under the Plan and later repurchased by the Company pursuant to any
repurchase right which the Company may have shall not be available for future grant under the Plan.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt">2.</TD><TD>All other terms and provisions of the Plan shall remain unchanged
                                         and in full force and effect as written.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt">3.</TD><TD>A majority in voting interest of the stockholders present in person
                                         or by proxy and entitled to vote at the meeting of stockholders at which this Amendment
                                         No. 6 was considered, has duly approved this Amendment No. 6 to the Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF</B></FONT>, this Amendment No. 5 to the Plan is made effective this &#8199;&#8199;&#8199;&#8199; day of &#8199;&#8199;&#8199;&#8199;,
2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">ACTINIUM PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 42; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Appendix B</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF AMENDMENT TO<BR>
CERTIFICATE OF INCORPORATION<BR>
OF ACTINIUM PHARMACEUTICALS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Actinium Pharmaceuticals, Inc., a Delaware corporation, hereby
certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt">1.</TD><TD>The Certificate of Incorporation is amended (a) by replacing Article
                                         FOURTH thereof to read in its entirety as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Article FOURTH</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;FOURTH: The amount of the total stock this Corporation
is authorized to issue is 650,000,000 shares with a par value of $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Common Stock. The aggregate number of shares of Common
Stock which the Corporation shall have authority to issue is 600,000,000 shares at a par value of $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Preferred Stock. The aggregate number of shares of Preferred
Stock which the corporation shall have authority to issue is 50,000,000 shares, par value $0.001, which may be issued in series,
with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Board of
Directors of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) Preemptive rights. No stockholder of the Corporation shall
have any preemptive right to subscribe to an additional issue of stock or to any security convertible into such stock of the Corporation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt">2.</TD><TD>This Certificate of Amendment has been duly adopted in accordance
                                         with Section 242 of the General Corporation Law of the State of Delaware (the &ldquo;DGCL&rdquo;),
                                         including approval by the stockholders of the corporation upon notice in accordance with
                                         Section 222 of the DGCL, at the annual meeting of the stockholders on the Corporation
                                         held on December 18, 2018.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, the corporation has caused this certificate
to be signed by its duly authorized officer this __ day of December, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sandesh Seth, Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;<IMG SRC="proxy1.jpg" ALT=""></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="proxy2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !> 84# 2(  A$! Q$!_\0
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MQ^-P].&(GC<KP<<)B7#]3:*CC?>.AP,<D8SD C' !X/.._&*DKX _70HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\>]5_X*5ZY<_%7XO_
M  OT71O NBZK\)/B-XN\"7MIX@N]9N+[5[+PWK,VF6OB.V-N;2W>WOTB5[F"
M!9'T^X<6T^^)H)YN@M?V[_B),V)3\*8AD# 7Q"3G'/)NE!)YX]1C Q@?-OQ>
M_P""/_C7X@?%WXK?%#3?BUX:A;XG_$7QAXY6TGT?4(I])L_$^M7.IV^E>8LK
MK-);PS1PSSH8XYY49Q'&BH%\X/\ P10^)S$-_P +E\- =#G3=4)Q@]Q< *<$
M8^4,!ZG.?Z9P^5?1^>39=B*G$>&695,KR^>.P'U;-G*CF#P&#>.IK$O"N,TL
M;]:O9N,=8QG.$82/X1Q>=?3!AQ1G>%PO"N:U.'Z6?9O'*,R>)X7A"OD_]JYB
MLLJ+#1QD:B@LL^I<CGRU9Q4)UZ=.M*I!_;6N_MB^,_$&CWFE2>(_A9I2WT+0
M2W"V>OS.B2H4?$9O45R58YRVTC!)XP?QMU?]@?\ 9UUKXWWGQLUG7?A1JNKZ
MQKL/B/7=.N/#&O1Z;JFKQSQ7!O+NQ&KO8S75Q,BO<W36H>\<&2[$\A\P\C_P
M4%_9&N/^"=OP1L/CC\2?&K>-]'U7Q[X;^'VG:#X1MWL=2DU7Q)%J=S'=RWNJ
MW M(+.QLM(O;B8LK22NL5M"!).&7Y&_8FN?!?[<_[0.G?L\_#O4_$GAC7=6\
M#>(?&]AXE\0K;7>B$>&%TN34-&FM].F6\ANF@U)W@O&S;2O9R0$*T\+CS:V&
MI8'(<US?P_5>EDM*GB5C\RP%6K3:ITH*E7]I*M.EB5",*\(U(TJ:C:HN5[R/
MU;AA\=8[-,!2\085XX_]U"EA<2L"XKGE&:A;!RJ49MSA=<]W=)Z;G]+Y_;L\
M2>$M,M-)TW4?A"UKI=I!9VL1MO$\(6&WB6-%V)<L%PJ@9 Q[=J\WUK_@J-X^
MTK?Y<7P8N-N<;Y?%Z9^I0OTSC.>O4BOF+5O^"&'Q3U)'"?&OPK$6+8W:;K!&
M#D#&)CP/KTQ]*\GUO_@WK^,&J[Q'^T#X*@WC!$FBZ\Q'T*W*CZ\&OQK+WDDI
MMX]4I-R<I>T==-W=Y-NDWJVWUVZ=_P"@L1]?4$J'.FHI)1C!)6T27,DDDDM-
MO2Q]-:W_ ,%D?B3I1/E>'_@G<%<DAM2\91 XSTVPN<<9[\=Z\BUK_@N]\5-)
M#[? GP+N"A( .O\ C9 <>I%BV!C^O-?-6L_\&TGQMU0L(OVE? $08G)?P]XD
M;&03@A;@=S@\\_K7DVL_\&KGQXU0DI^U3\-8B23A_"GBME&2<<BZ'KV.:_0\
MK?A9[O\ :-/ 7M[W/5SE:Z7NZ,K+3R:TM8^:QJXNL_JLL1?HHPP3\OMN^E[V
MYM6DM3VSQ]_P<I?%#P%_9:S?!_X(ZY>:OKND:/8Z3IGBOQR-1NCJ.I6MC-/$
MTNEM!;PV<5RT\US<,(@4CA"R/.B'^JCX)_$*?XI_#?P[XXN;..PGUJ!Y)+6,
MDQQE)&4;2V6P1@\G/J<]?XOK+_@U"_:&LM:T?4_^&K_A+)'IFM:1JDD4G@[Q
MAOFBTW4(+Z2%'^U86218"B-D!"RL21E:_M!^"7P]N?A9\-O#G@>ZO([Z?18)
M(I+F-=J2;W+C:,#IG!..2"1P17S?'SX+E6RM\'4\'3I+#XA8]86ICZC=95:7
ML)57C[2BW3]HHQI)04;\UW9GM</PSB%&NLXK8BM6=2,J<L12P])1@X.\*4,/
M[MHR2YISDYRD]E%6/Q9_X+6_\$HM;_;RMOAA\4/ACK%OH7Q*^%-OK6D/:W%F
MUW8>(/"NO7%E?7UA<10303P7EI?Z?!?:=>P>?Y;R7<%Q;/'<B2+P3_@F!^RE
MKG[ >F>,(/$%U+J'B3X@ZQIEWXE%S$L-N\&BP3VFG:<EH6<+%:)=WUPCRN\E
MQ-=3%MJQHH_IW(R,<>G(R,'J".X(ZBOB']J[PMH/A/P9XH^*4L3"T\+>'M<\
M2ZM:6@"W=U::#IEWJ]Q'9+_S]216CI;C _?O&&^4G/K\'<:XNIERX*S2?UC*
ML7+DPT94X2G"<FW&A*HXNI*GSRYJ493Y83;::TY?E>-,@K0@L]RF7L,5A)QK
MUX0?*IJ$HM3AK&,6G\:27->[NDT_:-6^,F@6?@B+5[&:'[7-;>5%:1[4,4FS
M "H" J@X50HP.@]*_F+_ ."F7_!.SQQ^W_\ %#P#\5OA]K'V/QYX9TNX\'7\
M5W;37MCK'AJ?5)=5MX\1312VMUI.HW-[):W*B6*>*\N()X1Y<,R_G?\ #G_@
MMA\4?$?B?P9J^MQV^HZ%XH^(.F:5KGPSL=#TZWT[1_ OB'4[.QM1X?UY;==?
ME\5:5;WHN3J&H:A>VFKW=O)%/IEO!<Q);?VV_ 7X?Z;HFB1:V3!<W5R/W4B@
M$1Q#.T#KCIQST'M7U^-RM>$F'_M2E[*OC\P<YY?53C7A&[5J$FX0CRT.>/.G
M>%17M)JZ/G:&(SOC'-L!A,1*.$PV#H)XI4YI\ZY?9UW.-VG5FG9)*T)-.+LF
M?&W_  28_P""?:?L ? 37/">KZDVN^.OB)XK_P"$U\8ZG)$D(2[CTRTTC3M-
ML[>-Y!;6>GZ=9QQQK))+<2SRW,\SJ)5BB_5<G )/89_*BBOPC-LTQV=YEC,V
MS*O+$8['5I5\15:C%.<K)1A""C"G3A",*=.G",80A",4K*[_ &/!8/#X##4<
M)A::IT:$%"$5=NRNW*4G>4I2;<I2DVVWT227RS^U7K'QCN/A=XJ\%? _X;Z]
MXQ\9^-O#&MZ#8^([37?!^@Z'X0_M* :9<:A?7'B+Q!IFHSZBEE>7=QI,6DZ=
M>K]K@0W5U9JH+5O#NA+9?LP6GP[NO@7XWM[+3? D?PSF^$[:K\/)O$U]I*Z3
M#X>GN8=4A\7R^#C#>P2S:DUY<^(+>\!62X:R%ZT=LWU9MC4YX4].N!ZXQG'O
M2;(\YXSP?O9[Y'4GTQ],BNVEGLJ.58'*J>782$<'G4,\EC:>)S.EC,7BZ=&G
MAJ4:\J>)5&%.AAZ4*>&>&I4JV%DZM:C4]OB*LE\Y7X46(X@S+B"KG..J3S#A
MNKPO2RVM@<DKY=E^ K8BKC:T\+&M@WBJM;$8RM5KXV&-Q%;#8ZFJ&%Q-%87"
M48R_&3]ASX+?M*_!+2/B3\&_BS\%_$K?"CXKO);P:[IOC'X=7]QX-N-5TVY\
M-ZSJ6JZ?#XM%P]C?:$VGRWDFC6^HWJ:AIV^#3YEN7<;O[,GAO]JC]BR'Q#\%
MM4^!&L_'#X9W?B2_USP#XV^&_B#PI93VDU^D$-Q#KFG^)M5TQ].L;Y+2RO)O
M[0EMY-)OVO%M)-7M'BEA_7_"''3UX./Y'FD"1\XQDYSAB>IP>Y[\?I7V.:^*
M.89WB>(JF9\/</8G"<53RS%9UET/[7P]"OF^30E1R_.\-B*.8?7<#F<*$IX?
M%.A5GAL=2G4^LX;VD_:+\XR'P)RGAG!\(4<CXPXPPF/X$CGF"X9SBI+A_%XO
M"Y!Q'4CB,WX8QF$Q&3O+<TR.>*ITL7@*6+P\,7E-:C16 QL:,/8R_.G]JGX5
M?M ?M!?L?^*O"FI>'_"]I\5-3\2:9XKT_P !>&M6%U;66@Z/X@AOK3PE/XDU
M*6UT_6O%,&CJS:CJ4,>EZ/J&JH]GI\,5L8;B;FO'@_:"^)G[&^K?"6+]FWQE
MI/BCQ#X!T+X=:;I]YXR^'D<]C)HNBZ%%J/B37XKKQ#8MIFE7-[:7$&AV5K-J
M^LW:12SZGIVBPR1>9^GGEH.B@<D\9')ZGC&<^O\ 6D,49QE<[3N')ZD$$GGG
M\>E>/@>.L9@L)EF"CD^2U:&3<65.+\JBXYE0C@L=5IY=">%A##9@E7P+>4Y>
MU#$SK8B*HUDL2WC,1)?1YGX68#,\QSG,Y<1\24<5Q%P%#P]SZ;EDV,GFF4TZ
MN;U*>.JSQN4MX?-(_P!OYO%U,%3PV$DL10;P:_L_"0E^37B3X=_'?5_^"?\
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MITY5IQA&,ZLJ=%*E3E4E&524*25*#FXTTH1@D4449'3//I4EA129'J/S%+0
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C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# 1<# 2(  A$! Q$!_\0
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MLN![UYU=Z?XFCU6_:*P$\$ER[PL^#A2>._3VJK>-XBT^SFN[O388;:%"\DC
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MY";< <8[,WJWZ=_IG'XA2ZQXV_L%+3;#]J:V7&=W&?G/MD=/2KR>.;*?5?[
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MU)6=2I*;][H;QBDM Q1BBBH*$Q2XHHH ,4444 )BEQ110 8HQ110 8HQ110
M48HHH ,4C*&4J1D$8(I:* (X+>*VA6&"-8XT&%51@"I*** M8*,444 &****
M "BBB@ HHHH **** "BBB@ HHHH *2BB@!:*** "BBB@ HHHH **** "BBB@
C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &- G\# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** *VHW7V'3;FZ"AC#$SA2<9(&<5PO_  LB?/\
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M?\+(G_Z!\?\ WV:XB38)7$>=FX[<G)QVIM=']GX;^3\_\SD>;X[_ )^/\/\
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MY=F=(UE$,^(7N/,C#G!#*V>,G/!-8U,)AX-+V=_O.FCF.,J1;]M9_+_(T?\
MA9$__0/C_P"^S1_PLB?_ *!\?_?9K*MK31HFLWDEMW;S5\U6FR"ICSS]&X/3
M'ZU6CM=+>S5W>))3:R%E\[I,'^4 9[K^%+ZOA?\ GW^9?US,+?QE^'^1O?\
M"R)_^@?'_P!]FC_A9$__ $#X_P#OLUS.L0:?"T!L),A@V]2VXKSQD@D'\,?0
M5F5K# X64>90_/\ S.>IFF.IR<75OZ6_R.Y_X61/_P! ^/\ [[-'_"R)_P#H
M'Q_]]FN&HJO[/PW\GY_YF?\ ;&._Y^/\/\CN?^%D3_\ 0/C_ .^S1_PLB?\
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M^_\ UJ/J&(_E_%!_:^#_ )_P9U]%<A_PFS_\^"_]_?\ ZU'_  FS_P#/@O\
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M _\ /M?C_F>5?\(=>?W&_+_Z]'_"'7G]QOR_^O7JM%'U_$_SO\/\@_LC _\
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M#U-=-;"=;=%NGC>8##-&I53[@$G'YUDVWAJ&S,,MM>7,5TENEL]P-A:6-,[
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MVYI47&<CC!PRD#G@]>*BA\3_ &FPTF6&R(N=3=TB@DD "% S-N8 ]E/0'^M
M%K0]'_LG3IK52L222O)'# 3LMPV/D3/0#D] ,DX '%698+RWTR6.QF$MWM/E
M/=L2N[_:VC.*JP:ZEYX>CU2WA8/+\B0N>?-W;-IQ_M<9].:F&J$:ZFE&W?+6
MS3^<2 IVLJE0.O\ $.: ,>WT76'E@NKQ=.2ZM)_/B\EY&$K,C(^]B 1E6&,
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MG^;J&H2-/:R6LC-(N2CL6/\ #P><#T&*$\*60-X);F[G2[2-9$D=< Q@!&&
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M3?"MYK,-_P"5+%;&86[0JP#%B<$GG 4@8'H36PVA(IG$<\A2ZG2:X20@AMH
M., 8W;5SVZ],U/K>D0Z]I$^FW$T\4$XVR&!@K$>F2#B@"B=6.E7-Y!<SW.H-
M#&+F3RX5!MXB".<8SDJQ  )X/%.;Q58 -*L=P]JD\<#W(0>6K.%*'DY*G>OS
M $<U-<>'[:Z9W>XN1)+ +>X='"F=!G ; Z_,W(P>36=9:!OU+4TN8)X=/-Q#
M);PAT\J18XXU7@9(P4Z'&<#- #+#Q!]ELQ)JEY<22Q+?2/L@&'CAF*Y.T?>
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M@>WTH U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<.4CQ1BI,48HN'*1XHQ4F*,47#E&*/F'UKN](_Y!=O\ [@KAU'S#ZUW&D_\
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M\P\#T %;E% &;H.F2:/H\-A+<K<-$6_>"/9G+$],GU]:TJ** "BBB@ HHHH
M**** .=\0#-S'_N?UK&Q6WKPS<I_N?UK(Q7IX=_NT>/BHWJL2.(RRI&O5V"C
M/O4\EO'Y\EO$)&E#[$/&&.>>.U0@$$$'!'0BI_M4P<N"H<D$N%&216K;OH91
M4;:D?V.7:6PNP+NW;AC&<?SJ6#3W:X$<PV+N*Y!&20,\>M-^TR["GR[2I7;M
MX )R?UI_VV??NRF0VX?*.#C''X5+<QJ--,B-FQCWC"XB#G<PYR<<4KV,OFLJ
M1D?-M 9ADG&<#UI3<2%=IV;=@3&WC&<_SIQO)R^_<N[=N!V]#C&1^%%YARTR
M+[', "5&,*V PS@G -.:QEW-M7 W, "PS\O44X74H&/D^Z%^[V!R*7[9-NW9
M3.YF^[W;K1>8<M,A:TE6+S6 "@ GGD9Z<>]0XJ_/<1RP"-588"A><#CUYJIB
MJC)M:DSA%/08H^8?6NNTO_D'0_[M<JH^8?6NJTT$Z9$ <';P?2N7%O1'9@5:
M4C@?#GB673'UW[;->7TLOB:32K"*28L%X!5<G[J@;B3R>._%;"^/A/>0:?::
M1/-?R75S9M%YR*J30*&8%CU!!!! [\@5/#X&MK>*XCCN3MN+K[9(6CW'S\Y\
MT$G*OP.1CI3T\%PQ7%M<1W6R:V>62*18L,'D&)')S\S-GDG)KA/2*FE_$*+4
MS:-_9%Y'%>V$M[:D,C-)Y14.FT'@Y88.<'VK+U/QE=7^I:4NF)*LMOK*6D\,
M5PICN5>V:4#?T(Z?B#UXK73X?6$=K#:B;-O!;RVL<90E5BE_UB?>Z'C\A4B>
M!+-)1*LJB4&-A)Y7S*T:;$8'/#!3MSUQ0 FF_$+2+I8HKY9["_>[DLC:O&TF
M)D8*PWH"N,L,$D=:RY_%-_:?$^SCEDD_L&]WZ9&#&P1;I/G#[B,$L=\> ?X*
MZ6QT&?3;3[+9:@(8BS,0MNN69CEF)ZEB222>:S[CP-;W6G6^GSWDDEK;3_:(
M4(.4DR2&SNSG))Z]Z ,_P[<7OC";Q2][?WEF+74I=.MHK64Q&!(P,/Q]YF+9
M^;(Z #%0>*8KK2;KPN(=8OY&U'6XHKF07+*LD;1M\H53A1\HZ?UK=N/!Z74E
MS))>,KW2!+EHH_+,Z@8 ?:1NXXR><<4E]X.CU'[!]IO&(T]U>T5(]@A91@%0
MI R!P* -W3[/^S[);;[1-<;68B2=RSD%B<$GKC./H*M5%;QRQPA9IO.<=7VA
M<_@*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3R;FT%H\*C:H0%CD8Y!^;\,#%5;C2M476++[<7U72[=TD@VE4EBE&0'E!P)
M,Y!&,$9VG@BYH^O37ES>V%U;DWME=FVD>!28V'EB1'Y^Z"K 8.<'CFJK>(;^
M/0;^]E@C\VVOFMSY*L^R,2!=P7JY .<#J>@[4 6;W0M4NIXI8_$5Q 8TV@"U
MA;YLGYAE3@X('X>YJ>+P]!'=(YE=X$N#=+"P&!,0<OGKU)./4Y]*=X=U0ZQI
M9NC)%*OFNB21@C>JG )4\JWJIY'MTK2N#,MO(;=%>;:=BN< GMD^E &/'X<
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MX.>*U_['T[[2MS]DB\Y<$,1W P#[D#C/6H8_#>CPF I81#R/,\KJ=N_[^/\
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M<8R:NUR<OB'4(=:\N18UC_M)+$6I3YFC9,B8-WYS[8!'45UE !1110 4444
M%%%% &-JW_'R/]S^M9V*TM5_X^1_N?UK/Q772?N(XZJ]]C<48IV*,5I<SL-Q
M1BG8HQ1<+#<48IV*,47"PW%&*=BC%%PL-Q1BG8HQ1<+ H^<?6M[3O^/&/Z5A
MJ/G'UK<T_P#X\H_I6%?9&]!:LH:?K<E[KM_I[6CQI;8VR$=?K]>H]JV:0(H9
MF"@,W4@<FEK*I*,G>*L:4H3C&TY7=WY:7T7R.>\8W]U8Z9:+;2M EU?06UQ<
MKP8(G;#,#V/1<]MV>U0:[I]M9VT!MYKA9/MEH?+-R[?\MT&[!/?)!['O72RQ
M1SQ-%+&LD;C#(XR"/0BJ!\/:.R,ATRU*LRL08QR5^[^7;TJ#4R;;7)S*EG9Z
M?%%)-+>_-)*656BDQDX&3N)S[5"OBCF*Z73@DUY;V)1VER,SLX4-QP%(//?(
M%;B>'M'C9633;564N01& 07^_P#GW]:2+P[HT".D6EVB(\0A91$,% <A?H#T
M':@#/N=?OM/N;*VN[>U\V6>.*3RY&(8.Y4%>,C P3NXYP":ATZZFTOP7J5U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %34--L]4M7M[R".561DRR@E0PP<9'!K-E\,010QOI,[Z=?0VHM8KF-%
M;Y!RH=",, <GL>3@C)JSKVJC2M,FD22$7)BD:%96P"54G)]A_AZUDZ7KEWKN
MHBQ@N4@6WL+>YN)44,TCRAL!<Y 4;#G@\G'&* +N@Z;<VD&VYA^S3K,TLSPS
M>8MV[+@NQ8;AVXXQ@#D"I(_#=K':SP&XN7\V\-Z'9EW1R[MV5PN,9[$&H-#U
MF\NKK4-.NH?.N+"\-L]Q$ J,IC61&8$\'#!2!GGT!XIMKFIQZ!?W+[);F#46
MMP($&[RQ(%PBD_,^#P#U/Y4 =#9Z=!9PSH-TIN)#),\N"9&( )/&.@ P!C H
MGT^*33I;*W=[))%*A[7",F>Z\$ _A5+PYJC:EI<EQ+,'\N:2/+IY;J%/212!
MM<=Q@=JT7E::T=K*2%Y""$8G*;O?% &5;>&D@11)JFH7#QLKP23-'F @,/E"
MH!R&(.0<BIIO#UK)!8PI-<1+9W/VI2C+F23DDOD'.2S$].M8MMJ6LP7Z:9<7
MJW*7-YY-O?"!4;:L322#;]TX*[0?<]<<S)KNH20Z<5:(?\362PN6*<R!&=<K
MS\N=H/?TH WFTV&34DOY6DEEB!$*N?EBR,$J/4CN<GDCH:N5R4VNZG!K8CD
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MN-*FATPQ)Y<@SYVY4;<WS8&"QP,'/'(J/7M>6\M]<TVXDM'M3IUX2I (5XR
M!N)P20V2,?*<<]:[,V-H<YM8#NZ_NQS3FM+9@0UO$03D@H.?\XH +-@]E RL
M&4QJ00<@\5-2*JHH55"J!@ #  I: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***"0 2>@H RY/#^
MGRIJ2.LQ74O^/H>>_P _R[>.?E^4 <8X%.DT.RF&GA_//]GL&M\3N-I"E<GG
MYN"1SGJ:Y+5O&TUI)K-U:3QR1P:;'-;P%?N$R,ID;O@##$=@/K6MJ\MYH+Z1
M<P7]Q=&XOH;6>*8AA,LAP64 ?*5^]QQ@'([@ OW7A;3;R19)I-0W"/RLIJ$Z
M97).#M<9Y)Z^WH*N1Z190W8N4A(<'<!N.T-C;NVYQNQQGK63KD&KW5G'+;7L
MUC?@?Z/;6[*Z-)GK(2OS)C&>F.>^*J)J]\;B"]\R0^;K$FG&W_@$2EU#8]?E
M#9]_2@#=BT+3XHKR(1NR7DWGS!Y6;,G'S#)^4\#IC&!5NUM(;*(QPJ0&8LQ8
MEF9CU))Y)KF5NM9DTO5Q#/)<3PZF(MR(H=8,QEP@Z9"EL9R?J:T?#-W<74.H
M+++)-#!>O#;RR#YF0!<@GOABZY_V>>: -RBBB@ HHHH **** "BBB@#)U$?Z
M43_L#^=4ZNZC_P ?/_ !_.J5=$/A,)_$%%%%60%%%% !1110 4444 %%%% "
MI]]?K6OIXQ9I^-9"??7ZUL6'_'FE95=D:T]S.TZ^U.?7]1MKFV"6D6/*?^7/
M?(Y]NE;5%%1.2D[I6"E3<(V<F]7OYO;Y'+?$7[-_PA-]]I$)7,>T2XQG>O3/
M?&:KWGB62UO+Y([RQCMK*[LX4C&/GCEVALG/&-Q((]/K78,JN,,H/U%-\J/_
M )YI_P!\BH-3B8M>N)[VU==1M(+<2ZA'(L:KY4C1N FXGG)&2<'G)-.LO%5Q
M/+H2)-:JETD ECA4%5\R%FSG/R_,N% ST.>HKM?*CV[=BX],4!$'15'X4 >?
MV'B+6_L>GP)=0W$\EN\S37+)&'E#[?*/I@<G'S<CTK4\>?9?L^A/<"W)&K6^
MWS\8Y)!Z]N>:ZS8G]U>N>G?UH9%?[RAOJ,T <1;V=YH-ZFCVEW8Q76HB\NX0
M(\K;O\FU8U)^YU)'<Y(Q4T&MZE+;Z;<O>>3;7KB":26!1]E=$;?D^ID78,\#
M!ZY%=EM4L&*C<.AQS05#*58 @]0: .(3Q!J+74=Q->Q0P1V]Z4WJ%BNO*= D
MF<$@%23QZ$CBF0:NNHZII)NYX7F@UB2*!W14<H;9F'&3UW8XZ\=Z[HJIQD#C
MIQTI/+3(.Q>.G'2@#F->U2\T[7':._2&"/2YITAF4>7)(I&,GKWZ U0C\431
M"VFFO],F,^FM=^9MVF/YXQMX))4;FXZDBNW9%;[R@_44T11CI&H_"@#B=/U0
M:AXAT22[DA-VDE_;@D*KE5( R 3@D 'CCO7<TW8F[=M7/KBG4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 5VL;62YEN'@1I98A!(6&=R D[2.F/F/YUB
MCPTUEJ\%]ITR^3&H06EUND2$="83G]V<<$<@^U=%10!B7?A'1KUU>X@N&98_
M*!%Y,N5R3@X<9Y)ZU?CTJRBNOM,< 64<@Y. <8SC.,XXSC.*N44 4(-&L;:.
M\2&)T6\D,L^)GRS'J<YXZ#IBK<$$-K D$$211(-JH@P%'L*DHH **** "BBB
M@ HHHH **** ,K4?^/G_ ( /YU2JYJ/_ !\_\ '\ZIYKHA\)A/X@HHS1FK("
MC!/:C-2ELK'L8 !>><<]Z3&1X(Z@_E28JR&Q+$Q<; @W?-GZBHP?W9&0,D%?
MFI7"Q%TZT4^5@2O/.W!YSBF9I@%%&:,TQ"I]]?K6Q8?\>:5CJ?G7ZUK698:>
M"@!;!V@]S6579&M/<Q_^$MA'CT>&'MV4/:F6*Y)^6252"\0]PC*WXUI3Z_I%
MO<R6TNHVRSQJS-'Y@W *-S<>H')'7'-</>^$M7N3I=]%:1PZU9:BU\]X I$H
M;.Z/'F9 *D*>>BBKNE^']6TYK^V: S:?<W%Q<H&BB^T1/,#N ?S,8!8X.,XX
M-8FIMP>++"[FM)X+RQ&F3637;337 CD505P=A'W>3ECC!QZU8_X2WPZ%+'7-
M/VJZQD_:%P&;[HZ]^U<4?!^O-8VEJ\<;?9]#FT8/L4;E<* ^/,/0(..^3TI+
M[P7K%[;7\!@11=Z'#I&=J?)Y9)\S[_0[CQ[#F@#O;W6K.U>2V6YMVOPC-';M
M*%+L%+;>YZ#/3..:H>%/%NG^)]+LYH[FV6_EM8[F:S28,\6X9Y'7 /&<5SEU
MX8UNZUB*_9600W8N8HECC"@& Q.#B0;F.XD.<G@#H*;8^"IHUTJ&_L[F>WTO
M3GT^$6[I"\BOMRSL),@X08"GJ2<T =-XQ\3KX3T%]3-J]T5=08H^NS.7?Z*@
M9OPK=AFCN((YX7#Q2*'1U/# C((KB7\-R.8[1]%>?28+26""VN9Q*X>0Y9F=
MI"2#T]0,_2J_ARS\8^'(=!T=HA>Z=:12Q7+[$5F0#]U@F0X*\+CN.: .C\8^
M)/\ A%/#L^J+:/>21D8@CZL.KGZ*@9O^ U?EUO3(-/@OYKZ".UG0/%([@!U(
MW9'KQS]*PM5L+W6-3CDO-&$]A';R1I;2,F?,? +$A\8P,8]":YO2O!_B/2K7
M0?+D$MSHRSP0F:-&CDMY<?*P\T$,N  P/08(H Z^^\7Z9%%?Q65[92WEK:K<
M@3S>7"5<$H3+@@ XZ\U<?Q+HL,ZVUQJUA%=%E1HC<+E7(R%Z_EZUQ^K^%=7O
MX]:BMX?+CU73(K"17CC C,>X!U"R8 PY^7V'-0ZAX0UJ_76LV\:-J<UE+]U"
M$^SE3@_/SNVCZ9H [F+Q!H\]B;Z+4[62U$AB,J2@C>.J\=_:L8>.M-B\27.G
MWEW8V]DMK;W%M>-<C;.)2X&,\?P]03G(K(/AK6O[0O;F.(Q"[U,7SA5CW!#"
M(F16WY4G:#N7&>1T-9]MX$U6WT>XTXJ9%N=)BTB5VBC^6)"^'4>9]_#GKQD
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MGUKQGK6CK:1Q6>FI$R3ER7GWY&0,8"@HPZ\\5TEU<Q6=I-<S'$4*%W/L!FN
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MZ>",&\O+*[(VI\IM\<?ZS^+'X9[T =I;>)M"O)K>&VU>REDN2RPHDZDR%?O
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M$E1%"CRBB! N0QSD =A774 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHSO.3CTHY9ARE\V%TKJK! Q!X+<C"[L?E3?LL@@:5I(PH1)!R?F#' ^E9?\
M:MQYZS>8/-48W[1DC&.?7CCF@ZK<E=ID!7:J;2HQ@'(&/:GR2#E-6>VECDER
M$B5795#R=2HR0#WID]M<6TD22A0TOW>>/S/'XUFRZK<3!Q)(&#L7.5'WCP2/
M2D;5+AGB8R<Q-N3"@ 'UQ^ H49!RFJUI.@8LT:JJ+(26_A)P#Z]:GM[!_M/E
MW6$&9% #<EE&3CVZ5C-K%TZ,K2AE9=I!0=,[L=/7FE_MN\WE_.^8L6SL'!(P
M<<<9%+DF'*3)/RIKO](.=*MC_L"O+UF^8?6O3]$.=&M#_P!,U_E6.*5D@:L3
M0W]K/>3VL4RM/!CS$';-6:SK31+*RU2ZU"%,37'WO1>YQ]3R:T:YI\E_<V_J
MYC2=1Q_>)7N]NU]/P,?Q1JEUHN@SZA9QP220E<I,2 06"]1TZU.=:L(9OLT]
MW']H22.&4("0DCCY0>NW.1C/J/6H_$6D/KNBSZ:ERMN)BNZ0Q;\ $'@9'H*H
MW7AJZN9;Z3^THT-W/;3G%MD*82IQ]_G.T?2H-2R/$5FDT5N]RDLDYGV2PQ,8
MD$;88,>0"N0"<CH>E3P:W8E;*-[V*2:YC5D:)3MD)4L,=<9 ) )R0.]9\/AF
MYAD28:DAF66Z?/V;Y<3L&(QN[$=<]/SJ*U\)2V[Z:6U/<+'R=JK %#F-#&2V
M&Y)4CDYQCCCB@"_:^*=*NK*"Z$TD<<X+*)865@H(!8C'"Y(^8\<]:UY)$BC:
M21U1%&2S' 'XUR\7@J"/[-YLT-P(86MBL]L'5HBVX#&?O#)YZ'TK>O;2>Y:W
M5)XTA1PTL;Q;_, Z#.1CUZ'I0!4T[Q!:W>B1ZC.R0?O#!(@??ME#%"@(^\=P
MXQUXJ&7Q5IK"6.&Y,3+;-<>?/ XB10S+EB<8P5/!(Z57E\)L]U=RQWRPI)=Q
M7L$:0<0S( N?O?,& P1QW(P:EU3PY<:E]J;^T5CDNK%K*4_9]PP23N4;N,;C
MU)[4 79/$&EPS^1)>)YHE$#!58@2%0P0D# 8@C /)S2GQ!I8@BF-VH25_+4E
M6!#;]A##&5^;"\XYXK.D\-W4DSR-J4?S7L-X0+;O&BKM^_WV@YJO+X.GF256
MU0 23O.=EOCYC,)0"=V2 01CH<YZT 7=,\1Q3W$MK?/'#<?;9K6$*C!9-G(&
MX\;L<XSV-.\0:U<:)+93^3%)8O*$NF)(:%#QY@[$ E<^Q)[4S_A&%>?][=L]
MJ+\WXB$>&\SJ!NS]T'GIGWJ6]\/)=A(!,%L3'+%/!(K2&19!@_,6R./K0!4U
M7Q!?6VLWEC9V]NR6VFM>&25FRS@D; !T'3GWZ50TCQC>ZIIU[-';VDC0:='>
M+-"[-$LC*6,+]PP !X[,#@=[0\(W2."NL%_^)9_9S-/;[W?/)D+;AEB<\8Q3
M+?P;<6=OY=IJPC\W3UL;H&VW+,478DN-PVN%X/)!&/04 ._X2;4++2]+U;4;
M6V.G7OD+*\#,&MC+@*2#]Y=S*"1@C.<5O7^JV^FRVD<XF+7<ODQ^7$S_ #;2
MW.!P,*:QHO"D\FG:5INHZG]HL=/$1\F.#R_/:+&PR'<<@%0<#&2!VXK7U+3F
MOI+*6.?R9+2X\]24W!OE92",CLQH KIX@TZZGACM-1MVW3>6<J2)#A\JC< L
M"ASUP <BH+[Q%'M@.FRP3$7L%O.'5N$D8 %>F<@@@\@U!#X8NX[6SMWU*)TM
MKZ2\_P"/7&[>7)3[_3]X>?85#'X/N(AD:J&<RVTKEK?@F$Y  W84'C@<#M0!
MU=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQZ8LMT)GL&+1S>2JR?>+8##D YP1T(H Z2BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "J/]B:3]M^V_P!F67VO=O\ /^SIOW>N[&<^]<K>
MM NF>/(S<>8(T8MYDF[8?LRGOTYZ=*BEB9?^$+2Z33Q"+E1%Y;')_P!'D/&>
MO(!^H% ';I:6\8E"6\2B4DR80#?]?6FQ6%G#%%%%:01QQ-NC1(P A]0.QKDO
M$B:1?VT45_K%D-2\O=#<BY$*VPW']\@W\'C'4Y*XZ9ID,UQ)>V\\9!U%M:DB
MDY^;[+\V!_N[-C#MD@]30!W%%<3! ]WI.OP6MZI\G5]TGG3G#HOEL\;-_"&
M8>@SZ5K^$Q(;.]E"LEG+>.]FA/"Q84?+Z*6#D>Q&.* -^BBB@ HHHH ****
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M699Z+#::M=:D&S/<+M;"*F1G(W;0-Q'0$\@5IT %%%% !1110 4444 %%%%
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M#)$CD=V4&I** &^6FX-L7(& <=!Z4U+>&)MT<,:-TRJ@&I** $1%10J*%4=
M!@4M%% !1110 4444 %%%% $%S>VMGM^TW,,.[[OF.%S],U7_MO2O^@G9_\
M?]?\:XWXD,?.L%[!7/ZK7"Y/K7KX7+85J2J.35_0^<Q^=U,+B)48P32MU?8]
ML_MO2O\ H)V?_?\ 7_&C^V]*_P"@G9_]_P!?\:\2R?6C)]:Z/['A_._N1R?Z
MRU?^?:^]GMO]MZ5_T$[/_O\ K_C1_;>E?]!.S_[_ *_XUXED^M&3ZT?V/#^=
M_<@_UEJ_\^U][/;?[;TK_H)V?_?]?\:/[;TK_H)V?_?]?\:\3R?6C)]:/['A
M_._N0?ZRU?\ GVOO9[9_;>E?]!.S_P"_Z_XT?VWI7_03L_\ O^O^->)9/K2Y
M/K1_8\/YW]R#_66K_P ^U][/;/[;TK_H)V?_ '_7_&C^V]*_Z"=G_P!_U_QK
MQ/)]:,GUH_L>'\[^Y!_K+5_Y]K[V>V?VWI7_ $$[/_O^O^-6H+F"ZC\RWFCE
M3.-T;!AGZBO"<GUKU#P Q.@,/29OY+7+C,OCAZ7.I-ZG?EN<SQE?V4H):-[O
MH=71638Z]!?ZS>:<D<BO;?QD'#8X/TY_.M:O-G"4':2L>W3JPJKF@[J[7W:,
M**YWQS<W5EX2N[NRN)H+B)HRC1$ G+J".>.032&[O=-MKZZBL=2N#"BD07,Z
M9<<EBF,\@=L\_P X-#HZ*Y;_ (3.,-"!9/+YL0N%\AC)F%FVHPPO+'!.WC !
MR<\5+)XJD&GR:E#IKRZ>K,BS><JEBLHC/R]>3DCV'.,T =)17.R^(KM=4CLT
ML(P/MSVLCO/@;1!YH<87T.,>U3Z%XCCUTDQ6L\4;1+-$[J<,C$XR<8#8P<9/
M!% &W16%XGU6XTNP^T6J3.]N5GF6.+<#"#\X)[97<1[BI+CQ!%#J]G8K&"MW
M&'BG9]J29SA4.,,W )&0<$$9H V:*Y"U\;LUE9O<Z<QN9H/M+Q6[-)MCW;1C
MY<EB<X7_ &3S56UU"[M]7A:2[O)H8[W4$:(-O+HHW*N.Y'0"@#N:*YF7QA'!
M9RW#V9 BNS:R.)0T2$('#,X!"@[@,G@'@D=:T]6U?^S(;1H[22YDNYA!$J,H
M&XJ6&23P/EZC- &G17,IXP61[E4TV[E\@3+B%"Y9XN&7@8QG< <\[3QTIC>-
MK;9;F*W:X>2)IF%NQDP@?;QA<EB<_*0#P0<&@#J:*YRY\70VLFH![*=EM+5[
MK"D;W5&VGY3C;ZC/4<U-'KMW<7CV46EN;B$1M<+YZCRT=F"D'HQVJ6([=,DT
M ;M%<OX;U:=8+"QNQ-.;@W(CNI) S,8Y6&&'^[C!]NU6IO$RQ?;YULW?3]/>
M1+JXW@%"B;SA.K#H/J>F.: -ZBN0UW7KG[$UJ\<UA>[8;J(QRAMT?G(K*2!P
M?F (]^":2'Q#)H]CJDUR)[M8;ZXP9) -L:E?E#'C/S?*O?!]* .PHKE8]:N-
M,OM5:YCEN+)=4C@\PR@F 2)$%PN.5WOZY&>]6(O%D;P6MTUC*+2]$AM'5@6D
M*(SX*\;=RHQ'/;G% '145S1\6E+*TNYM-EBBN3$R;I%SLD*A3Z%LMRH/ !/I
M38_$3/.&OK5X8X]0GMXW@F)4B-'8F0<<84\<\X]* .GHKF9/&,=O91W=SI\Z
M1SV<E[;*CJS2(@#$$<!6VL#C)'7GBM:PU0WE_>V<EN89;4H3\X8,KC(.?7@@
MCVH T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ J&.ZMY7E2.XB=X3B55<$H?1O3\:E8A5)8X &2?2O-IY=#U*2XFT!XOM"
MP)&T-O$P>6 3QM*TG')V@@ \_,W=J /14N8)(//2:-H>OF*P*_GTI9+B&%T2
M6:-&D.$5F +'T'K7!ZXD;Z'XINCM;39'A:U"CY6<*H9E Z\X_$&IO%J2S:E-
M+;.A5K%!Y$L987HWL0D3#E''J,_>7CC- '=5%/=6]J$-Q/%"'8(ID<+N8] ,
M]3[4R2:=9852U9T?[[[P-GX=_P *YOQE<Z!Y?V#5GMEGN8'1'N(RZQ(>&8#!
M&[T[G'I0!U!GB$ZP&5!*PW",L-Q'KBG>8F7&]?D^]S]WOSZ5PD4<DB20PEGN
MY-3M9[-W4[S:@1?-D\XV"0'W)!Y-3FQM=0;QCI\5RML'FB9Y.2 ?*0DMZ@E2
M#SZB@#LH9XKB(2P2I+&>C(P8'\14E<]X9MY_M&JZ@\/D07DR-%$%*@[8U5G
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ME0D).<J<98A>.O?D5:N_%4FG$QWFG$7#0)<1QQ3!@5:18R"2!@J77/7(Z9H
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M?"NCS+<*]J^+A)(Y<3R#<KMN=>&Z$U971;%9XYPDGG1QB+S/.?<R Y 8Y^8
MDXSG&:YG4$O;?Q%H<"3ZE*EW%=RS0)=E>AC*CDC[NXCK^==#;WBZ=X>EO+M+
MA!;QR32QROYLB 98C/?CI^% "VOA_3K.2V>".56MFD:+,\C;2YR_4\Y//-3'
M1[ W-Q<&#YKC_7+N.R3Y=N63.TG'&<=*S1X@O1)90R:9&DM^P^R@7.5(\LNQ
M<[?EV@8P,Y)X]L/5M6FU%;V:":[M'BTS4(I8XIV 2:%H\,I&.>>&ZX...E '
M2R>&-)E@>&2WD965%),[[@J'*J&W9"@\X!Q3'\*:-(LBR6TCB1I'<//(<F0
M.?O=\#\N*HWVOME],,<D;RVDVV=9=KADC#;@.N#GAL]0>.]5[7Q7-86>GVU[
M:-)<3V5O);NLV[SF=DCPQ(&T[G4D\C!/IB@#?_L/3C<FX,!,AD69LR,5:10
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MRP0&([X..3]*K8-&#50I*#NFR*N(E45FDO1"44N#1@UJ<XE>H?#_ /Y +_\
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MVDFL.+O446*%R& WR.X1<MC'5AEL>IQVH NCPYI(N$G%FN^-I&4%V*@R??\
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M!&R'_6%I2"OT&TY_,5A>*+NP16LKJWN"]W;O$\T=E+.$B/##Y%89/8'TR>E
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MK'#&MC$$AD$L2C(",.A'IC)P.V:GCTJQALYK2.W5+>9F>1 3ABQRQ_$U<HH
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@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #8 7<# 2(  A$! Q$!_\0
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M9'/4#\JG_L2#_GZU#_P-E_\ BJK:]_Q_:%_V$!_Z+DK;HNTE8+7;,W^Q(/\
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MG>Y'_P )-H/_ $&;#_P(7_&C_A)M!_Z#-A_X$+_C4G]A:9_SYQ_E1_86F?\
M/G'^5'NAJ1_\)-H/_09L/_ A?\:/^$FT'_H,V'_@0O\ C4G]A:9_SYQ_E1_8
M6F?\^<?Y4>Z&I'_PDV@_]!FP_P# A?\ &C_A)M!_Z#-A_P"!"_XU)_86F?\
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M9/0YSTX/I5^+3[.!E:*VBC**57:H& <9 ^N!^51II&G1JJI8VZA1@ 1C@>E
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M3S%[-CM_D]ZY<?@E0M.+T?Y_U]QW91FCQ=Z<U[RZ]+?Y_F;%%%%>:>V%%%%
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M=Q='?';!L18X<G'7V&.G>M3H,"BBJ<FTDWL2H13;2U>X4445)04444 %%%%
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M\S*GBMKJT,'V2W1'C" HK@A2"0/N=, C\<<9HCAM([;RGM+>6,#_ ):AW^4
MN!RG0!C@=LXK5_M2T_OR?]^G_P */[4M/[\G_?I_\*-.P:]R@&MX3E;*S4QD
MD$*_!!SQ\GJ^?Q/O4LMTT\L(D\M%CEW,5WL>#MQ]T=R/YU:_M2T_OR?]^G_P
MIT>H6TLJQJ[;V.%#(PSQGN/:CY!\Q1?VS$ .V20!\C=R5]/4&D74;5MN)&^;
M!'R-W!([>QJU14Z%:E7^TK7;GS#C&?N-_=W>GI0VHVJ@DR'Y<D_(W8 GMZ$5
M:HI^Z&I6;4+5209",$@_(>Q"GMZD4#4+4L ).20/NGJ6V^GJ,59HHT#4JKJ-
MJ^W;+G=C'RGOG';V-(-2M"H(EX(!^X?[N[T].:L331V\,DTTBQQ1J7=V. H'
M))/85D+XO\-N,KKVFD>URG^-)RBMQJ,WM^1H'4K1029L  D_*>P#'MZ$4-J%
MJI8&7&W(/RGL0#V]2*HKXK\/,Q5=;T\L.H%PN?YT[_A*-!QG^V;#'K]H7_&E
MSP_IC]G4[?@R[_:%KNQYO.<?=/7=M_GQ2+J-JQ4"4?-C'RGN2!_(U2/BKP^!
MDZWIX'_7PO\ C3D\3:%+-'#'K%BTDK!403J2Q)P !GG-'/#^F')46Z_!EL:C
M:, 1,,$ C@]U+#] 30VHVB@DS 8!)X/9=Q_0@U:HJO=)U*S:A:)NW3 ;<YX/
M;&?YC\Z/M]J&QYRYSCOUW;?Y\59J(W,(F>$RJ)$4.RDXPI) /Z&EH&I&NH6K
M$ 3*<X Z]R0/U!I!J-HP!$ZD$ CKW!(_0&I%NH'3>DJLOJIR#]/7\*?YT7_/
M5.N/O"C0-2#^T;/&?/7&,_AMW?RYI6U"T7=F=!MSGVQC/\Q^=$]_;6SE)I-K
M!2Y^4]!U/X9&:47ML3'^]7]X6"'L2.O/X4] U$-_:@D&=<@D'\&V_P SB@7]
MJ2 )UR2 /Q)4?J"*%O[5K;[0)E,6[;NP>N<8QUZT\W4 N8[<RKYTBLR+W(&,
MG]12T#48NH6C;=MPAW8QSUR"1_(_E0-1LR,BX3&,]?\ 9W?RYJSBC%/W0U*S
M:A:*"3<(,9SSTP 3^A'YT&_M%)!G0$$@\^A /ZD#\:LT8%+0-2N+^T) %PF2
M<=>^[;_/BD74+1MNVXC.[&.>N<X_D?RJS@>E&!Z4:!J51J-F0"+F/! .<]MN
M[^0S0=1LU!)N8P "3\WH Q_0@_C5K ]*3 ]!3]T-2NVH6BE@UQ&-N<\],$ _
MJ1^='V^TW8^T1YSC&>^[;_Z%Q5C ]!1@>E+0-2NNH6C$ 7,9W8Q\W7)('Z@_
ME0-1LV (N8B" 1\W7(+#] 3^%6,#T%&!Z"G[H:E8ZC9 $FZBP!DG=VV[OY'-
M*=0LUSNN8AMSG+=,8S_,?G5C ]!05!Z@?E1[H:D!OK4'!N(L@XQN'7=M_GQ]
M:!?6C$ 7$1)( ^8<Y) _4$?A4^U?[H_*C:O]T?E2T#4KB_LV (N8CG&/F'.0
M2/T!_*E^WVFW/VF+&,YWCIMW?RY^E3[%_NC\J3RT_N+^5/W0U(TNK>201I-&
MSDD!0PSP 3_,?G14H10<A0#ZXHI.W0%?J5HO^0C<_P"Y'_[-5JJL7_(1N?\
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E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #T 7T# 2(  A$! Q$!_\0
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MUFOBZULX8BEO.P!WM,^7R6<DYSS@;,#W/I3M.7Q7;6RI/'#*RIDL\FYG8*H
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M_P#A(K;_ )]KO_OV/\:/^$BMO^?:[_[]C_&GVFM6\^G6-W.OD?;$62).7X8
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MQ_YXW?\ WX-10>);)%8&&[Y=C_J#W-;VU?0?E1M7T'Y4 8W_  E%C_SQN_\
MOP:JV6MZ;8K,L<=Z1+,\QW0="QR0,=JZ/:OH/RHVKZ#\J ,;_A*+'_GC=_\
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MF5CCYHV!& P[9!/Y4#*X\3V1Z0W?_?@U5MM7T^VO;NZ$=^TER5+!H.!M&!C
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M6]I#-*6C>2)9#&$+8RH8C('. PS]:^1K?Q)>K_,_1,+_  (>B_)&K]AM^?\
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M=SR6XA%NJ-C>&+[HEDP..N& J%_$;1SO ^GXD2X^SMB3Y<^1YQ.<>G% &_\
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MGYF0$\C![=P /I6>/$^C-")1<_*5W#,3 D8!Z8ST93^(IS^(](C.U[@H=S*
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M?^1V%%9VBVE_96<D>HWGVJ9I6</SPIZ"M&M4<\DD[)W"BBBF2%%%% '%>*;
M:EKHA$*.8[=7)>0KU9AV!]*Q_P#A&#_S[6__ '_;_P")KI]1_P"1GE_Z\X__
M $-ZSM8U.32;47(LGN8P?WC+*J"/T)SV^E=$<57@E&,FD<=3+\+4DYSIIM_U
MW,G_ (1@_P#/M;_]_P!O_B:/^$8)_P"7:W_[_M_\372QOYD2/M*[E#8/49'2
MGCJ*KZ[B/YV1_9>"_P"?:_KYE_P^[2Z%:,JA1M(QNSC!(]*T\2>H_/\ ^M67
MX:S_ ,(Y:XQG#XS_ +QJI;Z5KT*7$7]J)Y<C22(PY=6< XY!^4-NP!C@CTQ7
M.VV[L[8Q44HQV1OXD]1^?_UJ,2>H_/\ ^M6"-.\0QAQ%J%N@.2,KGG#<GY>>
M=GY'UH73->.HBZ?48!C*@!20$)4X(P,]#SP>>M(9O8D]1^?_ -:C$GJ/S_\
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M1?QV;*W:TLXH'F>9D&/,?JWUK$B\-01*%&HW14D%P9!^\P%'S>O"?J:WQ(H
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M(JM9R$QO&',<N"4;*DAAP5*]<E:Z6!F>WC9L[B@)R,'./3M2[G_NT;G_ +M
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M9<U"UK9,,-;P$<]8QWZU.I7@+C '0=J '4444AA1110 4444 %%%% !1110
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MCAN=0CE6*(1I@$[P.,MWR1CG/7/!J@OAN^*A6^S1_)("8YWX9VW$ %2-HP,
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M3WETMP\Y7! QPN>W0<$<#TJY<W4%J%\TG+= .2>,_P!*9;W]M<E]C$!,?,W
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ME!\Q'0GU(JO)J=C%+Y3SJ'],$]\5&NM:<PR+A<?CQ[4 6FL[5UVM;0LN",%
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MRS3T^Z*/)BY_=ISU^4444 "0Q1G*1(I]54"D\B'.?*3/^Z*** $2U@C4JD*
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><D 8YHHH D,,1SF)#GK\HIX&!@=*** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "@ 3T# 2(  A$! Q$!_\0
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M_?DUYA_PD-__ 'U_[X%'_"0W_P#?7_O@4?V1+N'^L5#L_N_X)Z?_ ,))9?\
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MZ,]*TK_4BM&L[2O]2*T:^3J_$S]!I_"@KD_&O_+C_P!M/_9:ZRN3\:_\N/\
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MF*XB/&Z-@<'T/H?:@"S534RJZ7<E@<",].O2H]3U>UTB-9KTM';89I)R/DB
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MG'9FD:LX_"VCQR3X#VS-F/57C]/ESB@_ E'D+S:W+*QZEEY/XU['15_6*O\
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M]"/HOR1+1117"=X4444 %%%% !1110 4444 %<GXU_Y<?^VG_LM=97)^-?\
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MN=_X?_X\K7_=_J:[B#_5#Z5P_A__ (\K7_=_J:[B#_5+]*^9QW\1^K/O\O\
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B!&Y_)/\ XFJ=]X?BU+R_M5[=/Y>=N"@QG&?X?:MBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "] G8# 2(  A$! Q$!_\0
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MG-MS&WE'#;613& . 0"<'UF?P+=F2^E755\V:Z6YC9XW(*B02&&1=^&CXVC
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ME613RP')''*D>HQTKF;/XAK)I.F:C>V"6L.IVLUQ;L9RRHT:EBDAVY'R@G<
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M[_UP?_T$U4^U:_\ ] FP_P#!@W_QJH;N3Q!<V<\ TK3P9(V0'^T&XR,?\\J
M+VC?\@+3_P#KVC_]!%5?#G_'I>_]A"Z_]&M5_3X'M=-M;>0@O%"B,5Z9  .*
MR+.'6]-^U1165A-%)=33([WC(2'<L,CRS@\^M ">,KS4;+2+=]/,B*]Y!'=S
M1IN>&W+@2.!ST'?!P"3VK*N_$QT:2YCT[[3JD($LV^5BPWJ(_P#1XF ^9FW$
MC)..1]-_[7KW_0,T[_P8/_\ &J/M>O?] S3O_!@__P :H YJZ\?7UI-=[]*C
MDBB:Y1/*D9GS$Z+N8;?NX<L<9/R'&:RX_%^JV\&H21N;N>-;^> L6,>Q)(@@
MV@ L-K$J<] >O6NY^UZ]_P! S3O_  8/_P#&J/M>O?\ 0,T[_P &#_\ QJ@#
MFI/&EW:2:EY-DUP(IYL2&1BC^7#&ZHGRY#.6(4<\JW7I4.H^.K](=21].2*.
M-+I(S'.RR[HD1A_#@$[R.,_,.]=7]KU[_H&:=_X,'_\ C5'VO7O^@9IW_@P?
M_P"-4 <S=>/KJRGO-]A;/;0&Y2-Q<$%VBC1P22N &W8Z]1WKH_#.L7&N:?+>
M2QVRQ><T<#P2[Q(@XWG^[GT/(J*^35]2LI;.ZTG3W@E&UU&HN,CZB*HM.M=2
MTJ.5+/1M,C$K^9(1?M\S8 R?W/H /PH O>(O^09%_P!?MI_Z41UK5S]['KFH
MQ0P26.GPQBYAE=UO6<A4D5S@>6,G"XZUT% &1;?\C=J7_7E;?^AST^[\/:=?
MQZC%>Q-<P:BH2XAE;*$ 8&!V/N.XS4,]OJMOKUQ>V5M:3PSVT46)KAHV5D:0
MGHC9!WC\JD^TZ_\ ] O3O_ ]_P#XU0 RW\+Z7:WLMU%%(&FA6&9#*Q24*FP%
ME)P3M&,^E01^"]$@LWM;:WD@C=X';RYF!8PX\LDY[;5^N.<U:^TZ_P#] O3O
M_ ]__C5'VG7_ /H%Z=_X'O\ _&J5T FBZ,-.L+F-E6*:\FDN)Q Y*J[GG83R
M!WZ=2:H0^ ]#ATV.P"7#V\-M):P"2=F,,<@PX4]B1QGKCBM#[3K_ /T"]._\
M#W_^-4?:=?\ ^@7IW_@>_P#\:HN@,G5? UG<VEVUD\L5_/"81-),S (P167'
M(P1&O&",\XY.4L/!,?\ 9[6^J74LYV3PQF-@A6*7:75BBJ&8E<[L _S.O]IU
M_P#Z!>G?^![_ /QJC[3K_P#T"]._\#W_ /C5%T!7?P=HS[\P/AA( -YPGF,'
MDVCH-S*"?7Z5%'X&T"**X@2T=;>YMQ;S0"9MDBA=H)&?O!0!GKP/2KGVG7_^
M@7IW_@>__P :I?M.O_\ 0+T[_P #W_\ C5.X$NDZ+:Z,EP+9IW:XD$LKSS-(
MSOM"Y))]% _"JWA?_D%3_P#7]=_^CWJ3[3K_ /T"]._\#W_^-51TJ'Q!IMI)
M"=/TYRUQ--D7SC[\C/C_ %7;=B@#I*P#X-T8V@L_*F^PKNV6@F811ECDE5SQ
M@\CT[8JQ]KU[_H&:=_X,'_\ C5'VO7O^@9IW_@P?_P"-4 5)?!6CS+,&6XS.
MDJ2D3,#)YC*SD^Y*+SZ#%2#P=HZW4MVL,B74DOF^>LA#JV&&0?H[#Z''88G^
MUZ]_T#-._P#!@_\ \:H^UZ]_T#-._P#!@_\ \:H H_\ "!Z#N ^SR^2%""W\
MUO+VB(PXV^GEDC\<]::W@+0Y+9X)4NY4D^_YEW(Q?]WY0SD\X7@>F >M:'VO
M7O\ H&:=_P"#!_\ XU1]KU[_ *!FG?\ @P?_ .-4 5I_!>BW,[R3PRR"1Y))
M(VF8H[/'Y3DC/=>OOSUHF\&:1.7:1;@R2+(LDGGMND\R,1MN/?Y%"CTQ5G[7
MKW_0,T[_ ,&#_P#QJC[7KW_0,T[_ ,&#_P#QJ@#3@A2WMXH(\[(T"+DY. ,5
MC^+_ /D6KC_KK#_Z-2IOM.O_ /0+T[_P/?\ ^-50UFW\0:KI<EF-/TZ,NR-N
M-\Y^ZZM_SR]J .EHK(-UKX_YAFG?^#!__C5'VO7O^@9IW_@P?_XU0!KT'I61
M]KU[_H&:=_X,'_\ C5'VO7O^@9IW_@P?_P"-4 9P^'WA_P D1/;S.GESPL&G
M;YTE?>ZMSR-_S#T/3%69?"&F3M&TSWDC)"(=S7+991().?7YE&?4<=*L?:]>
M_P"@9IW_ (,'_P#C5'VO7O\ H&:=_P"#!_\ XU0!DV7@>VMM6N&<[]+\FVC@
MM?,<E3"SLI;/4 OD>FT5<MO!.B6<]O<6\$L4\+LXD25E+;MNX-CJ#L4D>HSU
M)JU]KU[_ *!FG?\ @P?_ .-4?:]>_P"@9IW_ (,'_P#C5 %!? VDP1S)9F>
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MOS/7?^$ST+_G\/\ W[;_  H_X3/0O^?P_P#?MO\ "O(J*ZO[(H]W^'^1Y_\
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MC\47T7EF.&V BV;?D8XVQ&(?Q?W21]:O6FL6T%Q?R2ZQ<S+<17:1JT3X4RJ
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M77^JKPJGQGB4?X1YYX^_Y%6\_P!^/_T(5X_&_ERHY17VL#M;H<=C[5[!X_\
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M#(PR"/<5O1RI+"LJ'*L P/L:KS2QJ><5Y].<HL]BK3BTM3D?^$5TG_H$6?\
MWY%'_"+:3_T";/\ [\BNF\^+VH^T1>U=/MIG/RO^=_>_\SF?^$6TG_H$V?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF2WFRP^4,&^;'L=O-?1X&7)@T[7U?YGQ>:T_:9DXWMHM?D8R7-Y'$VR:=8W
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C1?:Q@^;CG(&T'TSM)&>N..E7:* "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>proxy1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxy1.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC?XO?#GPWXFDE6WDTV\UF);BUD8(5$R DP[A)&P\T)D'() )'6>/?VL/A_\
M#/X'-\2]:\8^'[/X>K'#<#Q(MP+C2S#*X2.7SXBZ>6S,JB3.S+J,YX/P/_P1
MC_X(^_ OQ-_P3Q\&>+O''@;PQ\3O&'Q2T==<UC7?$NFIJ%U&;D/MM[9W+&V\
MI-JEX&1G<.^5+ +QW_!(+X9VO[.?_!0?]KO]CV#^U_&'P6TBUBU+3K>[C$EC
MIRW\$ N+"63<SB26&[2+E@)CI]Q+M1R] 'Z2Z)^UO\/?$7[/8^*MGXR\.S_#
MI;.:_?Q']I":<L$+O')(7;&%5T=3GNN!DD ^>Z3_ ,%9OV=_$$_AN.S^+GA%
MF\87@L="=GD6'69_/6W,5O*RA)6$[+$=K$*YVM@\#\)?B'X/3X9_M@>)/V =
M ^,VA6_P!\7_ !-L=3U/5YE=KC3I"L9_LYY?,9)#%*EM V<J;JV@9S%B91^O
MW_!57_@DGX:_:X_X)XVOPW\"Z#INA^)/A;IZ/\.=L>9+'[-&B_V>LSN)%CN8
MHEC8E\&18)9/,\H*0#Z>_:._:Z^'G[(OA*UUWXE^,O#_ ()T>^NA8V]YJUP(
M([BX*N_EIW+;4=L < 5W7A'Q-;^,?#=GJEFS26>H0QW-N[1/$9(W0.I*. RY
M5APP!'0@'('X:_\ !.=/B#_P7[_;$^'_ (H^,FFO%\./V8]!L[+5=-U"+[3;
M>+?$6)%:2XC?:B3RM$DUQ"$<1QP1Q-Q<*P_=>SA:"'#D,Q.21TS0!+1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PW\-O^"='Q"\(_\%V_
M'_[2=S>^&6^'7BKP>N@6MM'?7#:JEP(=-C)>$Q")8RUG)RLA)_=G')Q]PFWC
M9U8J"R]"?\_YQ3Z* /A?_@AS_P $Y_B'_P $X?@G\1?#?Q!OO#-]>>*O&,FO
MV3:#?7%Q"EL]K!%AO-BB*R;HFR%!&,'.>*Q?V2/^"47B;X-?MB?M97/BZS\%
MZE\!_P!HN)ECT32[J6WN"LGF+-#/ L*"/='=7*F2*<DG+  LH3] J* /RK^$
M'_!,O]M__@G[X<U+X;_L\_&SX<:S\*+ZYF;2F\=V,O\ :WA42[#)+ L<$D3R
MF5I9"IS [AG\I&EDSZ1^S7_P2B^)7[ _[(/Q8G^&_BO1O''[4GQ>E6XU?QOX
MJN;JVL4E=N2@3S9#Y(EN94=E+R3R[GVQ[8T_0RB@#\F_#_\ P;=1W7_!)[6O
MA7KVLVE]\<O$.K'QM/XEDO'N+*'7$A>"* SM$)WM&A>1)696D>2XFE[HJ_>7
M_!/_ ,%_%[X??LN>%?#_ ,<KCP[JWQ"\/PC3;O5M&U"XU"/6((558;N:2>.-
M_M4BJ#,0N&D#.,!@%]RHH ^%_P#@B7_P3F^(7_!//0?B[:^/IO"]T_CKQC)K
M^E_V+?S78AMW5AB8RPQ$29/(&_.2=QYK[HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHIL[[(';D;5)R.U #J*^%/^"I?
M_!<KP3_P2[^+7@GP?KFA:IXKOO%5H=2U(:=>P6\V@6/GB%+C9*NV4R%+G:K,
MB[K8[F16W+Z9_P %//\ @I+I_P#P3;_9<L_BA+X?N/'5CJ&KVNE06FGZA%:B
M3SXII$F65E=2F(?0YW#'3! /I^BODW]IS_@JWX5^ O\ P3,C_:>T'3;CQYX5
MNK'3;VWL+2\CMKB07ES#;M&SE6"2022E9$*Y1HG0@,I%<[^U_P#\%G_"?[%'
M[8OPE^%OC+0;JUTSXH6%K>R>)Y=1B@L- %Q-+"IN R_<5XP7EWJJ*^XX"DD
M^U**^=?VA/V](?V?/VS_ (#?!NX\-WVK77QR?6$AU:.[2&/1CI]O'.V^(H3(
M)!)@8*XQDYIO['_[?UK^US\??CMX#M/#E]HEQ\#/$47A^YNY;M)EUAG\[$J*
M%!C7]R?E8L?F'(QR ?1E%?/?P%_;WL_C=^W5\<O@BOAN\TRZ^"<>CR7&KRWJ
M21:M_:-JMRNR((#'L!V\LV2,\5XW9_\ !=7X?W__  5=_P"&7X='NY9FOGT4
M>*EU.W%@NIQVK3O:-$P#@B1&MLJS$W!"!>I4 ^Z**^=?VNO^"@-G^RG^TO\
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MAE92"".""* +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_B3XD^&O_!.36(_.3X>_'#4-6U^X^V1?9[OP[9A;U@&\K]\96EO[A%D!8/\
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M_P $%OCK-^RIX[\:?L5_$C1/#GA?XB_#N]GU/0[VQCBLX_&]G)B5KC_6$S7
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M_LH_$7Q9K6N:U\&M#U#5O$5Y/J&H7,VI:CNN;B9R\DC 7('S,[G  'S$#'<
M_+_Q)=Q_$?\ X(\_\%$OB1X9CED^$/Q$^*MMJ?@W_1I+);E!K6GBYN([>1$:
M-7 MU)(#EH"C -%@?8_[,5GX@TGP;\.-0U+_ (*.:2-(L[+2KBZ\*W.F>$8E
M^SHD+M8/( )5^0&(OG>,[OO#)^[OB%^QQ\,/BA^S=)\(M7\#Z#_PK66""W_X
M1VQB-A8Q1PSQW$:1K;F,QJLT2/A"N2O.><_/Z_\ !OG^QZKJP^"&A[E.X?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX3^,GP?\9GP7=W.BV?VO1Y+E-2TM#);1W#S%HS;7_EYD))<,X"@J!QO[&/\
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MO'?AZXM9)7"JZ6>GO'.8_M'0$'S,"16(4; P!XQ\)_VC/VWOVU/VC?VAM/\
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MXE_X([>/[6PM+B^N)M5T8)%;(9I'_P")A">%49/&#QVSZ4 =#)JW[6'[(7[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>6MO>6UW$T$\,\8DCFC8$,C*V05()!!X(/-6@-HH _);]M_]B;]IG]IS]O\
MN?%WC3X+^$?C?\&_ LVSX?>#[SQ[%X>TB%P8F.H7L BEDNYGVNC12D1%#M*L
MC,A]8_:6_95_:%_:_MO@C\9+#P?\/OA3\>?@5XLO+W3_  ]?^)Y-5T?5M'GB
MABN+4WD%OMB:=(U4?Z.Q3'$D><U^AL=K'$/E15SUP.O:AK2)VW-&K'IDC/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5_X+1_'%O@+_ ,$HOCCXA_?)(WAQ]&B$4:2L)=0FCL$R&RH3==*&/.U0Q&<
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MWLW_  <\>(M2N?\ @F;%X T56EUKXQ>-=%\&6$)2(QW,\DKWB1R/(0L:L;+
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M\+/!.E?L8?L;^&=#N+ZWAT/X2^#+6P>YO[R.*&.VTZP2,R33LJJJA82S2%5
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M!\0(I)OCA\=[Y_&'CN\G5DN/.G>66VLRAQY0MX9L&)5&V1Y0  JJ/FG]K?\
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M/V_PG:TM=+NO!?PZU[5-;T7P[K<$N-T,EY;)$A>(W+2+;R%3OB+(5\IJS?\
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MS="U@UB^FL[F:[BFDBG\BVA#%H#%()$5(*\PU7QO:? '2/V_K[P;H/@_X=^
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MMRW]FUEMW_:!,OE;<XSNSC&>,YZ\5^(G[+7B#Q!^R1^R)^W#\0/#_B3X7_\
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M\6ZC&;6&*>UN434+:1K?,T4<B:8(!/\ =:.[<L&*;%T/^">GASPA^QG_ ,%
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M1_"_X1_ 33O%UQI?B35&T6W\;ZULC@N+G45E82RK%"\Z-$TD@0V,VYE5YXW
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M>$EV;O+->C_#_P#X+ ?L^_%3]I'P_P#"WP[\2M/UCQ-XHMFNM'FM[*<Z5J^
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M"'ACX?\ PLT_P+I'A_2+7P;INF?V-!HX@#6D=EL\O[-Y;9#1[#MVMD$<=^.
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M+XI>)9?$VN)X;MKBUT>S<QI%';VT<\DDFT!&D:1VWO)<2=$"*OTM10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5\ _\'&OPVO/$_P"P7H?B33])U[Q)
MJGPY^(6@^*[+2=+MS-)J#12O;O$X2.1_+\JYE8E%W JISM!4_?U% '\^GQ_^
M!OQZ\&^(/@[XXC\-WVH_M!?M6Z=XK;6KR"WG^P^%9-??2+*PM+BX$;-;PVFF
MHR!2V87,I0N59W^E?^"B/[!FC^!/@C^QC^QGX-T/Q)K7@_5/'EMJ?BS4[&SN
MRMY96T<BWLUV;<!4%R][+*?WT9@$ ,>%B#)^NV,4T1*%QM7'IB@#\N_VW?%.
MN:A_P6A;Q[9>&+S6-&_9K^!.M>)M&GFTC4&2XU^^$T A@> ?Z9OMY[=/*5L+
MOF*D2)\GRK\+OV)_$7[/7_!,7]B7Q1K'PS\0>+OASX9^(-YX]^*'AF#PJ;S5
M\S(T-C?2V1CWS6\%K$RL?EW(]N?*?@I^^&,_AS31!&&#;%W+D@XZ9Z_G0!^6
MWQY_:JOOCY\#_P!I3X\:1^SGK7A2/1_ EUX&\">.]2AO+/QKXK6[(@46]A%:
MFY@LDGN/.$ID!!V$A")O(\X_:/\ V7/$7PY_X(+_ +,'[.>B^']<76OC!XA\
M,V7B.SOM)NT_LF2^N!J=Z;UH]\E@L5Y)&DC@ 1JD@5%X4?L@8U+[MJ[AT..>
M_P#B?SH6%54J%4*>" .M 'CO[9OQ*D_9\_8S^(_B71=-U"_OO#/A2].D6-DD
M\ES>W*P,EK;QM$&D4O,8DW@':&W$C:2/S_\ V2OV'_&/@?\ X-F/$W@?P'I<
MEK\5OBCX0U;5=3MY[9X+[5YKV27?:NDZNRW#Z<JVB9"C>H8-%DR#]8PH'84!
M%"XVC&<XQ0!_/Y\&?V.M._:R^$?P_P#V>(8OV]&T^XAC@\:>&=<CT[PSX5^'
M\L3%Y+@O/ITJNKS>;-"L323-P)&$K,I^M/BG\3]1_8/_ ."T'QL^+/Q#^%?Q
M#\?6/CCP=I%C\+-0\+^%3JWEM#%Y5WI1GCC!MKB:Z!;+EE\LJ6D4-&C?J=Y2
M[57:NU> ,=.U*J*O10/H* /QL_;A_9X\::W^RM^SQX^U#]F"W\/^%;3XI?\
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M?7_B2UUKQ3HVFS^#[:PO-:2XN C:;#?3206;RC^$32PRHA_B,;"NXC?S$W4
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M>$+^\\+WTVKZ;8RZQ;0Z/<*T^G6=OJ#W-Q#-$L40M8RUPB2O7J?A_P"%.M?
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M^&=9\36(U/Q1!IU['=6^CW.V[T^1'RCR);,-L\(D;"/'U7QH\8?'31OVH?\
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MX6.XG'EKC XKJ_!W@+PW\%?"FHV^CVMGH.DRWVH:[>MOVQ_:;NYEO+RY=F)
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MQJD5MAX;JY!6YN8H\^7%/*&</+&JN_FRY8^8^X ^%/A;XE^(O[%W[$/B6_\
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MG_$=H=<U[1Q8P6U\W]G2PHUZBSQK]GE:2)_W9+*YV[6+(N'"Y!\WU>Y^(WQ
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MGZGJ6JR74L,5AI%M>Q16,&8+B:5VGE<R7"@(1ND.7X1_;5^,'[57CWX6^$_
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MCL7XPMR7N4A+F&.9MR1KY<2Q_1=I(L5B=OS% <A,M@]<"@#\DO /ASXM0?\
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MQ&U6S^'HN4\):!KGB:XOM%\(B>.2W;[% YPI2VDDMXC*\IBAE9%P'R0#AO\
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M^PSX'T7PG\1-$1]8:U^)WAVS\,:Z9;M6D%G;Z<VG1&,A/D<P,V6.<OS@ 8H
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M/XH_8_"&C3Z;/X7_ +%CL+B>Q26YN9!?"2+4D59)%M\-;;BO[P[?6_V?+_\
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M!^"=%TO?JJ1R--?:Q>B6Y>WCDW",Q0V)LI255@QOX\/E'0=A\>3M^!OC,_\
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MX>^%]5\*VVH:]>Q75SJL.HW6FW,\]VZQ(9)PVEVZJ5V*%9P5.5*@'S5\-O\
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MB"QNM0N+WXF:]!XAU-+B1&C@N(M*L-+580J*50PZ="Q#%CO:0@A2JKQ7QO\
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MI'QO^,_A'7M=TRWT[Q3?:+<Z-&WBYX$\J.\NHI-->&"\$($7VBRCMG*)&/\
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M?&&J-X9UWP:VJ:IJ&E1RC2-7LEM+FV$-OI\5LK*R17"W A%P98HQ+++"H@H
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MXC:3XEMUOENK67[.VH0V,>)EL?M230"X64R83S3"(2SCU/QI^V%;_ _XN_M
M>7I_C/QIX@L/$?ASPYX?\+2ZU ;?6-4U#3(&MK33DD1%LXG+M)<O*\@"I/.<
M*FRN<^+G_!,+XA>,/@9\0?@_X?\ C78^&O@]XMN;Z_L--D\&B[US1OM<QNWT
M\7_VM(I=/^UR3-L-J+GR9/*%R#MD%73_ -G&\_:R^./[36H:=<>(_ ^H67C_
M ,/ZCX(\4:CX;GB2VUC2-*@MWN8K>Z6,7UIY@F@9TQ'-%+)Y4H.R8 '7>*/^
M"EGB#X/^!/B8OQ*^%S>%?''PXTJR\0QZ%!XGAU&S\2:5=3BV6YM+Q88SF*X$
MD<T;P!HRL. PGC:NT_:A_;VC_9JUOXHV,GAF?5F^&?PFO_BE)(NH+;C4$MFN
ME^Q &-C&S?9LB4[@-_W#CGA_&?\ P3=\0?'[PU\4KCXK?$S3=:\:?$'PW!X6
MTS5?#'AD:+IOA*P@F^U)Y%K/<W<DTCWF)IFGN'#B.-$$(#%L?Q-_P3<^)OQF
MO?C9J'Q.^,WAWQ!JWQ;^%=[\+[*/0_!#Z3I_AF&=)@;I(GOYY)R7G:1UDER3
MPK1H-H -CQ-_P47^+-E\1_!/A'2?V<=:O->^)5CJVL:#:WOBVUL9+33+ Z8&
MO-2_<N+/?_:.WR@9G6184*_O6,5/PY_P51\4?$>[^&&C^"_@KKWB+Q;\1=)\
M37-QIEUXAL[&'PQ>^']5MM*U"&\N561&@%Q+,B7$ D+ND&V+;.SP^^7GP*:[
M_:;\"_$3^UE \%^#-;\)G3_LIS>'4;O1;C[1YF[Y/+_LDKLVMN^T [ALPWF?
M[-'[!$W[/7Q;\+^*/^$JAUD>&[+QW9FV&G&W,Y\2^*+77@V[S7VBW%OY&,'S
M"P?Y!\E '*_##_@J5XD\=6/@3Q)JGP;UKPW\._&_B2/P0=:N?$=E<:AI>NM<
MRV+PR64(;=:QZC#):?:$E+$KYOD^4?,&%XW_ ."X7@?P1X_U226VT*7X<Z%K
M<OAS4]>?QSHT.JVUS#=&UGO4TAI1/)IL4@.Z<R+.5261;9H@DK]_HG_!/^?1
M_P!G;P3X#/BZ"1O"'Q2;XCO?_P!EE1<JWB2ZUK['Y?F_(=MQY/F[VY3?LYV#
ME=)_X)BZMX/\5:UIFB^+?A_:_#77-=NM<%M??#:VO/%ND)=3F\N+*UU9Y_(\
MAKIYRAGL9YHX[AT$A*QR1@$=C_P57\52^-M8N[KX*Z]9_"?PO\2F^&&J>-&\
M0VK2/?OJQTB"YM]/:-9)[4W<MFDCJZM&TTH59A Q;H_V _VC_B]\8OC9\?M+
M\?\ A[3=/\/>#_'5QI>EW$.O0WDFEJFF:5*FGK'';1%T99WNO.=BRM<-%@A%
M:M'4?V )K[]G7Q-X#;Q<BOX@^+"_$U;[^R6_T95\5V_B 6)C\WYCB#[/YNX#
M+;]G&P]9\"_V=?$GP2^._P 6M>A\5Z'J'@WXF:R/% TF3194U+2]2-EI]D^;
MS[2T4EL8K ,(A;1NK2$F1A@D P_C3^VAXXT3XNZ]X+^$_P )KCXM:EX(TN+4
M/%,Q\3VFAPZ?/<+YMKIL'FK(9[V6$-*4?RHXT>W+2CSACG=._P""F%]\6/B%
MX+T'X4_#C5?'W_"=^"[;QQ:7D^L6^DVVDV;WIMIXKTNCM'/%@KY:"1VFS&51
M4DF3:^+O[*/Q*B^,WBKQI\'?BAX=^'5S\0["&U\26^M^$G\1(;ZVC\BVU*TV
MW=OY-TD&V%A+Y]NXMX#Y.0^^]^S?^P=I7[,GQ<\,ZQX=UJ\NM#\+_#V#P%#9
MWT(>\NG2_:[DOYIU*H9)6<ED6)%W.Q7:N$ !<_;%_;!\2_LU>-/AEX8\*?#>
M_P#B5XD^*&KW6DV-M%J\6EP6)M[9KA[BXFDC8+"J([,0"X5#L61L(>+;_@I?
MJ7A[P9K6DZ]\,=8TWXW:9X@M/"]E\/8=:MKLZY=WT4UQI]Q;:AA8_L4EM;7,
M\D[QJT(LKU3$S0@/-^W]\,O&WQ"_:I_9LG\#ZAJ/A_4M'U;7[AM<31#JNG:>
M3HTPCCOX_E'V6=P(F E@D;<!%-%)L<8MY_P3=\1>*M)UCQ=X@^)FFS?'>^\2
MV/BO2O%VG^'3;:1HDNGP7%G96<>ER7$A:S^RWM[%*KW+32'4)V$J$1&, LZU
M_P %2+CX1>$_&*_%+P#/X'\8>$9M(W:5%X@M=0TV\L]7NS:66I_VD5B2&Q2X
M2:*>6:)#!Y1)#[H]_$_M*?M]?%QOV(9/&'@_P'_PCOB:U\5^%K&2^B\366I:
M)JFGWVJ6J>=IFI)!)%>1S[ULY2\,+PFZDD 81(TOIND_L/?$O5=2\;>.->^,
MFGQ_%SQ1!I>F6FK:'X.BM=#TK2M/E>>/33I]Q<7,TT-Q-<737#->"1Q,%B>
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M?"OQ(OBZ;7-2\"Z5XLCUNYNM+2&X\4:IXAOK"_O=0_=%8[8&YM)G\E$9<3J
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M?5[");2XDDM+2&&._A23S5BE22%)D5O,56 #>8 <@%#X??M;?$Z?2]:;XA?
M/QKX/NK+PU=^)K./0M5LO$ZWH@$1;2B\)C,>J,90(X=KPR%6*7$FQP.#U#_@
MJO>?"OQYJ^@?%+X<7G@_5(_#6J^*]-TK0_$^G>)M7DM=/M'NYH+JS@*/;W3P
MH?+"-/!)(LJ"X!$9DZ?1_P!DGXO>/=*UJ'XJ?'R\U*:^\$ZCX,LSX"T.3PG'
M;-?K"LFM2H]W=[]4C, \B5#%'!YDVV(>8U>=?#K_ ()9^+O"6N^#+S_A9'@3
MPG<^![6_TRR3X<?#&W\+VX@N],GLVN_+:XN$_M&.66&6.0YME$4B?9"9"R '
M.?M*?\%0/B7KG[!OQG\8>!? EOIUUH'A#5M=T'QCH7C'2_$&AV\,"*KN]Q'&
MZIJ5OYJSBPDB*2HA"7#,)%3["TWX@?$!_@1<ZY?>!=-MOB%#8W=S#X2B\1I+
M;W-Q&7$%L-0,*(OF_NOG,0"&3!!VEC\K?$'_ ()':]\?)?&%QXY\??#V'5?$
MW@?7/!<.I>"OAVOAVZU1-3MVA-UJTC7MP;YH2\DD<2?9XUEGE?&64#Z]^%]I
MXLL/!&FIXTUGP_KGB:..1[R]T/2)M+LK@F5BACM9;BXDC41E%*M-(2XW KD
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M-/\ AG;0>#-0LHHIHTL[C2C<M=R+NF,Y<Z@)/-50NR,&(@'N'[/WQ?U?XP^
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M?V;E_9J_99T?X=7VJKXF32TO4GO%M3:"[6XNIYR/+\QRN!-MX<YQD8S@>3?
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MFT\4:9K*_#^VM?'L[6UR)X;.?6DF$/V=E'V67R+&&26U4QLXWRE@#DOV0O\
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M^(/#_AW['*LWA6:Y'F7]LEPT[K):371EN8XA%&(7N9E#.A1$ /./BS_P4?\
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M-U%%O&1#<6\$@B=]KK'L8E2V?,_%O@;]J;]HN7PQX5\9+\//A;X0T[4[._\
M%/B+P/XQU2;6/$L5I-',;6SA^RVLFG173QA9,W<[I"[Q[G^9G .BO?\ @I[X
M T#XGW'A^;P[\2&\-V/BG_A#+SQR/#<G_"+V>K&46_V>2Z+;\?;'6T,RQF$3
MML9QAF#?C)_P59^'?P4^*GCOPEJ7AWXF:I>?"U;*\\77VD>&)K[3O#NGW5L+
MD:A/<(=@ACC+ET4M.!%*RQ,B%Z\EU3]B/XT77P5\1?LXQP_#63X)>(M:N]WB
M\:M=P>(K30+N^>]N+#^R_L[P27BM)/;+=B[CCVLDOV;*F)N^^+?[%WC3QMH'
M[9%M9RZ%YOQ\T#^SO#2S7$JI;S?\(W_9O^E$1G8IN.<J'^3G;N^4@&V/^"J7
M@*UL_&-QK/A3XG>&8_"_A#4_'>G_ -M^'38_\)=HVGC==7.G>8XW%%>V8Q7'
MD2J+R LBY?99^"G_  5!\!_&;Q1H6GR>&?B1X-L?&%A=:GX7UCQ1X<?3=.\4
M6]O$9Y&M7+,P8VP-PL<RQN\*NZJ=CA?%_P#@J;^S?X@B_9E\2^-I6TQ=(^'/
M[./Q(\-ZL@N'\^2ZOM,TIH6B'EX:,#3+D,S%2,QX4Y(7K-'^"'QV_:%U_P"$
MT?CJ3X<>&?"?PN<>(K#Q!H%[>7VI^*M4&G365C(^GRQ1Q:= BWD\\L)N+PNZ
M0QK(%#2, >A_"O\ X*9^ _BGXV\)Z9_PCOQ+\-:=\0[C[)X-U_Q!X4N=/TKQ
M7(;:2[5+>1QOB9[>&69%ND@,BQMM#$8KG/V</^"OGPW_ &GM5\*KH/A/XI:;
MI/CQKBS\+:[K/AO[#I/B+48+9[F;3;:Y:0J;A4AN@"^V%VLK@)*^T%O'_AY_
MP3^^-A^(_P &?$_B[1_ 6H>)_A-XGL[[5_%%YX\UK7=4\9VK6VHVEY/"MU:[
M-* -\]VNGP^9%(WEPK+;I A;T;X/_L+^-? W[./['?A/4)-#_M/X":_:ZEXC
M>*[D:&>./P_K.FD6K&-3(WGW\!&Y8P4W'/ 4@'KWA+]NOP3XU^$?PK\7V-KK
MSV_Q>UF'0-%TXVB?VA;7[)<R3V]U$'/DR6BV=X;A"Q:$VLRD%D*UPO[37[;'
MB#X'_MM_"'X9Z?X'\4>(M%\>Z?J-WJM]IVD+=&-HW@CB,4C7*!! 7:2XS&Y$
M4L)3DD#RW]A'1_#7QG_;-\>>)/ .N>&_%WP8^&VH7]QX1U#0=22_TD:YKT%C
M=ZK%!(IE3=;21W,F^&41+_;LD7E!H2[>Y?M,?!?QYK_[2OP;^('@G2_#FN1>
M!7U?3=9L-6UB?26%IJ*6J/<P21VUQYDD(MR1$P02;QB1,&@#QO\ 9L_X*K6)
M\>^,?"_C[3?'MY'HOQ;UGP,?&%MX7*^&=#=M8GM=)TZYNDQF5T-E%YH1UWW=
MN)9%9SCUCQI_P4^^'O@3Q3JT=[H/Q$;P;X9U&;1=>\<Q>&9V\-:%?0RF":":
M<XE98YMD;SPQ26\;.=\JB*<Q<+K'["OCJ]_91\9>"?M.@#6=<^-H^(EI)]JE
M^SKI@\;VNN!&8QY$_P!DA==@4KYF%W;<L/+/VM?^"=GQP_:+'Q:T75/^$!\7
M6_BB\U'5/"GBK7O&6M!=!MVA86.G1^'5C:PMIHE/V8ZA#)N95-P\,DQ96 /?
M_P!A;]MO7_VG?BU\8O#NM^!_$GA^W\ ^++G2-,O+K2DM;=K:.VLG$$[_ &B7
M?>E[B64[%5#"\)X;<#C77[>_B:[_ &VOC)\*T\$^)['2?!/@[3]7TO73HZ?9
M[>YE36&DGN)3.P-K)]AMTMR(@S2)<JPQM(ZS]D;X*_$3X/?'?XP2^(M'\+GP
M?\0O$LGC'3]2LM>GGOH;F6PTZTDL9;1[2-1&AM)&6=9SO!4&)>HSO%W[/7Q$
MTW]M7XC>*-%TWPOJ?@GXJ^ M+\+WEY=:Y/:ZEH=UIPUR2)DMUM)$N(YGU2)6
M8SQ-$(V;$F0E ')?\$X_^"HFE_M*_#+X0Z7XLTOQYI?B[Q]X/M]1@U[6O#C:
M7HOBN^MK.)]2^Q/G VN9I &2-9(U9XO,C7=7HOPU_P""E?P]^)WC[0=*L]+\
M>:?HOC2Y-EX2\5:EX:N;/0/%MP(9)C%:7#@%24AF,9G2);@1%H&F5D9O/_"G
M["'BR/X<?LG>']:?1Y(?@YX4E\/>*WM[R0L[R^&O[+9K,F'+GSR?F<)B,EB"
M3M'DO[)G_!)+6/@[XH\ Z5XB^%?P.AL_AMJ%K<P^/;36]6O-1\0QV$H-BRZ-
M*J0:?=OM@D>4W=U''+%)LB;?&T8!]S>,OCYH/@+XO^!_ ]['??VQ\0!J!TPQ
M0JT"_8H5FF\UMP*Y5QMP#D^E>1_%/_@J/\._A1X,M]9N-%\=:PU_\0[[X866
MGZ-HGVZ_O];M8[MS''$CY,<C6;HDAP SH7\M-[I8_:V^"WQ$\1?%KX3?$CX;
MZ?X5\2:W\-[G5(IM"\0:K-HMOJ=MJ%GY#.MY#;71BDA:.)@I@99%=QN0JN?+
MOV;/V)OBUX4TWX9:EX_N/ __  E6@?&OQ%\3/$(T*YNO[/-MJ>C:Y:)':^=&
M'++/J< *R=$5SO8@!@#U2R_X*8_#^X^!VK>,I-&\>6>I:+XE/@RX\'SZ!(OB
M9M<81/'IZ6@)$DDL,\$ZNKF'R91*TBH&9>$^'7_!2/3/$_Q]^,UYXFD\2>!_
MA_\ "WP#X;UG4='U[0)+;5M%U"[O]>6Y#Q1*\T[36]KIQC2$RJY91&"[LM5?
M%_[$_P 1],^(WC+Q]X5D\*W7BZS^,L7Q.\*Z=J]W/#8:G9OX1LO#EW:7<T43
M/:RO%_:!CD1)Q&XMF9)%+H.8^+7_  3X^*_[9#_&B\^)B_#WPQ/\1_"GA#3]
M#TO2;R\UBSTJ\T'7-3U:*WO9VBMI+JWEFG@,DD*6[>7-)$JJT*W$H!Z_??\
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MNO#FIZ1=>*O"GB35_$5_?W5YIUSI_P!HL[*\A@CT]0MU-(?,ENGV$0Y^8S*
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M1>8MJ8@ZQR;#(K%6 .:_PU^"WC-OVI/%GQ)\16.BZ2/&7PV\,^&YM-L=3EU
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MEJ##0'N;:%[768+%[>."V>,F)8IXYXF1II#M@BDWEI#&@![-=?\ !3+X=_\
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MOC'^RK/H/A72[C6-8;Q5X5OUM89$C<P6GB/3+JXDR[*N(X(99",Y(0@ D@$
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M$XO#OCEG3P[J5G>_VA:Z\Z%0R6DENL@G?+ !8\L<-@':V+6J_M^?"'1?V?\
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MDU*TDF5A*0A41)(2&." 1SG! -#X1_\ !1/X*_&SX?\ B3Q-X9^)'A6Z\/\
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M+6O$'[-^MVVB_"K25NHY?^$FTBWN-8B:]6)KB*$2OIFMQQ$.\1EFTG>X*^4
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M&"0R>5F!!&=I82Y#?(PKB[3_ (*P_#7X>_M._$3P#\2/&GA;PC_PCFIZ1;Z
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M'3$@$Z07\Y@^T?9XIY(EA:<1AB80_FJ4D4H&C=1TF@?M_?!_Q1\;I/ASI_Q
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M\?:/8G2;JZ"1ZII;232C2[AE#^2)I(8O.PC(V]$"G=@'(->*? ']EGQ;\/O
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M?Q_\0-*O='TV2XL)+5K32XK#S9;R(NR\3+91JD,,NTR)'" #]"H9/-B5NFX
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M/A-EX>\%Z'XP354NMWVLZC>ZM:^4$Q@*JZ6&#ACN$Q&!@$^;>%/^"@L>I_\
M!2_Q5^SSJWAV#28M/T>+4- U]M25FUVZ2WM;F\M/LYC!1X8+J*0,&8,H;H00
MOEG_  2#^#?C#X6Z]X;3Q1X/\1>%VT?]GOP!X,NQJ=B;=5U;2[[Q'%?6ZL,H
MY0R12 J2&CN(9!\LBFJO[0?P)\=1_&_X]?$[PUX7\17WB3P'XO\ "7COP=:V
ML*QMXK6QT<6FJ:?;R.IW&>RGOK3*8(DE0'?S&P![)9_\%"/[?_X*9-^SOI?A
M^SOM-L?"MUJ^I>(UU$[K/4X#9N^E_9O+RQ6VO[*9I0^W%RJC<Z2!?4/AG^U/
M\,?C1X\U[PGX.^(G@OQ7XE\+[!JFEZ5K%O>WFFJ6V_O8XV)CRP(YP =H..!7
MQ'X7_8J^)VH:E\/;R0:[X;^(GQ+^&WQ,U7Q5X@DAWCPGXC\0MH$EI:2RPD'-
MH(A;0[7R8]* 3 10OG?@#]B[QI\=? G@OP38_P##37@[QQ\-?#.KZ+I4OBK0
M?"^C^&O 5S-H]SI<BV.H:?I,%Q?P&1X]B6DZK<(D<SNIC% 'Z(>'/VT_@YXQ
MO/&%KI/Q4^&^J7'P^M);_P 3BU\26D__  C=M%O,MQ= /^XC0(VYGP!M.XC&
M:\X_98_X*6^'?VR?!_PGU;P3+X)N+'Q^;ZTU?3YO%EJ^I>'KRWL?M2V:P1@M
M<3;2K2(NUHXV$A!6OG/]C7]GG5M?^+?P)34M)_:<TC4/@D)4&G^*] \*Z)X=
M\(1&SDLKBSM+[3]'BEU""5BB".UF$4J1)/(ZB.,-L?L+^!O'$.F_L>:-K7@'
MQYX?OO@V_B+P_P"+'U;2)+:WLYQI+(D\<V62:VDD<1QS(Q20AL$XH ^M?A/^
MW%\%OCSXX;POX'^+/PW\7>(TLO[2?2=&\0VM[>"T*HQF,4;EMNV6,YQQN%'B
M3]MWX->%OB/=>"]4^+'PYT_Q=8^1'<Z'/XDM4U"W:2>.WC1X"X8%IIHXP",E
MI .I%?*/[*O[*>L?#7]DO]@'38_A_?\ A_6O!OBY=7\5VJ:88;C1GG\+^(([
MF>[PN4,EW/;I(SGYI)8P3DK7AOQ+\80>!/\ @FA\/_A#K7PD\0:MK7A;QUX3
MN)_'K6%G)X9UNX?Q#92-XFL=3\W9=3ZBEP6VP%[H-?SK)\D4\B@'Z^?9UDMB
M[>8IY(ZY7Z5Y;K_[8GPE\.?&RS^&NJ?$KX?V'Q$U(1I:>&KG7K:/5+C>K,BI
M 6\QMP5L?*"1C Y!/1?"OXS6GQ<LO$JV^C:UH[>'/$%]X>N8=5C2&2:6WDP9
MT"NW[B9&26)CAFCD4E5R!7YO_MK?##XD?$+X4?M&?"_3/A7\1M.;Q!K6LZUI
MF@>#?!6C#PKXHB,?VB/4]0U.X#37EW<R"*5HX'ANUN4$822-!(X!]ZZI^V[\
M&=#^,<?P^U'XJ_#VQ\<W6I)I$'AZYUZT34Y+Q@K+ D!?>TI\Z+"8SAUX^;F;
MXO\ [7_PU^!WC*P\)^(/'G@O1_'>L6;W6B>&;_6K>SU+7"2Z1+;PNXD?S)8V
MC7:I+.I !(Q7QY\:?V6-7\:?LG_MTR6OP[U*Y\3?%#QE%?:/%-HV[4->M(=*
MT1K0H"OF2)#<K>&-<D1RB?&#NKJ/'VAZI\(?B5^TQX5UGX(^*OBU-\>+Y;[1
M]6T[1H+K2];LI-)@LHM+U&[<D6D=E)#,W^D J8[K?"DCLT= &I:Z'\(/#_[%
M;_MM6?P+^'4/Q.C^&<OQ7$L%G$MX;M]%:^>+[8(@Y9PS1&<Q[VR7*DG%?1GP
M+_:S^&7[2\NJ6?@'X@>#?%VJ>'Q$NM6.AZS;ZE-HTCY CF$3L4^9)%Y')0^F
M*\#UWX0>+/\ B'TO/ 2Z'K4GCO\ X9W?PZ-$6V9M1?4_^$9-N+7RL&3SS/\
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MV3?B)\7O"_Q"\!_$'0?AWI<UW=C1/$EI,EU=K$QMM/$BNRI<7,NV&)6&7>0
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M"OAGQSHGAOX)Z[X?L]#GT"WFT??#KOA>YLK)8'*02O##:75Q;6CO&CO:E0Z
MLZ\)#X!^(GQW_:,\0>*_^$6^-FN?\)1\$/%W@>WUGQOX7TG0,ZC,=*FM[2."
M%89[6U=X+MD:_.UI7D"2E,$@'WK^RY^T+X3_ &M/@?H?CSPCK.EZQI&N0),7
MT[4HKZ.UGP&DMFDC)7S(I&*.O4,I!':J_P (/VKOA?\ M":SK.D^ _B)X%\;
M:EX<<QZI9:)KUMJ,VFLK;3YJ1,S+AAC+#[PQ]//_ -GY9?CE_P $ZM+TC6O
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MWO[8K:CX@EU+4+?2;UO$UPAN'%O-'=E=RZ!_9)MEV+*+(P$Q>693Y9 /UO\
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MEF_X0_3I-<L?#GF7D\^KR-$Z;K>)I6^TWS6C2D9!=4DD.$WK]R1DE/FZ_3%
M#'LH9%96BC97.6!4$,>G/K3WC61<,H8=>:=10 Q;:-5P(U X& /3I2&TC*X,
M:$$8(([<#'Z#\JDHH C-K&?^6:],=.V<_P Z'M8Y58-&K!LY!&0<C!_2I**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU?#\$=8\6ZM;_$R;4K'24TR/PKK$\'VF\CADMD-Y':M:@,D\1+&7:F[#%2K
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M_P#X*C?%#P>'F\/>//A+H&HVPN8=D\7_ !(7C>&8JQ_>1R))&RJ6 ,9()W
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MO38M*L9=0E66Z>*,84R,JJK-SR0H'M7>44 -V_-]YOI3B,D>U%% 'S#\%/\
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MA9_#SQA8>-=*72+F.WS>V4<\<,<F^-P8-L[Y10I.%PPQS[41Q110!^>_@?\
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MXS:/\+YG=KKX7Z?\0-1M_!-X'+/(CV ?_5O(WF,BR*I8=-I*G[8HH \%T_\
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M[^.\ME)=;O!?Q"D^QW!@;RM)+B8Y<;X_G&Z/Y>I_O*<<U$/VDB!SX"^)F?\
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M_#?]GO1] \,W5Y?^)/#^JV%[=7]M"Z3R6AC@@C?:5A\T98C=$HQ7PA_P1_\
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M;XN\,:%+);Z3KEC%I*S_ &V73T;R1+!-';K]H5 ?WRB0M^[V_>WQU^ _A/\
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M.Z/X0@7X;Z_'>Q:EHUW>W5\M\+PL;HR2SR/,S2,[,6+[MQR"#S65XU_X)L?
MWXC>&_"NEZY\.](U*/P7I%OX?TJ[FFG.HQZ9",+I\MX)/M%Q:,,B2":1XI@S
M>8K[FR ? ?Q_\>>'9O@3^PWJ/P8\;>)OVA])T7XV2VGA[4O$VL)%?:V]O9:M
M$;9[V6VCW+$ZM&LKQL66-?GDR'KU_P#9;\:>+O&__!=OQQJOCOP/#X$UR/X&
M:7;IIT.NQ:R'M_[>NRDWFQ1HOSL6!3&5\O))#KC[#U;]COX8ZOI7PZT\^#=)
ML]-^$NI1:OX0LM/#6-KH-S'#) C110LB;1'+(NQ@4^8G;G!K7@_9W\&VWQ_O
M/BE'HL:>/-0T"+PO<:L+B;?)IL=P]PEOY>_RP!-([;@N_P"8C=CB@#\J?^#A
M_P"(LG[2WQOL_@_ILGB:*W^%7@N]^(8.A^';[7Y-0\42(\6AZ;)':Q2) Q"3
MRAK@&-EEYVCEO4O"7[3UE^VI^W'_ ,$[?BA:VZ6DGBSPA\0)[NW$B2M:7J66
MG074!9!SY=Q#,F<#.PY5#\H^]_AA^RSX#^#?Q?\ 'WC[PWH/]G^+OBA+9S>)
M]1-[<3R:HUHDB6V5DD9(UC660!8U48;H<#'EVK?\$B/V>=5T?P_IZ^ )--M/
M"E]J^H:*FE^(-4TW^R9=5DCEOQ;FWN4,4<SQ(3$A$:X(55#," >2_M>:8O[1
MO_!6GX8?!;X@/>)\(+OX<:SXOM]%6ZDL[/QQKD-];6K6-Z%8?;;>"QFDF-G@
M(WG,91(AVCP/]H'S/@OX$_X**?!?PK?:A=?"?P1\(XM:TW2;R\EU"'P?J-[H
M]WY]A;R2LSPVS0PV]PMHS%8_,)B$<;!*^^KC_@G)\&=2^$%IX%U/P:NO^']-
MU)]9T_\ MO5;[5;_ $J^9=OVJUO;F:2ZMIE'W)(94:,\H5/-;6C_ +$7PG\-
M_L]>(/A3I?@71-*\ ^++:YMM:TJQ1K7^UA<Q"&XEGEC82R3RQ@!YV<RMU+D\
MT ?D/X?^+7B;X=WO[&G[.GQ$U&\US6O"?QA\'>,? ^N75O*I\1^%KO1[TG=(
MQDC:6PO+G[(0K+^Z-MM3Y6:NHT30? _Q2_X)+:7^U=\:K+XT:G\8&UN_UCQ'
MXR\"^(;6R\3_  TN;>_N8I+.Q34KN*&SM42-+(V,:2/(9D!BDDQ(OZH>,/V(
M_A7X^F^&<VL>#=.O;KX.W4%YX-NFDE6YT.2&)8DV2JXD=-B(&21F1S&A96*J
M1P_Q(_X)*_L[?%WXI:]XR\1?##2=2USQ5(T^L9O+N*RU.<V\EM]IFLTE6V>X
M$<C[9VC,J.1(K!U5@ 6OVQ/$D'CC_@F)\5M:MS<26NM?##5[Z)KB-8YGCETB
M=U\Q5^4/AOF"_+G..*^!?^"97[)NI:O9?L6^-?AC\"]2^"[:#X<L=4^('Q!-
MSI%M;_$*QN- 1&B^RV=[--??:[HQ3B2^ABEM_P#6!5D9P/U6UKX.>&_$/PCO
M? E[IJW'A/4=(?0KBP,T@$MD\'V=H=X;>,Q$KN#;N^<\U-\+_A7X?^#'PU\.
M>#_#.FQZ7X=\):7:Z+I-FLCR"TL[:)8H(@[EG8(B* 68DXR23DT ?DK_ ,$8
M/V7]+\3?!KX?^,?^&2_AQXTNH/'>JW2_$Z\UFPAU: P>)+L"]6%X&FWVOEC8
MOF;F^SKM8;ACP7XK?"[PQ=_LR_M6>)O^%'ZG:^.+'X_^)&TSXYVZZ9;P^ ]O
MB2(K>2W"W8U95M<F5O+M63YA\P&67]=OAW_P2;^!/PE\3Z;JWAKPOX@T6XTG
M51K=K#:^--<2RCNQ<?:2YM?MGD,&FR[(R%'R0RD$@]9?_L!_"/5/@G\0/AS/
MX/AD\&_%+6;[Q!XHT[[?=@:K?7LZSW,YD$OF1EY55L1LJK@!0HXH _/[]I;X
M&:?\:?\ @M-\1(+[X#^"_P!HK^S_ (5^&G%KXCU*RLX=.W7=\#<1&XBF#-)@
M @;>!U->@_ 7]GCPW^T]^W?\9/AG\3/!=KI_@OX)^&O"-CX"^'EMJ,L.A:-;
M7NFO<W5W%;PLD4T\=\)(([S9F+[''Y7ENI8_=7A[]FWP3X4^-NK_ !&T_0H[
M?QIKVD6F@W^IBXF9KBRM6D>"(H7,8V-+)\P4,=V"2  ,+X__ +$'PG_:CU'3
M[[QYX'T?7M4TF$VMIJ3;[?4(;=FW26WVF)DF-O)R)("YCE5F5U968$ _*?\
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MW=KI>E:]]KU&]TZS^T7T:QSV\NE2/:1Q6[,&9E!7E=OU!^Q-_P $^?@;H_\
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M2^7QEJ.E:OK,K:WJ*W%[>:7;I;6-P9EG$BR111H RL"Q&YMS9:NJ_9\_8W\
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M?V$?AM^S;XRN-?\ "=EXJ@U.YLCI\C:EXRUG6(C"7BDP(KRZEC#;H8\.%#@
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MR_!7P!^RAJGP/T?P'I]A\+-;$XU#0H[JYV7GG2>9(9)C(9F)8#DR9"JJC"J
M #YK_9!_9ET_X2Z#K.M6O[(_PY^"K7'@*\B/B_0]:T^ZO;TO!"QMVB@MXWVR
M;3(6+$ P#(.X&C_@GOX[\2?"7_@W'\&^)O!MBNH>,/#/P>O-5T*U:V-PEQ?V
M]E<RV\9C'+[IE0;<@MG&>:^DO@Y_P3N^%'P%\076I>&M(\20W-YIL^D2I?\
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MT5@LJ29^D/!G[&'PF_:P_P""J_[>EQ\2O#^GS7'AF^\$7.F^)1)]CU3PH?\
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M@ HHHH **"<"FM.J*#SSTP"<T .HIOFKOVY^;Z4Z@ HHHH **9).L1&X\D@
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M?%N]\6_\$N)HOASXLDB^%.FV2^,F%E_R+!6;2V87>3F/ AE)S_SS;TH K?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=&PT<8,EU= N0<L ?L5ITVGZDI:TDM;A8FVDQ,&53UP<<9YZ>A]ZL_882?\
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M8W"2^;%^\QME+AOFR#D?,:$LXX]NU<;22!GUH ;:V_E%]R_>8D'/_P!8?3Z
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M.6.5+==:@59$DL))F1Q&K"4R(Q4CS(8PVU69E_//]NCP_P#M4?\ !5KX(O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV]CN[>5E.&"R1DJ2I!! /!%:YD4#[P].M?C)^SU\._$/[#G_  6!_:%_9O\
MV=M57PGH_B[P$?$WAO3]9G>\T70=>,-HZW7ELDC[ A>/'SN5V!BXCC5<C_@G
M9X/^+7A+_@Y5\66/QT\6Z)XY^(UO\.KMKG4])@,5A#:R?898+2!&AB*)$LI&
M-ISNRQ9F9B ?MDKJZY!!'J#2E@#UK\V/^"RO_!,']E.T\&_$G]J+XR^$]<\0
MZ]I&F6\T\=OXCGT]=5N(8H[2RMEVDK&TC>5'N /+EB&Y!Z'_ (-[O^"6\/\
MP3\_99D\5:EYUGXZ^,5KI^L:YIH0);Z'!$+B6SLD&-QDC2\E$KN26=B!@**
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M.XQ)(Y=XT"[G!'S9\,O^"GW[2?[+?[3'PR\#_M<?"[X=^&=!^,TT>E>']?\
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MBOQ)H/AFQNIQ:PW&K:A%9133%681JTC*&<JK':#G"D]C63X#_:2^'?Q3U_\
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MKF@62GX/?$G3+Y-!M_*EM%N-0=X+B26=XXOM4:^1*6268AL0N-X!^U)=5/)
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M\L+@"_?PK=:>9K=+OS5BN9;CSEMI1)"Z2@,US&KQQ-#*& /U :158*64,P)
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M7_ASJ^B:)X,\,7C:I/I]M]D>6YFO;YI91*\LD$3(L;[44-N&X\?,'[ /A/\
M:X_:#_X(OV/P9^$?PW\!Z_\ #;XF3:I8S>,KCQ%'977AV)M0VW4%S;3$F0OL
MGVRVR.5BF0@"6/YOWJ^)O@S3?B9\/=;\-ZQ&T^D>(+*;2[^)9&C:2WGC:.5
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MI\-V?PQ^'?Q6M?A_X:MM+\>_"/Q<FE2-?SK!L2:QU*0/'!<1.Q)99@IV1,C
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M[G=Y[SYI;BWB:*:XFE(VF5L)%]S!!_;#=FDWKZC\Z /Q,_;)_P""(7QNN?\
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M Z+X;O/CCH^EZ;XCD6V62>XO8%U%7\[[1//"'4(P@A"*0)'=P#A/!WQB\3_
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ML:E;W7AOQ%\2M*;Q-X,@U0VNK>/='MY%>>RM(EP\V)'@+890C-$Y8$+CS?\
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M/[#M/^?6V_[\K_A1_8=I_P ^MM_WY7_"K=% %3^P[3_GUMO^_*_X4?V':?\
M/K;?]^5_PJW10!4_L.T_Y];;_ORO^%']AVG_ #ZVW_?E?\*MT4 5/[#M/^?6
MV_[\K_A1_8=I_P ^MM_WY7_"K=% &-XG\ :3XP\.7^DZA8V\UAJ=O):7,87R
M_-BD4JR[EPRY!/*D$=B#7"_LJ_L6?#7]B?X2Q^!OAGX;_P"$?\+Q7DU^MG/J
M%UJ3":7'F-YMW+++SM'&_ QP!7J=% %3^P[3_GUMO^_*_P"%']AVG_/K;?\
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MRO\ A5NB@"I_8=I_SZVW_?E?\*/[#M/^?6V_[\K_ (5;HH JC0[0'_CVM_\
MOTO^%>3_ +/?[!'PI_96\??$#Q-X#\+MHNL_%+5/[9\3S2:G>7R:C=>9<2[U
MCN)9$@&^ZG;; L:_.!C"J![%10!4_L.T_P"?6V_[\K_A1_8=I_SZVW_?E?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>proxy2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxy2.jpg
M_]C_X  02D9)1@ ! 0$!3 %+  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X@( 24-#7U!23T9)3$4  0$   'P2T--4P(   !M;G1R
M4D="(%A96B 'V  $ !< "0 >  5A8W-P35-&5        *P0  "@/
M            ]M4  0    #3*TM/1$$
M                                  EC<')T    \    "%W='!T   !
M%    !1D97-C   !*    '-R6%E:   !G    !1G6%E:   !L    !1B6%E:
M   !Q    !1R5%)#   !V    !9G5%)#   !V    !9B5%)#   !V    !9T
M97AT     $-O<'ER:6=H=" R,# X($1E;&P@26YC+@    !865H@
M]MP  0    #3.F1E<V,         &41E;&P@,3DP.5<@0V]L;W(@4')O9FEL
M90                      V+)       #_____$0$   $
M                  $         L R3 ,0ODP#$+Y,     6%E:(
M &WO   VH    ]Y865H@        9:L  +<!   7(UA96B         C.P
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M #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF_&3PAK/B2'1K/Q5X;NM8N(UFBL8=3ADN94:-9598PVXJ8V5P0,%6!Z$&OQ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^"?\ @H3^
MU)XV^'__  4.\&_#W3_B+\8/!/@[4OAGJWB26'X<^ +?Q=JESJ=OJ-G! 983
MI6H2K;^7/*K$+$F_R@94+ , ?>U%?FO\$O\ @LK\4/A5\,M>LOCQ\(]2M]<^
M"W@#3?%_Q0U_3-1M(5L/MEGJ$UK FGL=[7MP]I;Q&.-_)CDN)V>2%8467U+Q
M?_P5YU'X:?$'3_A[XF^#?B'2?BAJ_BG0/#5GHO\ ;]C<6977+75+BQNY+R,D
M+'&VD7<=PJQN\93,0N%*%P#[6HKXAT[_ (+/VGC:3^P_"7PM\5:]\0-!T_Q)
MJGB[PY)JEC9GPY%H&HC3K^,73L8;F1[@XMQ$=LBD-(\'.)?AK_P6?T3XK?'G
MPSX;L/ ?B#2_"OC?3;74O#NMZW>PZ/<Z_'<Z5'J5N]E;W8CAO(Y!(+?%O=2W
M"SI)O@2)&E !]LT5^6/Q/_X+JZ[\5_#$>B^#=/C\#>*&U3P9K=KJ&GZI9^);
M&_T+4_$\6DW4#3_9_LXN!ED8VS7$0WYBN692:^E_^"K/[1_Q>_9P\/?#*^^'
M9\)Z;X=U[XB>&?#_ (CU6]N'DU6.VO=7M;=[>SM&MG@?S8Y'5YI)D:-"VQ"Y
M61 #ZWHKB/#WB;Q!\3H/'&D76B^(OA^VF7\NE:3K'FV5Q+J4)@C9=1M5(FC4
M"21U5+B,G="2T94@'YJ^!'Q\\8_#NV\6:IXH\?>-/B5J4WQ-O_AMX8T"^MM%
ML+6>7[3&()I)K6PAD3R88[B61RSCRDFVPS2^3&0#[,HKP^Z_;BT7PO\ LW_$
MWQ]XDT?5M-N/@_-J%EXFTBS:.^N%NK2)9A':OE$F%Q#+;RPLYBRMU&)5@<21
MQ^!?%/\ X*JZEX$^(NBW6L:)XB\/Z#X376+WQ%9V.GO=P>*+5-,N9[%;&>\M
MK9VG$\!C>+$/ER%-[-#)'-( ?=M%?+7A#_@HIJWC_P"(#?#_ $?X<W]Q\1Y$
MN]0M+:YO9]/T.]TNV$/FWL=_<V<<C;9;FVMFA%J94GF0E?LY%T=O]DO]I;X@
M_&_XY?%;2?%/AG3_  KHOAG^Q)-)L&O?M&KZ>;S3(KN6WO5CC,'FHSD,8IY5
M# JK.H$C 'T517PKX*_X*@?$/P?\'=3U+QM\.;/7/%%QK'CBP\/67AK63+#J
MUUI'BV/0;'22\UK$4GGDND1)=K!H[22=UC+-%'Z1X9_X*-M\4O%^KZ/X!\$Z
MAXR>QM;K6-/NAJEO8VVN:7;VVG,\UN\@_P!>]W?36D43[8FDT^X:6>!#&7 /
MJ*BO%?%/[9^F77PQ^%.N>!]-D\6WGQP\@^#H;BY_LRVN$ETV;4Q/=2LCO!"M
MK [,5AEDW,BB-B3CQ2]_X*%^,O WQT\6Z;KOA]=.N[VS\,6&A^%==U:TLX]*
MU.ZBU^:ZW75K%<7%R)DTI1&EM#=2']TWDPQFXDB /M6BOC_PI_P5:_X3"Z^$
M-Y'\/;[1_#?Q2TK1+Y-1U[5ETI?/U2;R%LK-Y81:W5U;R<RVTMS;7#(R&WAN
M781UW_[&W[<%U^U+XL\0Z+J?A ^"]4T6SMM2.EWNJ@ZS817#RJL&H:?-%!<V
MMPOE'+(D]G)D^1>3[6( /H&BOC?]B[]J+Q]\5/V@/"NB^(/$4FI:7J.E?$:X
MN8#8VL/FR:7XTATW3VW1Q*P\FS9HL @/G<X=\/7(?M:_\%)/&VD>%?"OB;PM
MHNK>'OA[?>)/&6DRZU:7^GR:EJL>B>&O%,S*(+BWF2U,E]I44]M)B?<EJ1<1
MQ!S!* ?>]%?'[_\ !3^ZTI+RWE\#WS*OBUO .BW=SJ>]M<U2/2#J\DTD=M:2
M/#:I:Q7!>58W<21[4@96#+T7PL_X*%ZQ\>M0FA\&_"?Q5?2>&KBTM?%MOJ5Y
M%I5UI<D]W/:XM8IE!NU1(1>%V,"/:30O"TTS&V !]/45\9_LW_\ !1+Q]XY^
M%UY'K7@?2?$7CK1U\3ZWJ5IH.MB*VBTG3=;O-.MXXI+F"+S+V=K:9(498X7%
MH\DT]KYL<9M:C_P5)U#7%\7:IX/^'=YXC\$^'-9TS1[?Q0]_<1V,POM T_78
MKRZAM[*YN[2S2WOA%),8'V2R6N0(Y+B6S /L*BOF']H+]LCQA:?L+^"_BE\.
M=+\)W.K>+/$'A6R-OJ'B"&ZT^.VU/6K&QE6.\L4N89PPN=BS1[E59#* [1B!
M]SP)^W=#XN^(WAVQD\+ZA:^%_&WBK6O _A[6?ML4CW>KZ2NHO=++; ;H;=UT
MJ_\ )EWNS_9_GCAWQ[P#Z"HKYD^-W_!1JU^ G[0=QX8\2>&Y-$\*V*EIM>U/
M4/L,E_&M@U]-<Z9#)"(-1BA56CEBANC?*\4S"S:)4EDY"T_X*KZMK>M>$='T
MWX2^)+C6O'FJZ;8:1'/=O9V<<=Y:WUPWVFZFME1+FU%B6N((A,OESH]O+=,K
MQJ ?95%?(NK_ /!5.U\*Z5;_ -K>"]2CUBUN;S2M=TZSO1=/HFH+XCM_#VGP
MG]RKR1W]Q-)<0R>6K&UMI9!&S;8VZ+6OVU?$?B[]B#XM^.O#WA>30_&7P[T[
M4PMMJ_VB/3;BYM[!+Q;BVG>V22XMC',A5C;QL9(Y(G6-E;: ?3%%?(WP%_;N
MUK1_AMX?7Q=I>JZ]9Z/K>A>!?$_BR34K.68Z_JR6'V=H[>"UMEFM!<:G9VSS
M+% ZR29%NT2/..W^!_[;=Y\2/V 8?C]XB\'GPGI&H>#AXWM-);7K268V!T]+
MQ?-N9O(M8'?+A3+((U3RWE>(M)'$ ?05%>%_LI?M<ZG^U#X.^(36OAO3;#Q1
MX"U;^Q#:?VG<MI>I3R:;9ZC;21W4UE#<"!XKZ!6<VF599"BRJ$9_E?\ 9Z_X
M*B_%V3P3I?COQMX7TO7O#*_ WP!\1?$<&D:G%;_V2^JW>NI=7=JDENLEQ/-!
M;6DAM'D2*$6LJ),S%6N #]'**^/;'_@J5J%]8Z4%^'-U#J7B:Y\0C0[2757E
M%W9Z'J<>G7UU*UO:2F //<6BP+M?S//_ 'A@5"YN?#3_ (*PZ)\5/%>CKI?@
M7Q^GAZ]U*UT2_N+S1KJ+5-&OKBTM;@>?9K ZK;Q/<K;3OYXEBG5SY+6ZFYH
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M$;X@?$*V\%_$W2/AYX9T":RT&TCU.74]#\/3P_:)H;"!UV7>JW$C2+(NV*/
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MM,CL[OQ)#9:#H\S>%XM9G>*XCTW[5Y##>/WD<\AE<8$<7$>E^RC_ ,%*;?\
M:*^*VEV=EI?BB+3_ (A7UN=.BU6YLL:!&?"NG:R8DC@@#,";HJWF3S'S?,9)
M!$4B4 ^P**^)? W_  5LUCXC^#]%\0:3\+U;2=6M?!H=KGQ.D4L-]XH6W%A
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MO-0OK/\ MC0;76]7D:75[^>!Q;3WMI%>7%XRP,3(8(XU+R$NP!QOP7_X)X?
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MQZ1:2/X-FU%T\2K<S6=KXKU+^S-):-%MPDTZ7(;[5&9$CBC&Z*:Z)V5Z);?
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M=['_ &>[/%>6L()BC2-Y(YWN+?LK?_@JII5GX2\+ZSJW@/Q%8P?$SP]:>)O
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M.,Q7<L9D!]\L_P!@/X->'(+:4^"])DMM+\"/\-%2\GGN(1X9)!;39%ED9'A
M! ,@+*C.H8*S ^8_ +X??LU?'?Q?8MX3C\2>*-<O]%TWQ0-1U6^\27,]Q8P_
M;['3KNXNKYR6,L=U?B#SI#)<PDRH)8HTD4 X/PC_ ,%6]6F^%'@K0;JUM]0\
M4:YX5L[2^\0Q7\,EY::[/X1.OI=36,$#V\%JZJ4'GRPRF4_+:-;LDSW+_P#X
M* ?$+3_@-\'+'7[&7PEXX\<2>!]8@U-;FROUU[2+GQ!H.G:PL\:Q".UN@NJQ
MK)'&K1JE[&UO<,Z2"#V'5_V /@1\+/"EWK&H:3_8/AWPS#%JL\ESXIU.WTO1
MQ9:=]B-[L:Z$,$@L%:&:<!7EA:597=9'SK>!/^">?P<\%>&=/M=)\-M)9:;_
M &*=,:XUO4+X:;!I-W%?:;!;--<.8+:&XAAE%O$5A8HNY&'% &5^Q[_P4,TW
M]KWQ'IMOIOA/7M+T?Q-X;7Q9H&J2QR203V+?9<179,:I;WA%W$ZPH\R/'O99
M2T<J1^9?LV?ML?%+7OB5X[T'5O#J^-/%-QXB\2RZ1HEAK=I;Z?I&C:)>P6+1
MQS26=O*UU/)<1B-9FECD=79Y[./"5]'_  C_ &4? 7P-\33:QX<T:2SO#;/9
M6GG:E=WD&BVDC1M):6$,\KQ6%L[0P,T%HL43F"$E"8TVYNM_L1_#/7[6YBF\
M.M%->WVIZA+<VNIWMK=2-J4B2ZA&9HIEE^SW$D<32V^[R7,464^1, '/?L;_
M +<]O^VWKOB:]\*^&;BW\ Z&NEFR\0W=Z%FU@ZCH6DZW;A+39OCVVVJ*)#(R
M[66,)YF^00>6>#_^"G5QH6M:'I6H>&]5N]-U;Q=JVAMX@\2ZQ::7%<.GBO4M
M%CM+&=;6&QN)X/LBRFUGFM[@VTEN(FU"Y,@/U%\,?@UX7^#]WXBN/#>E6NDM
MXLU&'5-26W+B&:>&PM-.B*1EBD2I:6%I$$B"IB$';N9F;SV#_@GS\)H/$,&J
MP>';BWN$OI-0G6WUO48K;4IGU6ZU<?:X4N!%>1IJ-]>7$<5PLB1-<R"-45L4
M >7^"O\ @JW_ ,)#XE_LS5/AW=>'[Z?6]#TI=*O=;BAUS2DU/4H[!#J.G2QQ
MW%O(AD$@:%;BSF56$5XY S4^*G_!7O3?AE=ZH&\&K=1>&]:U&RU:'^W$_M#[
M#9ZN=+>\M;6.&224;U:1C-Y$"+M7[07.T>JVO_!.OX16&AW^FQ^'+I;.YC@C
MMHSK^IL= BAN5NH4TQC<[M+6.>..118F !H(2 /*CVY4?_!+7X(+I&HV*^%]
M3^S:W;7%IJH'BK6,ZTL]W/>L]XWVO==RK=W5S<1RSEY(9;F9XV1I') .$\5_
M\%7H?ATVH:QXJ^&NK6O@G_A*_$?@C2=1T_6;:[U#5]6T9=0E*"T?RDAAN4TV
M=(I'G!$X"R)'$4N6[3XC?MX:Q\&QINC>+OAZV@^-/$6J3V.B6IU@W>D:A!#9
M?;)+QKNWMY)XXDRMNZ_9&D%PZA5D@S<CLO$O[#GPN\7^&8M%UCPK9:EI$.MZ
MQXD^QW,]Q) ]_JT-_!J,KJTA#K/%J=\IC;,:B<E%4JA6-_V%?AFGAFYTU=+U
MB.ZO=576Y=:'B;55\0/>K;-9K.-5%R+\.MJ[6X(GXA=HA\A*D X/XT_MJ^++
MG]G3X3^.OA]X7CT^3QYXST+0]1TOQBTNFWVFP7>H+:W$)2**96F5MZ;U8QA?
MWJ/*FT/YE\%_^"INK_"_X.6>H_%O1=0U1=67Q+=:#JVG3V\E[K)T[Q%%I4=I
M-:)%#%;22R7]C';LLD@=0[3FW88;ZIUK]EWP'KWPBTGP(V@QV_AG0;NTU#3[
M:SNI[.6SN;6X6YAG2>%TF643(':3?ND)?>6WOG%/[$GPOGT:PTU_"]G<:?IM
MAK.FVUK-<7$T2VVKW"7&HQLK2$.)IHT;+9*;0$*#((!Y'I7_  5+FO\ XH:/
MX3F^'.HVLTEOK.IZWK,M[+#HNFZ;ID6F3SW\$LMK'<7<7EZEY6Q;=)5NH&C*
M"%ENJD^''_!5:R^(/BOP7IO_  K_ ,1:?#X_OM,32KN9G\F&WO89I-ERYB"1
MWT!B426\;2Q,LZ-#<3A)A%Z]\-?V-?A_\)?'=IXHT?3=0?Q/8P7ML-7U/6[_
M %;4)X[S[$+A9I[N>62?<NG62J968QK;JL>Q=P;#M/\ @G7\([#1WL(?#M]'
M&OV8:?)_PD.J?:O#\=L<P0Z7-]I\W3(8SP(K)H8]I*[=I(H \A\3_P#!7.ZT
M6V\?:E9_"V[U+0/A5I?B/Q%XINU\00Q30:9HFOZQH]P;6%HO](NY!I$EQ'"S
M11;6='G1EC\Z'X\_\%(M;\/>(_!OB:STN[\+?"'3?B+XA\/^(-?DN+:YN-4M
MM!TOQ =2C:T,;20P_;-*8PR1.9I/LC[EA1U\WV+0?^"<_P '_#'P[\4^%;/P
MNRZ%XTT'4?#.MPRZQJ$TE_IVH7=]>7D+323M(#+<ZE>R&16$@,^%8!4"]')^
MQ]\.[GQ\OB6XT-KC4(=4DUN"&;4;N33K74)8)[>6ZCL6E-K'-+%=7*R.D2M)
MY\A8L6)(!X;'_P %3]2USQ+X1\.Z;\(=?OO$/CC6[+2])CFO_LMA&MUIVJWW
M^D74D 5+BU&E2&ZAB695CFC>WDNSF,=C\>OCY\2O W[;/A'POX/T+_A+M(U#
MP%K.N7^A-?VVG*\]MJ.EQK*EQ)&SF;RKB:.*(F.%WE!EDB $J==X'_8(^%_P
MZ\4:#K6EZ!>?VIX8OH=0TBYO-<U&_?3&AL[VRAA@\^X?R[6*WU*^2.U7$$?V
MEV6-6PPU/C;^QUX!_:&\9Z=X@\4:9J4^L:5IMUHUM>6&N:AI4RV-T\+W%LS6
MD\6^*5H(BZ/N#! ",9! /,?@E_P4UT?]H#6_"ECX=\+ZE</XTUFQCTHRW'E&
M30;SP\FNPZZR,@=8-CBS9-IQ=@Q;R/GJ7X\?M#>//A/^U):_VK9^)-!^#:W/
MAW1DURVTS2[JSFU/4+Z6V9+AWO/MJPR2SZ9;*T-H?*>:21V\H-)%VWP__9 T
MOP1^U-JWQ,_XD,;0^%K#P1X8T_3-&^P#P_HUO(;B2V=Q*RS[[DAEVQPI%'%'
M&J$^9))K^)_V0_A_XQ^+2^-=0T$3:X;FTOK@+?745EJ%S:,C6ES=6:2BUNKB
MW:.(PSSQ/)$88MC+Y:;0#SO]K?\ ;_NOV7/&6N6,?@2X\2:;X1\%OX\UV[35
MX[62"PCN'@>&WB9&\ZZ)0,B.\41 ?=+&0@D\3_;E_P""D/C+X?\ P0^):Z9#
M?^!/B+\.HO%VE2_V3?6>K:2=0L_ S>([*<O=V(DGB2.YM&V*EN1<1NK&>%2)
M?K;XK?LI^!OC9<^()O$NB+J4GBGP\_A34R;NXB^U:8TC2M;_ +N1=N7=CO7#
M\XW8XK ^)W[ OPK^,I\5?\)-X774_P#A-KF]O-:_XF-Y#]LEO-$CT&Y;]W,N
MS?I<4=OA-H7;YB[929" ?/7PT_X*&:]X5^+>JZ3XENO$GBS4+[Q+XCT'0=+M
M_P"S;2RE9/%XTBPC<^0DH:&)P7E,Q'D0RDPSSE-W9^/?^"G>K>%O%NK>&=/^
M&$FJ>*/!NF>(M4\66+^(X8(]-318M'N95MIO*87+7-IK=E/;[Q#GS52?[,PD
M$7J[_L'_  NFOM0NI/"\,EUJDEU/<2F^N]WG7.J)JTLT?[W]U*-0CCN4DCVO
M#)&AC*!0!8LOV)?AKIR#R?#O[U]&UC0)YY-0NY;B[M-6FMY]1$LK3%Y9)Y+6
M!FFD9IAY8VNH)! ,G]H7]LAOA#\"_"?C;0_"MYX@L?&$EOY=Q=R36FFZ%;S6
MTER+K4Y[>"YEM;?:@C\U8)$666(2&.,M*GA_PH_X*2^*M0^*GBK7-1\.MK'P
MKU#7_ ^EV%Q;ZUIL\_AY_$EGI4-K%!]E\R+4(A?7ZO/<"Z*+',K6[7(#1Q_3
MGC[]ESP7\2_A_P"&?#6J:=J$6G^#98IM"FTW6+W2[_2)([:2U5[>\MIH[F-C
M;S30L5E!>.616W*[ \_8_L%_"O3?!%YX;A\)V,>AZA?:)J5S8K<7'D33Z,UH
M^F,5,A^6%K&U)0?++Y6)!('<, >%^'/^"QEMXI\+:QJ&G_#^36)H_P#A#[G1
M;?2_$$5U'JMOXDUK^R+9&NC$MH+F"8$RK;S7-M@KLNW!++K0?\%7VN9+Y;'X
M5>,/$[6L^LZ/'#X92?5)Y=5TEKR*\C*?9T'V1IK&YC@N%+22LJ*UO$\L4<GI
MOAC_ ()S?"?PE!8QVN@ZG,--728K=[[Q)JM_(D6DZA'J6F1;Y[EV,=K=Q"2&
M,DI'OF0*$FE1]'Q1^P3\*_&^NZQ?:QX774EUTW,ES83ZE>OI<<]S'+'<WD%B
M9OLMM>2I/.K7<,23L)I<R'S&R 6/V.OVH4_:M^&VI:U]AT73[K1]7ET>ZCTG
M7HM8M&E2**4[7"13Q,%F57AN[>VN$='W0A#'))Y7K/[</C+P+^V+X]\!ZEX=
MT+5=/6Z\.Z1X*M;+57CO+^_U&&^FD-VTD"QPP1P65Q<2,C2.D=JPC2XED6*O
M3OAW^Q1X1^%'Q*T3Q-H,WB&VO-)&IO=&ZUV_U*;7+B^CL(6N+V>ZGEENI(X=
M/MXHVF9VCCC1$*(NPZWC[]D;P#\2O&&K:]JVAR3:MKEOI]O>W$6HW=L9#87#
M7%E.JQ2JL=S!*[&.Y0+.HPH?: H -'X!_'&U^.GAK5KA+"XTC5?#>M7GA[6=
M/FD28V=[;2;6V2(=LD4B&.:-OE8QS)O2*3?$G<U@_#7X9Z'\(?"46A^'K%=/
MTZ.>>Z*>8\TDT\\SSSSR22,SR2RS222/([,[N[,Q))-;U !1110 4444 %%%
M% !1110 4444 %4!X5TL>)SK?]FV/]M&U^PF_P#LZ_:OL^[?Y/F8W>7O^;;G
M&><9J_10!R%E^S[X"TVWT*&W\$^$;>'PO<2WFC)%H]NBZ1/*YDDEM@$_<N[L
MS,R8+,Q)))S6C9?"OPQIFI6]Y;^'-!M[RTO;C48)X[")9(;JX#"XG5@N5EE#
M,'<?,X8[B<FMZFS3I;QEI&5%4$DL<  =: .5\)_ ;P-X!DL'T+P;X5T632U1
M+)K#28+9K-4MH[1!&40; MM%%  N,11(@^50!':_L]^ ;'4O#-Y#X'\(0WG@
MNV%GX>G31K=9-!@"[!%:,$S;IM^7;'M&.,8K;\$>.='^)7@W2?$7A_4K/6="
MUZRAU+3K^SE$UO>VTT:R131N.&1T964C@@@UHRW,<5LTS.@C12Q8MA0!U)/:
M@#C;C]FGX<76G^*K27X?^"9+7QU*)_$L+Z%:M'XAD'1[Q=F+AAV,NXBM3PA\
M(?"?P^OX[K0?"_AW0[J+3+?1$FT_38;:1+"W:5[>T#(H(@B::9DB'R(99"H!
M9L\W\(/VL_A_\=?$-QI7AGQ##?:A#8QZK%!+;3VC7]A(<1W]KYT:"ZLW8A5N
MK?S(6)P'SQ7H@E4__JH =17._$;XJ:%\)_#4>L:]J$.GZ;-J%CI2SN&93=7M
MW#9VL7R@G,EQ<0QCL#("<#)&^DP(7=\K-_#GF@!]%<[%\4M$G^)]QX-2^B;Q
M)::;%K,UCAO,CLY99(8YB<;=K20R* #G*GC&"8/BK\9_#OP6T.SO_$%]-"NI
M7/V*PMK2RGO[[4[CRY)O)MK6W22>XD$44LA2)&8)%(Y 5&( .IHKG_AE\5?#
MOQD\#6'B3POK.GZYHFI*Y@O+.821,4=HY$)ZJ\<B/&Z, R.C*P5E(&>_Q_\
M!G_"3Z/H\/B32+K4=>U6[T*RAMK@7!DO[2&2>YM6*9"2Q10RLR.5*[",9XH
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MS2;0NZ1G=G.2S,Q)/K%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYKY;/7].O)E629TC4B&"5OF8#Y?7 KZBHH ^/3_P4.^/7_1D?QB_\*SPQ_\
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MCMKJ.<Z3N6>8QM$+EU>&Y3Y" ?9GQ<\?^!_ACH=GK7CS6O"OA[3;&Z\VUO\
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M%M8GO?#,PT'QCX]\2S.JR&>>/7[BY>U 8IS+'%,B2DG&%PI8 4 >J>*/B#\
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M/7PYI,NAZ#+<:7;ZII^EC5=TD=_]GEFTV4OJ2-"MO$\D$-M-;K=?Z69X-_\
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MFW\/0M$K%&DB8K;H8D4X)4%44] *ZSXAVTU_\/-=AAADFN)M/N$CC099V,;
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M OOMXD0VZ2 7"_6WQ0^&VF_&WX/>(/!_B6SCO-'\7:/<:-JUJ#E)K>YA:&9
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MT]=(TJUM%DN)EM8DA$D\K2RN% &7=B69CC)8DDGDU8H **** "BBB@ HHHH
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M'BQ)EU*^T]?#6@6BNWG@3F-);6>%#<#SRL \TM)N8@'TQ1110 4444 %%%%
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MPWUWXGV?C2]\!>"[[QEI:10VNNSZ!:R:E;)&<QK'<F/S5"'E0K +VQ5[X=?
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MZ6?X'>#+KXI0>.)/"7AB3QI;0FWBUYM*MVU2./:R;%N=GFA=K,N V,,1T)H
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MADF=O[0,!:5Y1;"4J8P#I/C=^W#XD\ ?MKS?#M;"S\/^$='LO"<]SK-UH_\
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M $V+_='Y4% 1T'Y4M% #1&H/W5_*G%01C''I110 @11_"/RI!$J]%4?A3J*
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MQ9T/Q5XB\.:!XNO)/[#T72?#5]I,(BU&*&UFDNI)[MI&$:QA4*C<<$5]9_\
M!+/]FSQ3^Q]^PWX-^&7C :/_ &MX-EU&PA;2MGV1K'^T;J2QVE8X]S"T>W5V
M= [2*[/N8EV!GT)1110(*_*S]CO_ ()5? 7]O+X]?M;>+/BQX%;Q9X@TGXZZ
MUHMI=-KNI6?D6::?I<RQ!+>XC3 DGF;)7/SGG  'ZIU^??PA^%'[6G['OQ@^
M/!\"_"WX1^-O#'Q0^)FI>.K"^U;Q[<:7=117-K9VZPO EA* 0+0,3O/,F,?+
MD@'G?[5'_!*CX"?L'_M$?LF>+/A/X%;PGX@U3XVZ9HUU=+KNI7GG6DFE:M,\
M12XN)$P9+>%LA<_)C."0?U(9MOYXKX#^)?PQ_:R_:X^-7P)D\>?"_P"$?@GP
MK\,/B-9>-[^^TCQW<:M=S1P65]:F%(7L802?MF[._P#@QCG(^LOVQO"_C/QS
M^R=\2-#^';VL/CS6O#5_IV@37,_D0VU]-;O%#*SX;:$=P_0_=Z&@#YE^!_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!39%WIM/?BG4C' _&@#\QOV#]/\ VS/V^/V9=+^*EG^UKX=\$V?B#5=9M(-%
M;X/Z?J9LDL=6O+!1]H^U1>9N6U#_ .K7&_'.,GT+X:ZU^TG^S1_P4D^#7PY^
M)WQ\T?XO^%?B=H'B;49;:V^'MGX;>PETQ+ QD21S3/)N-X>,H!Y?\6[CR/\
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M3Q%\?_#.GZQ\)Y[6?6DO9+/3=*^*!\,6)GN3+"$\O11F4QE'%H-26ZVX)AP
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1NKA==U*7^RVNKYY/AS?^*8[&*.43-')!YNFN)]AC:6*5&#Q#$WVK\5_V0O
M/QH\%>%_#^M:5J%OIO@J[BO= .C:U?:'<Z/+%;2VB&"XLIH9HU^S3S0E0^UH
MY&5@P)%>/>-?^"/?PA3P7]G\"Z--X-\0:3X>DT+P]=R:QJ]_I>DN="DT&*\E
MTS[=';W=RFFN+?SI?W[1H@,OR*0 >;>"O^"T.EZ9X4TG[1X)\9:MI:>&E/\
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MK6+6[TY)M2?5)&AN(KI9HI#>22/YJ.) LCQ!A$QC(!Y_X=_X+$P^,/CEX?\
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M1_$3>'=6T.[U7Q,(H98]+U#4='FM)/#SZC&R8\^W?4-0EA5]CF2&)B&-K&$
M/K"TNEO;2*9!(J3('421M&X!&>58 J?4$ CO7D?Q3_;W^$_P1^&7Q)\9>+/%
M7]@^&?A#J\6A>+;VZTV[4:3>2Q64L46SRM\P>/4;)E>%71OM"X8D-CV!1M&*
M^$_VBOV3M9^*W_!22/PU=>%;[4/@S\3K;3O&'C*Z:$MI=Q>Z/::GIYM;AONB
M>=KOPY+$A^\FD7##[F0 ?4?CG]KCX?\ PV^*</@G6M<DM/$]PNELMFNGW,X
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M\;+SQ'XMTZYTYUG\.VMGX"UOP] TY"_N[:26VADC9\(6U)",&8+4GPG^+?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA!-<^.6F^+[B7PO\8)-!"32#_B6S3R-'IUC+ BQ"42W+3VL+-(6SY< &Q5Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCJWBOXH)>:4T'@G6KRRO()M'T>WCE%W!:O;A#+%(I9I JE&W%0":^*OVJ?\
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M/+MDQO)8]3R30![0O2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(Y?%Y^($-S9S>([K5IK<VDT\PFMGLI(WLR+46S6OV>*&*!8HHOL\!CJ^&/\
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MQS[4 >K45Y3#:_&_S/WM]\*]FUON6-_G.#M_Y;=,XS[9IBVOQTVC_3_A/_X
M:A_\>H ]9HKRG[+\</(7%]\*_-W-OS8ZAMQQMQ^^Z_>S^%-^R_'/_G_^$_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_4;?5K*.YM9X;JWF&Z.6)PZ./4$<'\* )J*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKU2B@#RN/]NGX(S1321_&+X6R);IYDK+XKL&$2[E3<W[W@;F5<GNP'4BH_\
MAO+X&_\ 19OA3_X5MA_\=KUBB@#RNT_;G^"=_=Q6]O\ &+X6SSSNL<4<?BNP
M9Y&8X"J!+DDD@ #K4:?MZ_ R1 R_&?X4E6Z'_A+;#G_R+7K%% 'E?_#=/P1-
MMYW_  N+X6^2'\OS/^$KL-N[&=N?-QG'./2HS^WG\#5&?^%S?"G_ ,*VP_\
MCM>L44 >5W7[=/P2LKJ2&;XQ?"V&:%VCDCD\5V"O&P."I!ER""""#T(I$_;K
M^",EO),OQB^%IAB94=_^$KL-J,P8J"?-QDA'P.^QO0UZK10!Y/\ \-Y? W_H
MLWPI_P#"ML/_ ([4EO\ MU?!&[E,</QB^%LSA'D*IXKL&(5%+,W$O15!)/8
MFO5** /)_P#AO+X&_P#19OA3_P"%;8?_ !VI)?VZO@C D;2?&+X6QK,GF1LW
MBNP D7<R%E/F\C<K+D=U(ZBO5** /*[?]NGX(W<NR'XQ?"R5]K-M3Q78,<*"
MS' EZ  D^@!-1K^WI\#6&?\ A<WPIY_ZFVP_^.UZQ10!Y6W[=/P12W29OC%\
M+5AD9D1SXKL KE<;@#YN"1N7..F14?\ PWE\#?\ HLWPI_\ "ML/_CM>L44
M>5Q?MU?!&=)6C^,7PMD6!/,E9?%=@1&NY4#,?-X&YE7)[L!U-1_\-Y? W_HL
MWPI_\*VP_P#CM>L44 >5W'[=/P1M)?+F^,7PMA<HD@5_%=@I*NH96YEZ,I!!
M[@@T0_MT_!&X29H_C%\+9%MT$DK+XKL"(U+!0S'S>!N91D]V [UZI10!Y/\
M\-Y? W_HLWPI_P#"ML/_ ([4D_[=7P1M9-LOQB^%L3%%D ?Q78J2K*&5AF7H
MRD$'H0017JE% 'GW@;]K/X5_$_Q1;Z'X9^)GP_\ $6M7@<P6&F>(;2[NIPBE
MVVQQR%FVJK,<#@ GH*]!HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!&?8._X#-,%U&3U.<XQ@U\B_\ !0[X
M76_QI_:$^%_AQK3X3_$*]N-*UJZM_AA\2X)UT'Q*D4FFF7489UMKJ*.^LPRH
M@DMIF\J_G9!&%E9_GO0OVL8?V9?A_P#"=/!_AFQTV;1_#OC;PM#<>,=5DUR/
MP/.OCKPKHDL:ZDC1_:=#L'OFD(#1NUKI5M&\EM)%*4 /U"HK\]_'/[9/QZ\
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MU3[-\._%'C:PT3XB:A'(UA#)I\EG>&WAE=6)BM[S6$TJSE0L5DBO'A<[)&-
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M]UHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!X:T+5)QJ&N-J\]HUQI&AOX>U+6H]1 MYY5<[=.F5H0QD'DR_*=T)DR?&_\
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M%B+)N^.GQ4D:1 JLUCX;_='<IW #20,X!7Y@1ACQG!#?^&=O%_\ T7GXK_\
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M/>!OV>OV:X?VB_!7]E_$[0]7TJ\L]1O_  =X5L]<272P-/@M;.\DADBD,3-
MFUG'$\C--)-).(!Y/3:+_P $R?$FG>$I='N?&WAG5)K73Y_[)U/4?"4%XVG:
MA-X83P^TQM)',$D*1PQLL9 +Q2S0R%@Q=\EO^"4GB#4O$FL:I>^,M#F?Q'J]
MSK%[;WEC?ZO&K./#,L4$KWEY)+>0K/X8@21'DB$MM>21(+?RD) /4/%?@']F
M_7HK?QMJ7B#PG#9:LG]KKJD7C-[.QU58[J?4HKES'<K#<+!<K=7,,CAA;N)W
MB,9WFM#4OV3_ (&Z'X1T_P =7<./#/A32CJ5M?R>)]0ETJVL(OM%S',5^T&!
MXH8[FX\EF5A##)Y<6R(*@\]U+_@F=?\ B'Q!\1/%6I:EX+G\8?$":PU#?#H]
MU9P:/<6]Q9RNEM<6]U%>Q>8NGVK&>.='^TH+@H0JVX]5_9U^!OC#X<_!;6O
M?B;6[+5K*&":TTO5([;9=,EQYLKB7YSYHA,RQ+*^V:;R6>4L[F1P#/\ A!X<
M^ OB_P 8>&?%O@O5M U#4;BQM+G1X;'Q%*\%PK:?Y=O=?8/.\I[K^ST\M;AX
MC<?9TV;]BX%;X_>-OV>]>^T>+_&_C7PVD7@6&S&IW$'BF2W@MK34981:QZC%
M;3*D]G<2-$4CNU>!PY8 JS$\KX-_8)\7> M.TW5M+\2>#8?&VG^+;'Q4;N;0
MYIK&:2'P?'X99)$6=)9  )+E?W@.-L)9<F4<C\+/^"6?BCX2Z!86>F^--"B7
MP]H$6G:;!%87GV.[NEN]-O#++;R7;QVH>?3W:8V*PFZ>Z\V8/)$-X!ZUXB^$
MW[/NF>$+R:[U'PWH^F_#FUTOPY<ZK!XIDT^?PDEC%.EC";V.=);&98=3N(]P
MDCEDBOF1V=)=IAE_9"_9Y\3?$.]\*Q:;H/\ ;UCI&VY\+66O3PK8V4VGOI/G
MG3(IQ'$7L9&M?M'E*[1A%WG8FWR#1/\ @E%XT\+ZAX;U2S^*2SZOX)\BSTN6
M6VO(_P"TK-(;^!FO66Z.;G9?N5=%VK(]ZV"M\R0=W^SK_P $\]9_9Z^+/A75
MK/Q992:'X9TRWL)[:VM[M&UORM(M]./G0W%U/;POOMHYA<VR13LB1P2M*!)+
M, =EX*\._ /X$_$3Q7KVF>(/"^CZYX0@FMM<%SXL,D7A:WO"MV\+6\UP8M/A
ME-J)EC5(D_=NR@ N3D_&[P+\!/BU\1]/L]<U+3M3\5?$"&S>SL;/6GFCU! L
MLMKJ$E@KM;3+M@>,74T#K)&OD,SQ,8CQOA__ ()L>(/^&B="\::]XH\.ZII_
MA_6=3U6.P32KA1</=:K;:DDPB:X-I;2J\ WFVMT,TRBXD=Y6.V]\&?\ @G?X
MA^$GC'PTW_"2>$]0\/Z+XMM_&DPET!AJ0O(O#XT,103";;&GD*A$C(SK'O@Q
ML(90"OX-_9K^"O['MA\1+[XA^-+?Q%JEUX9O=4U]O$6HM<W</AR.WB@NF-NT
MDD\EL5ME#NV\;L1Q".-8H5WOAA\/?V<?BQJ_V?P[K%OX@U325:_N9'\8WUY>
MZ_:%;<_:+V22Z:35;#:;94:Z,]N%"*N  *I_'?\ X)Z:Q\9]7\=6<?B;P]IG
MA_QQK,OB-[@^'1/K=A?MH:Z.HCN?.53%Y2J&8H)# 9K8-LDWI#\1/^">&N?$
M[PAJRS>*-$T+Q%X@U:[UV_NK#2Y7MYKF:VL(Q#*GG))/:L]C&DL;2(TUN3%N
M0X< 'L'CBZ^$_P"UA\.(O"FL:EX1\;>'/&-O;W5O9QZE%<1ZO$KFXAFA,;YD
M4-:O(KQD\V[D'Y&QXUX*@_97^+^CZ]?Z3=>'H=+7Q!=O/KL6MRZ=#=ZM?ZZD
MLSP7BS(6N)-5T:!D,;A@;:$18C90W5_L@_L/7'[.?Q8\6>--8U;3M<USQ;IM
MK:2/':R!M/9+W4+J=8I99'<I,;N!Y<;!+<0S7!16FV)S-I_P3W\1>&OC6WCO
M2_$OA.^U)5NK>.RUO07O+(Q76I:_=RN0LRL)TCUI(U<'E([N(@+=[X@#U7]G
MJ_\ A8?!GAOQ/X(DT^ST_7/#^F:7IQ>=XYOL,=K)J%G:M%*V])$M[N2;8P$@
M20LWRC(Y/QZ_[.WQ)\'ZOKGB#5/!>I>#=?,WB74==GUI/["NVFL#X=EE>Z$H
M@^>S<VA3=M^;./,^:O';3_@DGXDMOA%H_P /SXV\(R^%;&U@DNEG\+R3R7=Y
M'X*'A3:8_M2QFR*1K,\#9:5)9(=\8&]^V\8_L'^./'/C>W\63>)/ >CZ[<:A
M+=ZE%HFA76FK<1R036^4NH+J.[CNE1XF:[CECEF$)MR8X)6  .KM/@U\!?"V
MMZEHH:VU+5?%EE<:=K+7?B2[U2]N+:YT^!I9;R::XDE EL](M5$\K;F2TB ?
M %7M0^'WP%\>?$?PWXB_M;P[<Z_X\G&LZ0UEXHDB3QCY,<3I(((IQ'J4,*QQ
MR(C)+%$2TBJK.S-XYI?_  24U31OV;-%\"V?C;2-/U/1=:T;6?[5M-$DACO7
MTOPQ9:'"DL*W <Q2FR5I$\[/V>5X X.)*UO#_P#P30\2:'XQ\/ZW'XTT^&^&
ML6VLZ[<0PWQDN#!K#:F+81/=&UNHV\R9-UU S0W-U=7L'DS3&-0#V/\ :)\5
M_"3Q+97VF^,=<LI-4\%)%KKVVF:O+:Z_H2R;K9+N(VDB7EN'2=XC(A4/'-(A
M)1V!J_#KPQ\"?#L/@U_"=YX'MK?5M6;4/"B:7JT0M[Z\M-).DM]A1)-DODZ=
M$8#'$"J*A)4,"U><_&C_ ()QZI\5_B]XLUB+Q'H^F^'O%@F-]I?V.YN(M1$U
MI!;21W%O-</:AMT"R&YM8;>6552&42*)'EG\6_\ !.[5==^(7Q U&W\1>&TT
MOXH)!8ZQ%=>'_M%YIEK;ZC>7\,MA-YRB.Z$M[*RO(KK',L-PJ[HV24 ]!^,&
ME?"+XE_$/P+=>(+K^T-8UQULM(_L[5[F.#4H)+6[U%%NX[:58KJRDBTZZ=%N
MED@8Q.%!+,#R7PZ^$?[-WQ%T'5-<T7^Q=>\,^"I%CU"]FURXOM!E2)5U&!IS
M),]I=PV?G*]N91(EEMVP^2(PJ^;ZI_P2B\3>,O#,>A:WXX\+MI.F^$['P1IR
MP>&W=C86>B>)M)CDN5DN"DTD@U^.5XPJ)BVDCY$@=?6X/V2/$WB+X=_%RU\0
MZEX)?Q!\4=;M=<66QTBZBL]/FMK'3[6%G*W*7$DRG3XW6XBE@EB/E&,H\"2$
M K>'/V;OV=;_ $2STZQ?0M9M_BAIFH6NG23>*I]1N/$5E-%9FY%G/)</++&D
M5C9%# Q^SK;QF,Q#D]Q\<_$WPOUGPKJGAOXA:YI^BZ7I]S:![K4M8;1FBN2T
M<EO);W@DCD299&BVR12+(KLF&R1GP_P9_P $T/$WANTO[2X\:Z#?6?BB^TV]
MU>2^T-[_ %/35L-:N=6MH;&^EG\YBDMPS)/=^=,ERTMT&+2>4G?_ !A_8=D^
M*OQ7\2>))-4TL)K>G7]G;PW&G><UE)<Z4FG>:&+=0HDS@ E)&7."<@'/^*_A
M%^S7H_B]_ DUK;W6I+I3:1J/A_3]9O)HTBF2"Q\R_MHIMANWAU"-1=7*FZ:.
M1F60A21U7CK2_P!GS6AXP\=^(?$G@]M/M;\:;XDU.Y\6>5I>GW\<0M#'./M
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M[0_%7_"/ZYX<T>);66\MS??:-8TYII="O+@EE,D5K+>ZDTL7#3_:EQ)'L^8
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M\-O$?PU?P#XJ\36>B_V?':>+DTFPOEM]8DL]'O8-0WVD,;+.%5K15$D #1D
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MXCM=+TR/QA.^G)9Z79:?<I,;GROE=_M%X"A7@01XY<U5_P""GW['OQ.^-/\
MP1P_9\^'_A;P;JFM>,_"^J^#)M7TF!HO.L$L[4+=%R7"GRV&#M)YZ9KK/^"N
M'[!6K?MN?\%$/V-YKKPKKNO?##PE<>+1XTOM,U2?3&TI+FRLOL9-Q;RQ7$?F
M3V^,Q,"=I#?*Q! T-K]E;_@KAXN?XY?&3X8_M(?#G1?A/XI^#O@Y?B!>:CH>
MMMK>DW>C;2TTI81JT4D7RX0EFD_>850F7\AB_P""P_[6&H_LUR_M06?[._@E
MOV;XHWU8:)+K]P/'LN@H3NU@($^R"+RP9O+Y8(-VXQXFI?A__P $E]4^$?[7
M_P"U5\*/#.@ZWI7P$_:!^$RVUIXEU&_;6)M/ULQM8&W-W<&2]8+$[2B.65D4
M(,?>"KY]'X__ &MM/_X)F/\ L6R?LM^*+SXEKX4?X80^.([^V_X0230S;-8+
MJ?VTR!Q*+,Y$!3?O 8J&/V< :'V)^S__ ,%54_:0_P""E%C\'_#>DZ=>> =<
M^#%G\6](\1^9(EY=I=7EM#%"T+#"*8[C=R=P9<'O7V17XY>#?V9?C;_P2S_X
M*/\ @OQ5X-^!?C+XY>$_"G[.^C_"M[[0+VTLDN-0ANX9YY\W$@(4FV8[<9'G
M+V%?J+^RM\9O$WQW^#FG^)/&'P\UKX5ZY>23I/X;U>ZAN;RQ6.5D1WDB)0B1
M0'&.@;!YH!GP_P#\$_/^#@"']L#5/V@?"NO^%]+\+_$#X26VL:OH-C'<RO:>
M)].L#)%(XD9<K+',B"11_!<1E=VV3;=_9,_X+<>*?VB_'W[%>CWW@?P_IL?[
M4ND^*=2U22"]F=M#;2(KEXUA!'SB0PKN+=,G&>*^4O!7_!'#XQ:I_P $\_B)
MK^E>'=0\#_M$?#[XN>+/%_@1;ET\SQ#HNHVT$%YI_P KLACO;<2*HDQF2)%)
MC21V.W\(?V'/CU^R%\!_^"?_ ,7K'X0>(/&7B+]F^V\5:7XR\"6=_:PZW':Z
MM]HACN+<,^R9HTD+F-6+-NC&%&]T T/L+]J#_@K;XB^ /[9GQV^%]KX/T74-
M/^$OP"U/XQ6=]-=RI-J%U:,JK9R*!A8FR<N#N&.E<!^QY_P<%VOQZ_X)8_&K
MX^>+O"ND^%?%'P:$RW/AV._D>&_::WBETIA(R!T2[DG2%6(/*LPRI%>8ZU^S
M+\9OVYOBW^V!^T%??"/Q9\-+7QM^SOJ?PJ\"^%/$,MLOB#Q!<7%L\YFEMXY&
M%L?/C6)4D8%O,![,%\F\)?\ !&+XR7?QB_9IT ^';K2?A/\ $SP9X'/QWL9V
MB:.WU'PG;9BM;A0^=MPB6\ V!\R!V) % :'K?@G_ (.)?BO\1OV'_A_\0M+^
M$?@Q?'GQ!^-:?""TT*\UFXM[."66U22*628INC;SG".",* 3UXKU[X4_\%??
MC%H7QS^*WPK^+OPC\&^'_&_@7X67OQ1T^?PQXG;6=,E@@W(EI>,(P;>21UW
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MLT<-Y<);$+;J(CNM1 Y9,[BQ+%G+D_5E @HHHH **** "BBB@ HHHH ****
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MCU_V5C5O_2:RKZ$H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^._AS^T+\.? /@_6/ACX9_X2SPUX@\0WVJ>,H+B:W0Z;=:+;QV\(BN(,,_\
M:KL2Q;B   9)'HGAGX!R:'^UKXP^)\FI1RKXH\(Z#X82Q6 AK8Z;>ZS=-+YF
M[YED_M55V[1M\@G)W +B_&[]C;PW^T%^TEX&\;>+-,\.>)-&\&^&=>T(:+K&
MD17\<T^I7>C3I=+YH95:)=+D3[I)^T\$ $, ?.OA3_@I'\1?C+<_#72?#NI?
M!GPO>>(;3QL=5U_6A=7V@ZI+X<UK3=)$NFNEQ;MY-TU[),-[2;/+,8:7;YS]
M9\.?V]?B'\;=*\,^$/".D_#V^^(^N:AXA@EU\7\MQX3.FZ)=6]I=:K;*A^T7
M'F7-Y:VZVHD7RY6N0;AQ;9F]6^*G[#WA'XO?'OX=^)M<T/PKJWACX?>$];\-
M6OAW4-$@NK5'O[G198IXE<&.+R(]*>,*$Z7'!4*0WG_A[_@GIX@^#LECJGPS
M\6>&?".N>$];U^3PQ;W/AUKS1+70=8G@N[K1IK5+B*3RUNX(YXI()HC"T,2*
MIA\R!P#S_P#:-_X*A_$?]ECX?:Y;^)/!/AO4_'G@'QAI5GKUKHTUQ<6^N>&K
MBSN+^35M/B?;)'<-!8ZA$EK(TFVXLW7?,A1W].^,/[?5[X6_;Z^!'PC\*Z;H
M^O\ A_XC1W-SXEUL3%_[*AETK5KW2#;%#L?[4VBZC\QR EOQDL"([7_@G[K?
MB/7])\6>,O&6E^(?'UQXVL/%6OWMOHIM-.FLK*SN[2UT>SMVFD>&VC6ZDDW2
MRS,\T]TYVK*L47.?LR?\$HE_9NU+P+<1^,Y=>D\"^/G\0V<UY8(LZ:#;>&-1
M\.:/HBNI!VVEK>1.96W&647,A :X) !Q'[/G_!1KXN?$_P '_ >^OM8^!.I:
MI^T5HBR:/H^CP7HU#PI?3:#-J\<]Y";N1KFSA:#[/.%\A@;B)@X.(VU-7_;/
M_:$^'GPW_:(\6:\WP9U+3_@"]_836>GZ/J5O-K%U'H-EJD+K))=NL<>^_CC=
M2K'$3D,"PV^^?L._L/\ A']BKX!^ _#&EZ'X5_X2;PMX3TWPWJGB+3M%AL+K
M7GM;:&*2:5E!D/F21>85=VY/))&:YWXE_L*7_CSX)?M-^$X?$UG;7'[0.H7-
M]:W,FGM)'H?FZ%IVE!702 S8:P,I(9,B7;QMW$ [[]KSXM^*O@)\&[CQMX9T
M&'Q-:^%KF'4?$6F*CO?7&BH3]N>R52-]W%#NFCB(;SC"8@ \BLN'^R[^T_>_
MM6?$#QIK/AL:'??!S19(=(\/>(;5VF?Q5J$>\ZA<6\BMY1L8&,=JK %GN(+S
ME4C0OT/P1T3XP:;J6H-\2O$?PVUZR9(_L$?AGPY>Z3+"X8[S*UQ?70D4C;@*
MJ$$').0 G['/[/[_ +*_[,/@GX=R:A;ZJWA#2X]--Y!;FWCN=F?G$>YMF<]-
MQ^M 'IE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5YS^U)>_$J/X0ZI9_".S\.3^/M4B>TTNZ\07;VV
MEZ1(R,1>7&R.2258\ B&-"97**3&A>5/1J* /R0_9:_X-&OA)X/UV7Q%\<O'
M?B[XV>([^=[R^C$CZ'IUU/(Q>227RI&NII"[$ES<*&.24YQ7Z:_ 3]F+X=?L
ML>$?[!^&W@CPMX%T9F$DEIH>FQ6,<[X"^9)Y:@R.0!EWRQ]:[JB@;DWN%%%%
M CYG_P"",7_*)?\ 9P_[)WHO_I''7TQ7S'\//^"5_A'X2^ ]'\+^&?B-\=]$
M\.^'[.+3]-T^T^(%]'!96\2A(XD7=PJJ  /05L_\.\=-_P"BM?M!_P#AP[__
M .*H ^@Z*^?/^'>.F_\ 16OV@_\ PX=__P#%4?\ #O'3?^BM?M!_^'#O_P#X
MJ@#Z#HKY\_X=XZ;_ -%:_:#_ /#AW_\ \51_P[QTW_HK7[0?_AP[_P#^*H ^
M@Z*^?/\ AWCIO_16OV@__#AW_P#\51_P[QTW_HK7[0?_ (<._P#_ (J@#Z#H
MKY\_X=XZ;_T5K]H/_P .'?\ _P 51_P[QTW_ **U^T'_ .'#O_\ XJ@#Z#HK
MY\_X=XZ;_P!%:_:#_P##AW__ ,51_P .\=-_Z*U^T'_X<.__ /BJ /H.BOGS
M_AWCIO\ T5K]H/\ \.'?_P#Q5'_#O'3?^BM?M!_^'#O_ /XJ@#Z#HKY\_P"'
M>.F_]%:_:#_\.'?_ /Q5'_#O'3?^BM?M!_\ AP[_ /\ BJ /H.BOGS_AWCIO
M_16OV@__  X=_P#_ !5'_#O'3?\ HK7[0?\ X<.__P#BJ /H.BOGS_AWCIO_
M $5K]H/_ ,.'?_\ Q5'_  [QTW_HK7[0?_AP[_\ ^*H ^@Z*^?/^'>.F_P#1
M6OV@_P#PX=__ /%4?\.\=-_Z*U^T'_X<._\ _BJ $_8%/_$W^/7_ &5C5O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA2^*+%-2-TSA%M_LYE\SS2Y"A-NXDXQF@#H+7XQZ9>2(J6/BA3)C'F>&]2C
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M4 R70-+X;^-?@WQEXFAT71_%OAG5=8GTN'7(K"SU2">ZDT^8XBO!&K%C;N2
MLH&QB>":-,^-7@W6_AI=>-+/Q9X9O/!UC!<W5QKT.J02:9;PVS2+<2/<AO*5
M(FBE#L6PAC<-C:< $<_Q>TVVN9(6LO$Q:-F1BGAS474D;P<,+?!&4;!!P05(
MSO7+E^+6FM??9_L?B3S/,\L$^'M1$><@??\ (VXR1\V<8R<X!KC=$_;\^!/B
M:YGATWXU?"74)K6TGOYDMO%^GRM%;P1--/,P68D1QQ(\CN>%1&8D $UW-_\
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MLI!! (.:]PH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M- '<45Q__"C=%_Y_O&'_ (5NJ_\ R11_PHW1?^?[QA_X5NJ__)% '845Q_\
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MC=%_Y_O&'_A6ZK_\D4 =A17'_P#"C=%_Y_O&'_A6ZK_\D4?\*-T7_G^\8?\
MA6ZK_P#)% '845Q__"C=%_Y_O&'_ (5NJ_\ R11_PHW1?^?[QA_X5NJ__)%
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MYKK* "B@\UY5\&OA5I_BCX0^%=3OM3\8W%]J6CVEU<R_\)7JB^9))"CNV%N
M!EB3@  =@!0!ZK17'_\ "C=%_P"?[QA_X5NJ_P#R11_PHW1?^?[QA_X5NJ__
M "10!V%%<?\ \*-T7_G^\8?^%;JO_P D4?\ "C=%_P"?[QA_X5NJ_P#R10!V
M%%<?_P *-T7_ )_O&'_A6ZK_ /)%'_"C=%_Y_O&'_A6ZK_\ )% '845Q_P#P
MHW1?^?[QA_X5NJ__ "11_P *-T7_ )_O&'_A6ZK_ /)% '845Q__  HW1?\
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M17'_ /"C=%_Y_O&'_A6ZK_\ )%'_  HW1?\ G^\8?^%;JO\ \D4 =A17'_\
M"C=%_P"?[QA_X5NJ_P#R11_PHW1?^?[QA_X5NJ__ "10!V%%<?\ \*-T7_G^
M\8?^%;JO_P D4?\ "C=%_P"?[QA_X5NJ_P#R10!V%%<?_P *-T7_ )_O&'_A
M6ZK_ /)%'_"C=%_Y_O&'_A6ZK_\ )% '845Q_P#PHW1?^?[QA_X5NJ__ "11
M_P *-T7_ )_O&'_A6ZK_ /)% '845Q__  HW1?\ G^\8?^%;JO\ \D4_X!7T
M^J? KP7=74\]U=7&@V,LTT\C22S.UNA9F=B69B222222<F@#K:*** "BBB@
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M"&W,I4@CKF@=F?H115>^>XBTVX:W59;A8V,2MT=L':#]3BOQ-_;2_P""V/\
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M7D-U);.;M1.1''YD;89"YQ@X'2OS"^$GP,\4>!/%W[6/[6'PILI-0^)O[/\
M^TQXW_MC1XI?+7QKX1FDA;4M,DX/S1KYEQ$V&*,)2J/(8]O+_ 6=/A!_P1F_
MX)R_&'6%NO\ A7?P?^,NH7_BW4[6UENCH]E)KE^!>/'$K-Y*F,ABH+;GC559
MG4$&?MK\7?\ @H/X%^"O[7GA?X*:Q:^(I/%_BWPU?^*K*6VM(WL5M+)9&F#R
M&0,)"(FVJ$(/&2,UQG_!/+_@L1\&?^"EWPJ\:>+O =WKNDZ?\/Y4&NP^(;2.
MSN+*!X&G2Z(221?)94F ;=G=!)D  $_%7BC]HOP;_P %&_\ @M_X=\=_!76H
M_'G@?X/_  6UY/%'B&Q@E73;"XO!<QV]J)F4*UPWF!]@ZHLA!)CD"?FU^S1X
M6^(OP$_85^#$/POMX0G[>?@74O@]>$.8XK?7(?%]S;+?7)VG@Z5=26ZXP0!*
MYX3D _9[P;_P<F_L_>.OV1_%WQIL-)^)S>$?!FOV'AR]A?1;<7TMS>KNA,4?
MVDJR8ZDL"/0UZ1^R]_P6@^&?[3'[1>F?"FX\(?&'X7>.?$%I<7FA:=\0?!\V
M@MX@6W5GN%M2[,':*-&=@=OR@XR0P'XE_M#^ /#WP(_8"_;B\':!MTGP[X+_
M &BM#T6P 8%K:VM7>%&)QRP6+).,E@2<G-?6?[,G[07P]^,G_!9']GO7O@A\
M=OB?^UO=V]MKFD>)'\::"\L?P\TR:W#_ -H6LZV-G%:2RR*(&?8YE0F(LNY%
M(.R/JKX:_P#!R=\+_C/X.@\0^#_@?^U?XLT.Z9DAU#1OAL]_:2LIPZK+#.R$
MJW! ;@C!KOOC_P#\%R?AY\!?VI?'/P@B^&/Q^^('BWX=BQ.MGP5X,.N6UJ+R
MTBNX"6BEW*&CE RZKED<#.W-?C/_ ,$@/VQ_A5\$OV-/!]AXL_;V^(WP/U#2
M]0NKFY\!Z1X9EU"Q@C^U,X/FI9RY,Z_.P#D@R$<'BONSX6?"?XL?'[_@N[^V
M])\&?CI'\%VAL? ES>W/_"%V7B1=9BD\/Q>0-MTZ>2(\.?EY?S<'&T4"/TH_
M8K_;7^'W_!0#X":;\2/AIJEQJGAS4)9;5A<VSVMU97$3;98)HFY2121Z@AE9
M2RL"?6*_//\ X-I+RU@_8(\4:'-IJ6GC3PG\2O$6C>-[SS)&DUS7(IXS/>R+
M( T;R1O "F!MV#@=!^AE @KC?V=/^3?/ G_8O:?_ .DT==E7&_LZ?\F^>!/^
MQ>T__P!)HZ .RHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C?B=_R.WP[_
M .QAE_\ 35J-?GS^Q]_RM%?M<?\ 9/O#W_I+IM?H-\3O^1V^'?\ V,,O_IJU
M&OSY_8^_Y6BOVN/^R?>'O_273: /TXHHHH ^:?\ @LO_ ,HF?VD/^R<ZY_Z1
M2UM?\$J/^48'[.?_ &3'PW_Z:[:L7_@LO_RB9_:0_P"R<ZY_Z12U#_P3I^+'
MACX3?\$MOV8[CQ3XAT/PW;ZMX \*:593:I?PV<=Y>3Z;;K#;1M(RAYI&&$C7
M+,> #0!].45P7Q,_:G^&?P7UZYTOQA\1/ WA75+/38]9N+/6-?M+&>WL9+I+
M..[=)9%98'NI(X%D(VF614!+$"L#XA_M_P#P)^$7Q'N?!OBSXT?"?PQXPLY(
MHI]"U;Q?IUCJ<+RHDD2M;RS+(I=)$905^974C(() /"_^"X^B_LU^+_V6- \
M.?M0:E?>&_!WBKQ/!I&C>)+)&$_AW5FMKJ6*X658Y/)!CAG1G>-XL/B0!"6'
MX[_!KQWK_P#P2%_X**?!3P-^S3^U!I?[1_PS^)VO6MK?>$](OUNK6UAN+V.)
M[>XAC>>VANGCE,B7$)CE!@D,D21@"3]]?BOK?P%_:F_9M;5O&E]\*_'WPDU2
MZCM_M^K75AJ.@7-Q]J^QQA9I&:'SA=MY"X;>)CL&'XKC/V?OV(?V4_V5?VC'
MTOX=^ ?A%X1^+#:3)KB6FG0VJ>(+?39)/L[W449)GBM6DS$70+&6RF<\4%*5
MC\E?AU\>=-_X(C_\'&_QP\1?':WU"Q\(?&B+5+O1/%,-C)>);V>H:C#?PR!5
M!E:",Q-:RB-799((SL\L!J_334/^"_W[*<OQ-\ ^#/#WQ0LO&WBCXD:WIV@Z
M38^';2:\\N:]N([>)KB7:L4"J\J[UD<2@;L(Q4@>T?&7P?\  ?\ ;,^#^I3>
M.K'X8_$SP-X7O+EKZ?5?L6J:=HEU:;TN6>1RR6\L&)%D)*L@#AL#(KR_X)?L
MO?L7_L;ZIX'\6>#/#'P'\$ZEX^FCA\%Z\LMA'>:_)>?-%'IEW*YDF,RS@(EN
MYW(\:J-FP4";/R*_;<_:R\:?M>_\'"C>.OA[\'_%7[07A?\ 99NX=,LO#FAS
M-"LEU:-,6O'E2*<1[=4+,K!&,BV,0RN?E?\ \$W?VJO%O["7_!>2_P!0\>?"
M3Q5^SWX$_:NNY;>7PQX@DEDAL;ZXEWV]Q#(((5E7^TFDA4>6H@BU)@?E4.WZ
MT_"/XR?L,?L$^-/&&D^$?B%^S5\+/$>H7@M?%%G#XMTG3K^6ZM7E79>(TXD\
MV)Y)@1(-RL[YY)K1_:W\5?L8_'/XL:)X6^-?BC]G_6?'GA.X$.E:/XF\1:8N
ML:3/="!U6*&2831R2A;=E  +8C(SD$@^8_*=?V0? _[=_P#P=!_M1_"_XA:=
M_:'AWQ#X5N0)(RJW6F7"V&B&&[MG(/ESQ,<JV"""RL&1W1OC#_@J9X-^-O["
M7@C0/V2?BI<+XD\&^ _$K^*OA]XF<2K]NTR6%K<Q0AF95A#,&,&=UM+YJ;I(
MWB:OZ-/ 7B/]D%?VWM8U3PQXB^!$G[1.KSW&C:F-.UW39/%ES+"H2XM9(DE-
MP7C6VP\97<H@.0-IQL?M)Z#^R[^UC\ =/^('Q6;X,>./ACX?N));+Q/KU[I]
MUHNFRF?[')LO7<PQDSJ(6 <9E14/S*  .8^AE.1^-?CG_P 'I9Q_P3^^&'_8
M_?\ N)U&OUEO/C/X/TG3/#-Y<>*O#MO:^-KB*U\/32ZG J:]--$TT4=HQ;%P
MSQ(\BK'N+(I8 @$UY-^WLG[,OBGP[X?\._M)7GP@_LVZO&N]$L/'>IV-K'<7
M*H8R]NEU(N]PLI7*Y(W]LB@E:,\H_P""KW[.?BK]K'_@B-XR\"^";6:_\4ZE
MX6TF^L+* $S:@UE<6=\]M&!UDECMGC5>C,ZCO7RC_P $$O\ @M7^S?\ !;_@
MG/X0^&'Q!\;:3\+?&?PQM[VQU33=:ADM([W_ $R>;[1 ^S;+))YN9(N)EE\P
M%""KO^KWB_XA>$?@9\+I-<U_6M!\)^#M$MD$NHZE>PV.G6$ PB%YI&6.-.54
M%F R5'4BOG'X_P#['O[%_P"TUX2_X7AX^\(_ _Q+H,R1:C/X\N9K);&\B1O*
M26XU!'6.>+)"9E=D. IS@  [Z6/S9_8H^(-O_P %5?\ @Z%OOC]\)=-O)/A/
M\+].:+4=?GLWMEU(G1[G3(&964,DL\MPQCCDQ(;>T+,J$;%_=RO,/AE:?"+]
MENR\(_#GPG'X"\ P^)!/_P (QX;TUK33O[9\F$37#V=LI4W#)%B21HU8A<,Q
MQS5#PK_P4!^!/CJW\13:'\9_A/K,/A"T>_UY['Q?IUPNAVR-M>>Z*3'R(E;@
MO)M4'C- KW/7J*\5\&_\%)/V=_B-J5Q9^'?CU\&-?O+2SN-1G@TWQOIEU+#;
M6\;2SSLL<Y*QQQHSNY^5%4L2 ":V/@M^W#\%_P!I+Q5-H7PZ^+GPQ\?:W:VK
M7T^G^&_%-CJMU!;JZ(TSQ6\KLL8>2-2Y&T-(HSEA0!\N_P#!PM_R:E\*_P#L
MM'@[_P!. KZU_:1_9=^'W[7WPJU#P7\2_"&A^-/#6H*RR66IV_F+&Q!42Q.,
M/#*H)VRQ,LB$Y5@>:^2O^#A;_DU+X5_]EH\'?^G 5]YKT_$T ?G7=_LP?M/?
M\$I0UW^S_K=Q^T5\%[<EO^%4^--4$?B+P];@$"/1=8<?O(D&P+;7*OMCBVIO
MD<N?H7]A[_@JE\)?V\+Z^T#P[J&J>%_B1H(<:]X \669T?Q3H3(5#^=92'<R
MJ73,D1=%,BAF#';7LGQL^.W@W]F_X<:AXO\ 'OB;1/"/A?2DWW6IZK>):V\7
MHNYR-SL>%1<LQX4$D _E3^UEHVN?\'!7C+PQ?? 7X3KX*\+>%[Z.YTO]H_Q9
M%>Z#JMNL<P.?#MO \-[=#EG5[@K!N212(9 D@ /V"!S17#_LW_"K6O@E\%O#
M_A?Q%XX\0?$C6-%M$MKGQ'K<5O'?ZFP_CD$$:)QG:"0SD*"[R.6=NXH ****
M "BBB@ HHHH **** "BBB@ HHHH **** .3^"W_(F77_ &&]7_\ 3E<UUE<G
M\%O^1,NO^PWJ_P#Z<KFNLH *X_\ 9[_Y('X'_P"Q?L/_ $GCKL*^0?V[?VHO
M%/[%G_!&[6/BAX*.E_\ "4>$?"&DW-A_:-N;BU+N]I$V] REAMD;HPYQ0!]?
M45_,)_Q%K_M<?WOA)_X3,_\ \E4?\1:_[7'][X2?^$S/_P#)5!I[-G]/=%?S
M"?\ $6O^UQ_>^$G_ (3,_P#\E4?\1:_[7'][X2?^$S/_ /)5 >S9_3W7#_M&
M_%^_^ OP@UGQ?8>#O$WCXZ! ;RXT/PXD,FKWD"D&4VL4SQI-*B;G$.]7D"%4
MWR%(W_F\_P"(M?\ :X_O?"3_ ,)F?_Y*H/\ P=K?M<'^+X2?^$Q-_P#)5 >S
M9^\O[&G_  6"_9Q_;W%I;_#7XI>']1UR[16&@:@YTO6 2H)5;2X"22A<X+PA
MX\]&(()^EMW-?PW_ !A\?2_&[XH>)O%FI:;HNGWGBK5;G6+JRTRV,%A!/<2M
M+(((F9_+CWNQ5-Q"@X&  !]0_L@?\%WOVI/V+[NVBT#XG:GXKT&UVA=!\9%]
M=T_:H 5%:1Q<0H ,!8)XP/2@/9G]=](X)7CCWK\LO^"3G_!Q[KG_  4)\06G
MAO6OV=OB0NIM,EI/XC\%6IUGPU ^TEWNY9?*-B.F$+SD_P![. ?U.!R*#/8^
M4?@W^TI^T=^T%X-G\3^%_ 'P1C\/S:OJFG60U3QIJD%XR66H7%EOD2/2Y$5F
M-N6PKL!NQDUU7_"5?M6?]"'^SW_X7>L?_*BG?\$OO^3/-/\ ^QF\4?\ J1:E
M7T%0!\VZJ?VF=>OK.ZOOAG^S=>7.FR&6TEG\::K)):.1@M&QT<E&(XRN#5X^
M)_VJV7:? ?[/A'_8^:QS_P"4BOH2B@#YG\,6'[2/@G2OL.B_"W]FK1['>9/L
MUCXSU6VAW' +;$T<#)P.<=JT$U[]J=(C&O@']GL(3DK_ ,)YK&/_ $T5]$44
M ?.XU_\ :G$7E_\ " ?L]>7G.T^.]8Q_Z:*5_$'[5$K*S> ?V>V*]/\ BO-8
MX_\ *17T/10!\[RZ[^U-.ZL_@#]GIF7H?^$[UC*_3_B4<=:H7-G^TE>^([?6
M)OA?^S7-K%I$88+]_&>JM=01G=E$E.C[U4[FX! ^8^IKZ7HH ^>6\0_M4.^Y
MO /[/3-C&3X[U<\?^"CWH3Q#^U1&^Y? /[/:L>#CQWK S_Y2*^AJ* /G9=:_
M:F4<> /V>_?_ (KS6.?K_P 2CFGIXC_:IC7:O@+]GM5SG"^/-8'_ +B*^AJ*
M /FWPW_PTQX-T>+3]'^&?[-^DZ?!N\JUL_&NJP01[F+-M1='"C+$DX'))/>K
M0US]J8=/A_\ L]CTQX[UCY?I_P 2CC\*^B** /G?^W/VIL?\D_\ V>NN[GQW
MK')]3_Q*.:<OB']JA&9E\ _L]JS#!(\=ZP,_^4BOH:B@#YW77OVIE3:OP_\
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M:PNM/C6]GP01&+MG+11%F8R#)_0:B@#X*_X.&Y%A_9.^%K,RJJ_&?P<2S'
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MJJQQ@*J@8"@= *=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M')_!;_D3+K_L-ZO_ .G*YKK*Y/X+?\B9=?\ 8;U?_P!.5S764 %>7^$?A+X8
M^.G[(?AGPGXS\/Z3XH\,ZQX=TZ.^TO5+5+JTO%6&)U62-P58!E5L$=5%>H5Q
M_P"SW_R0/P/_ -B_8?\ I/'0!XY_PYO_ &3O^C;_ (*?^$?8_P#QNC_AS?\
MLG?]&W_!3_PC['_XW7TG10.[/FS_ (<W_LG?]&W_  4_\(^Q_P#C='_#F_\
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MOH5O;^XO6CDFB\00I(4:X90RQ)D*/E%=-_PKO]JK_HL7[/O_ (9W5_\ YIJ
M/H*BOGW_ (5W^U5_T6+]GW_PSNK_ /S34?\ "N_VJO\ HL7[/O\ X9W5_P#Y
MIJ /H*BOGW_A7?[57_18OV??_#.ZO_\ --1_PKO]JK_HL7[/O_AG=7_^::@#
MZ"HKY]_X5W^U5_T6+]GW_P ,[J__ ,TU'_"N_P!JK_HL7[/O_AG=7_\ FFH
M^@J*^??^%=_M5?\ 18OV??\ PSNK_P#S34?\*[_:J_Z+%^S[_P"&=U?_ .::
M@#Z"HKY]_P"%=_M5?]%B_9]_\,[J_P#\TU'_  KO]JK_ *+%^S[_ .&=U?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@#CO^&B/A_\ ]#UX._\ !U;?_%T?\-$?#_\ Z'KP=_X.K;_XNNQQ1B@#CO\
MAHCX?_\ 0]>#O_!U;?\ Q='_  T1\/\ _H>O!W_@ZMO_ (NNQQ1B@#CO^&B/
MA_\ ]#UX._\ !U;?_%T?\-$?#_\ Z'KP=_X.K;_XNNQQ1B@#CO\ AHCX?_\
M0]>#O_!U;?\ Q='_  T1\/\ _H>O!W_@ZMO_ (NNQQ1B@#CO^&B/A_\ ]#UX
M._\ !U;?_%T?\-$?#_\ Z'KP=_X.K;_XNNQQ1B@#CO\ AHCX?_\ 0]>#O_!U
M;?\ Q='_  T1\/\ _H>O!W_@ZMO_ (NNQQ1B@#CO^&B/A_\ ]#UX._\ !U;?
M_%T?\-$?#_\ Z'KP=_X.K;_XNNQQ1B@#CO\ AHCX?_\ 0]>#O_!U;?\ Q='_
M  T1\/\ _H>O!W_@ZMO_ (NNQQ1B@#CO^&B/A_\ ]#UX._\ !U;?_%T?\-$?
M#_\ Z'KP=_X.K;_XNNQQ1B@#CO\ AHCX?_\ 0]>#O_!U;?\ Q='_  T1\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFJR7NG:E$S75MIK3B6TM9(F&Y62P:WB\EAN3;L(!!%!7+K8_;_X?_P#!9_\
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M\T7_  3R^(OQ _X)X_$[Q-^V'X;^TZQ\//"_Q0OOAW\2M%MK4R3C2+QH9TN
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MHI[>U#O Y*21,YN)V0KM>2:(G(C"T!RZ7/U-_9*_X*1? O\ ;I>XB^$_Q/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OE[_@L]^S-XQ_;&_X)G?%'X:^ -/M]4\7
M>*+:RBT^VGNTM8Y6BU"UG?,CD*N(XG/)&2 .IKZAHH ^7_\ @E-^QG)^R[^P
M7\'_  KXW\(^&]/^(7A#0XK74I88+>YF@N59\E;A =QPWWE8]3S7SS_P</?\
M$Y/BQ_P4"M/@,OPKT/3]9/@/Q3-JFL"YU.&Q\B!A!AE\PC>3L;A<GCWK])J*
M!\SO<^)?^#@']@7Q1_P49_X)RZQX'\"Z3INL>.;'6M.U;18+V:.W&Y)Q%.5E
MD94C/V6:X.6SD J!N*X\E_;V_P""/?Q(_;6_8^_9Q\5>'=:L?AS^U)\!=&TN
M:QFFG633GO8XK1KFVDG03-^[N;8202?O4SO5U*S,Z?II10(_'/\ :'^!?_!3
M+_@J#\,O^%(_$KPG\&?@O\/M:N;9/%?BK3=0^UW&JVL<RRLL$$=W<2;3M0F$
MB'S7BV&:.)VSVW_!27_@E3\9OBY^SS\#OV0?@78Q^%/V<_#L5@GC3QAJ&KV[
M:A>QPS9VO:IL:X=65[R0!%2:YD@ ,2QL3^JU%!7,?D?^VE_P1)\>_LJ_M<_!
M/X\?L1^&]&LM>\#V=MX?\1^%[O5([&TUBQMK=8$EDDD(WM/;*;>=B2Q9;>90
M)%>0_77_  6+_9L\>?MP_P#!*KQ_\/O!/A]6\>>+K+2FMM*OK^"$P21ZE97,
MT4D^XQ92.*3)#%6*<$Y&?K:B@5SP'_@EC\!_$W[+_P#P3O\ @_\ #WQE9PZ?
MXI\(>&K;3=3MXKA+A(ID!# 2(2K#IR#BO?B,T44"/P?^.'_!MG\3O'__  6:
MU3Q)8:+I;?LU^)OB!:>--7>76(E\Z(_Z9>6QLPV\DW$MY;1D+\D=SD$*6Q^D
M7_!:'_@EC:_\%6_V3X_"MIK2>%_'7A6]_MWPGJT@/D0WRQ/&8+@J#(MO*KE6
M:/YXV6*0!_+\M_KZB@?,V?CW\3?#G_!5[]H7X#ZA\#=8\(?!/P_::]IKZ!K'
MQ*7656:_LW3RI9 L<\DD4LJ*X>2.R!Q.#&D+KE?T*_X)I?L">&_^":'['_AG
MX3>&]0NM:CT?S;O4M7NH4AFU>_G<R3W!C7(12QV(FYBD4<:EY"I=O>J* N?F
MS_P03_X)S?%G]A#XV?M1:S\2M#T_2-.^)_BFWU3P]);:G#>-=0)<ZI(S.L9)
MC(6ZAX;!.X^AI?AC_P $Z/BSX<_X.2?B!^T=>:'I\?PG\0>%DTNRU(:G"UQ)
M.--TRW*FW#>:O[RVF&2N,*#G!%?I+10',?FC_P $8/\ @E!XJ^!'[+O[1?PT
M^/\ X0TF30?B]XRO[W^STU&*\CO],N+9(LEX6W1/E20<JZ$!@00"/)O^"%/_
M  1$^,'_  3&_P""EWQ,\0>+8=+U;X93>%+_ ,.>'?$$>HQ27&JHVHV$UJ9;
M4?/"YM[=]ZD;4="JEE*L?V'HH'S,_''PE_P3X_;'_P""+_QT\=-^R/X3\$?&
M3X)_$?5#JL7A'6]4CL+SPQ,$(7:TUS;)A5*1"1))#)%#&'C1E$E=;_P3P_X)
MK?M3^#O^"Q!_:9^/DWA'4KKQUX(O(M:70;I5M?"]V\D$5MI,,3,7DCBMK:(F
M5=R[V<-)*P,\OZPT4"N>1_M__"C7/CS^PA\:_ OAFVCO/$GC3P%KN@Z5!)*L
M*37=UIT\$*%V(509'4%F( SDD"OR@^-'_!%3]H;QE_P;I_#7]GG3_"NDR_%3
MPWX]O-=O].;7+5(([22?5G5UG+^6Q*W<!VAL_,<XP<?MW10"=C\Y?^"_G_!'
M#4/^"EW[.GAW7/ 5GIL'QH^'N(M*:>5;5=:T^8!+G3Y9\@*!GSHV?<%9)$&T
M7$CUYJ?^"2_[2NA_\$FOV;=!^'?C67X;_'S]G^[N=3.B#Q!*NA^(U>^:Y^R7
M;6Y,,W^JMV02J\1S+$VT2M(OZR44!?2Q^*W[7W[+O_!0K_@LI\.]'^#OQ>^#
MGP5^#/@VVU.#4]1\7G48=5N4DB4H7L88KVYEC+!Y?D(0NK+&TR*9-WW7_P %
M:_V+O$W[1'_!(WQK\$_A;IJ:EKUSINCZ9HMI>WR0"2*SU"RD^>:0A01!;L<D
M\D8ZD"OKZB@1\U?\$Z/V</%W[/'_  2X^&_PP\56-O9>,O#G@X:/?6D5TD\<
M=R(W7:)5)5ADCD$BO!O^#:W_ ()__%+_ ()P?L+^+/ _Q8T6ST/Q)JOC>XUR
MV@MM0@OD:U?2],MU8O$S*#YEM,-I.?E!Z$$_H=10!^6/_!.#_@CUXT^!WQ:_
M;L\%^./#=IH/P9_:*N+NU\,W&D7]N[0Z;--JT8B6)7+0,EKJ$04,F,Q<D8"G
MRW]D7]G[_@I9_P $GOA1/\%_AO\ #SX-_&+P+8:C=7/AW7K[5UM1IBW$AFDW
MQ/=VLIB:1I)#%M=TDFD E>,+C]H**!W/S=_X)/\ _!$[5OV?OV5/CUI'Q\U*
MP\3>./VGY+B3QJND3;X+6WFCN<0QRM&NZX$E[=R-(J[%>1 FX)O?Q']G#]E_
M_@HU_P $B?!NH?"+X.^%_A'\=OA7!J-S<^%M2UK4?L5WHB7$S2-YT+W5MA"V
M^22&,R_OKABDFW*K^R%% 7/@K_@AM_P2F\6?\$]] ^)WCGXL>(M-\4_&KXX:
MT-<\4W6G<V=N1)/,(U8HGF2M-=7,LCJB)F1$12L0=^<_9<_X)Z?%3X8?\'$G
MQZ_:$UG1+&W^%OCSP>-'T;44U*"2>XN?+T ;6@#>8@S87/+*!\@_O+G]&**
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M]!ET31_"GA699[F61HWMUNKZ:.26.5UM9'CW^<[/^Z&V)(44_J51102%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 UI KA><D9''T_QHDG6$98[1]*^!O\ @X!USPKHWPW_ &;H
M_'NN+X?\ :A\<M'M/$UU)J\VDV_]GMI6L&59KB*2-DC^523O X'I7A5IXA^
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MOADPO9@K.Z6TDLL6VY('EQ[WD\I2(T9YHP#[OIID"N%[MTXKX%\)_P#!1O\
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M#FI3^'_$$?B'QA+H]_XPUFUA1[VPT9?L[JBPR-Y(N+HJDLVY-J*C2UO>(O\
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M &.?'WQ2\/\ A6+QK?> =-.MSZ.]\;+[590NCWC"78^UH[432CY2"8PIQG(
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M?\._&+5&T'1[OP?XS;6KKPEJ[6TES;Z9JD<D$0F,ZP3QK<VNZ-9HPC*%=)2
M?:%%?F?X4_X+3?&KQ#_P3\T?]JV\^#/@'2?@W9()_$&G/XPN)O$MQ:B_^Q37
M=C&MH+<)$VYUCFD#SK&^/*.S?^D'BBXU2V\+:E)H]O9W>L1VLK6,%U*88)IP
MI\M9' 8JA;:"P!(!)P>E &A17QQX<_X*L3?$+]@[X0_$_P /^"PWCOXN>*=/
M\#6GA.^NY(5T[6FO9;;4H99EB+B.S2TU"8MY8+I:YPN[(4_MP_'+]H3Q]\09
MO@'\,? /B#P/\*/$-[X6U"Z\7^([O1[[QEJ=EL%W;:8([26*&.*7?!]IG9DD
ME5@%149Z /L:D#[B1Z>U?EW\8?\ @H/\6OVF_P!IW]B7QA\$K'1K;P7\3CXF
M:#0M?\7:CH9U/4+;1[Q;S3]:MX+*9$6QF@<QLOV@M<0XVQ#$M='XD_X*)R?L
ME?$/XN7'A'X8WGBC6_$/[1VB_#6XLY_%;C^T;C4-(LW6Z@\Z/R[;&8T$.1'G
M<Y<9- 'Z145\B_#O]OGX@?#+]IKQ!\-_C]X9^'_A9;?P%??$S3O$'A/7+O4]
M.@TNRN(8+RWNEN+:";SH?.202H@25"<*C*5/CGQ4_P""M?[0WPA_8VTW]H[5
M/@9X _X57XL32)M(TA?&4_\ PDFCVNI7=O#:WFH VGV<I(EPA,,#-)"\T*MO
M'FM$ ?HXS;!DTB2K(6VG.W@^U<M\>)7@^!WC*2-FCD30KYE93M92+=\$'L:_
M-S]B7]M[]HSX*_\ !'WX4_%F/X/^%O$'PQ\!^ ;*ZUJUO?%UP/&FO:?;6Z+<
M:K;1?9#:H J2W"02SL\T(4[XG(C(!^IU%?./P*_X* 67Q6_:;^(G@/4+32=+
MT?P_X5T7Q_X5U];]C%XI\.ZA'-NO?+=%,(MYH&C?)8$/&WRY*CK/V"_VF-6_
M;&_90\)_%#5O"S>#5\;PRZKI>F27/VB4:7)-)]@N)&VKAI[40S[0,+YP&3@T
M >PHX<<9_$8I:_-.']MG5OV'_#_[=GQ,CT2^\=2>$OC-H>G6>B&_,+2I?6GA
MZR,<+-E4(-VTBKPK,,$J&+#V";]N7X\?#3]J+PC\,?B!\-?A;I^J_&;1-:O?
MA^=)\7WMU%9:EIEK'<OI^K2M8J51XW+?:K>-PIC*^4^58@'V917YE?\ !/K_
M (*"_%#X&?\ !*N^^)/Q6TNQ\=7EQXNU'P]X,@M?%]S?:WXJU>Z\3ZAI\6GW
M,M]!'':P17!@ABE$LV+6)G,<900GTR[_ ."H7Q$_9]\7ZEX7^,?A/X8OK&K>
M#==\6^#M2\#^)I]1TK5+C2K5KJYT:Y,UNDL%PL \U9]ICEC64JJM&4(!]TT5
M^>FE_P#!7CXP0?L8>$_CWK'P-TBQ\*_$:]\(:7X4\.)XFSK^IRZM,D5S<N6B
M%M' S31_9 T@>1 'F\C?L3UGX?\ [;WQ0^'?[7^E_##XZ>#OA[X7M/&WA?5?
M%?AO6/"WB.ZU2&U336M1>6-X)[6!BZ1W2RBX54C8 J$#9H ^LJ*_/2V_X+&^
M/-+^%'A_X]:]X!\!Z;^SEXDNK0[$\5-+XVT32+N=8;;7+NS6(VYB820R26D,
MKRQ1RAM[E71;O_!/CXP_'[QE_P %0?VIO#_C2V\)2>%?#NJ^'XKJQ@\::CJ4
M7AEI/#\,L,>E0364<;QW!*33EC;E)9),+-@2, ??U%>(_MO_ +7=Y^RQX9\'
MV7AOPL_CCX@_$KQ+;^$_"NA?:S9P3W4D<L\MQ=3JDC0VEO;03SRR+%(0L8 7
M+ CPGXA?\%,_B=^Q\_C#PU\<O ?@>/Q=9_#;7_B'X/U3PGK=S+H/BIM'MVGO
M=+E%Q MQ9W,:-;N& GCDBD=\HR>4P!]R4V.59D#*=RGH:^>_^">'[2WQ2_;
M^%5O\1O&W@'0?AWX-\7Z/IFJ>$+!-7:_UN>*:)Y)Y[U500PQR!K=X(T=Y C-
MYHC?]V/E?_@X8_8P^'_AK]@[XV?'+3[#7K'XI0VNF2QZU:^)]4MQ&XNK&R!6
MWCN5MU_T<!.(QDY8Y8DD _2T.-VWOUZ4I.!7R!\1?"7PE_X(T_"/5O%WP_\
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MUI\(?@I>_#_73:7KRNVHRSZ:Z&$&-=\.VTERQ*GE?EK[JHH ^4_@M^QQXR\
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MZ0/"_P (SXJ;7Q<7+1W9_M'3([6V\B,(1)^\5M^YEVC!&[I7TE10!^;.G_\
M!*;XH>,O^"=_B?\ 9_\ $^D?"R2;P7XZ?QMX UR^OIM6TGQ1(WB&\UC[/JVF
MO;)]G@:*86LJ+)<AUN)#@A ';X9_X)O>*OB/J?BB^L?V7/V:/V;X[3P7K^AV
M/_"/V6EZEK&OZK?Z?):12)?V]A"]C91K+,&*_OI1+AHU3<K?I110!\4>,OV
MO'FM?\$SOV:?A+;R: ?%7PCO_A[<ZVS7;BTD70Y+%KWR7V9<D6\FS*KNXSMS
M7H?[2W['6L?'K]NSX3^-IETV7P+X7\&^+?#6OPR7!2ZF.K+IZ1K&FTAEVVTV
MXDC&5X.>/I2B@#\H?AG_ ,$@?%W@;X<>%?@Y-^R_^R/>R^'S:Z?=_&R\T'2]
M0N=2TN"5 9WTF>P,LFK2VR[',LS0F8M*96W;!]9_ K]G/XG_  -_X*8_'3QN
MNC^$]6^&/QODT75#J8UR6#5M!N-.T>.P-N;+[,R7"R/"K>8)X]BOT<@@?5=%
M 'SS^W[^S#XN^-?_  K+QO\ #>XT%/B1\&?%2^)]&M=;=XM/UJ"2UN+*]T^6
M9%=K?SK:YDVS+')LDCC)0KG'SI^T7^Q5\<O^"DLWBCQ9\1/!O@_X5W7AOX7>
M+O!G@#PS'XC_ +:N[O6=>T_[)/J%_>QPI%;VR11Q11Q1)*Y,LTCLNU8F_1&B
M@#@/V4?AQJGP;_9<^&WA#6OLO]L>%?"VEZ/?&VE,D)GM[2**38Q"EEWHV"0"
M1@X'2O+/^"O'[*OBK]MS_@G3\2_A;X);25\4>++:SBL3J=RUM: Q7UM.^^14
M<K\D3XPIR<#C.:^DJ* /FW_@J5^Q!-^WA^S38>'M/L_">H>)/"/B?3/&&AV'
MBNW-SH&IW-E-N:SU",([-:W%N]Q ^U25$P;#;=I^>/A9_P $Z/$WC/7/&&M+
M^S+^S9^S?"G@?6?#ND6/AFPTS4M9UC5;^U, NI-2M["!K2SBC:2,1Q@R3"=V
MD"A5C/Z,T4 ?F+XK_P""1GB+P7X>_9T\97/P=^#_ .T!XB^&OP=TCX5^+_!?
MB^2U-K/]C2!XK[2[FZM)HTFAG-XK"5466&<8*,HKS/\ ;/\ V5?&_P"SK^S'
M\&[K3_ OP)^$WQ$\;?M.>$]3T'PUX1T&&V\.^'0BS1:?9WUQ:PP3:BPD1I9Y
M]B'-RZ0JJQH3^PU8?CCX8^'?B:-)'B+0=%UX:!J4.LZ8-1L8KO\ L^^A),-U
M#YBGRYXR24D3#KDX(S0!\@V/P$^.O[7'[7W@'X@?%+P5X3^%?A?X,V6N-H>D
M:;XK_P"$@O?$.LZA9?8/M4DHM85BL8[:6Y"*<2L[JSHH 5>7\7_\$T?B3KG_
M  03\(?LVV[^&O\ A8FAZ=X:M;AWOW&FE]/UFQO9\3>66P8K>3:=G+8'&<U^
M@5% 'QOXC^$/QN_8\_:A^+/C?X2^ ?"_Q<\(_&J]L=9O=!O/$Z>&[[P[J\%B
MEE+,LKV\R3VD\5M;,W(ECDW[8Y%;CA_@K_P2S^('PS^*/P/\9:OJ7A/5/%%E
M\4_%/Q4^)4VG/+;V"7NLZ3=6:V^FI(IDDA@\RVA#3%7=83(P!;8/T HH ^$_
MVY/^"5>N?MK_ !M^/4M]>Z1IWA7XH?";1?".D73MY\UGK.G:K>:C!--;E"K6
MZRR6S$;B7"NN!D&N=_9D_8!\23_M'?#_ %?6OV3OV3_@3IOP]N7U+6=>\*:3
MIFKZEXJO4A>.W33#]@ADTZW69EN6ED8W ,21+@%Y6_0ZB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "B@]*^#-3_X+X^&4\;^+-%T']G/]KOQW%X.\0ZCX8O-7\*_#;^U=*GO
M+&Y>VG$-Q'<E64.AQG#8(RJG@ 'WG17P7_P_CMO^C0?V[O\ PSTW_P D4?\
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M_!3;P[^P3XZ\ ^&M0^'?QA^)7B#XC0:G<Z7IOP^\-KKMXL=A]E^T-)%YT;@
M7<1!56&%;<5XR ?2E%?!?_#^.V_Z-!_;N_\ #/3?_)%'_#^.V_Z-!_;N_P##
M/3?_ "10!]Z45\%_\/X[;_HT']N[_P ,]-_\D4?\/X[;_HT']N[_ ,,]-_\
M)% 'WI17P7_P_CMO^C0?V[O_  STW_R11_P_CMO^C0?V[O\ PSTW_P D4 ?>
ME%?!?_#^.V_Z-!_;N_\ #/3?_)%'_#^.V_Z-!_;N_P##/3?_ "10!]Z45\%_
M\/X[;_HT']N[_P ,]-_\D4?\/X[;_HT']N[_ ,,]-_\ )% 'WI17P7_P_CMO
M^C0?V[O_  STW_R11_P_CMO^C0?V[O\ PSTW_P D4 ?>E%?!?_#^.V_Z-!_;
MN_\ #/3?_)%'_#^.V_Z-!_;N_P##/3?_ "10!]Z45\%_\/X[;_HT']N[_P ,
M]-_\D4?\/X[;_HT']N[_ ,,]-_\ )% 'WI17P7_P_CMO^C0?V[O_  STW_R1
M1_P_CMO^C0?V[O\ PSTW_P D4 ?>E%?!?_#^.V_Z-!_;N_\ #/3?_)%'_#^.
MV_Z-!_;N_P##/3?_ "10!]Z45\%_\/X[;_HT']N[_P ,]-_\D4?\/X[;_HT'
M]N[_ ,,]-_\ )% 'WI17P7_P_CMO^C0?V[O_  STW_R11_P_CMO^C0?V[O\
MPSTW_P D4 ?>E%?!?_#^.V_Z-!_;N_\ #/3?_)%'_#^.V_Z-!_;N_P##/3?_
M "10!]Z45\%_\/X[;_HT']N[_P ,]-_\D4?\/X[;_HT']N[_ ,,]-_\ )% '
MWI17Y_\ B#_@X$T?PEH%]JVK?LH_MPZ7I6EV\EW>WMY\)7M[:S@C4O)++(]R
M%2-%!9F8@* 22 *^ROV;?CII?[3W[/\ X*^)&A6^H6FA>/=#L_$&G07\:1W<
M-O=0)-&LJH[JL@5P&"LP!SACUH [:BBB@ HHHH **** "BBB@ HHHH ****
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M4 %?'O\ P1=_Y(K\8O\ LN7CW_T^W-?85?'O_!%W_DBOQB_[+EX]_P#3[<T
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MF+\0_P#!L'^VAH6EM<0_#;0=6D5@!;6?B[3%F;/<&::-,#J<N#Z9KQ3XZ?\
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M+6S>ZC#PPI'(?D*C<74Y*M@;F #']&O NO#Q5X)T?5 5;^TK&&[R.A\Q%?\
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M'<7[6Q/_ !Y_!P#V\-7?'_DY09\C/Z<J*_FJ/_!X?^U-C_D2_@#_ ."'5_\
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M3%_X*GO\06^%7BG_ (9/+97P/F+^U G]BBWQC[=L_P"0GFXQ]KSL]_W=7/\
M@J#^TA^R#\?K#P7'^RS\)?%WPQNM+EO'\2OK;1'^THW6$6P39?W?W&68G(3_
M %@Y/8 _0O\ X+=?%?Q!\7?^"8O['_[4?P)\4>*M)TWP);3:'>:QHDT]CJ&C
M/>V]K;2+-)"08E2[TUK20%BC22QKE@Z[OAVR_P"#@'XV^*]!M=-^*GA7X&_'
M^WLHO(AF^(W@&UU&[BCVE2JRP&#DJ2I9@S'))))KUW_@VG_X*'Z+\%_CCJW[
M.?Q2M]/UOX1?'J=;"*RU6U6\L+76I%6"..6)\H8+V,);N"C9E6USA?,8?I)\
M=O\ @T:_9A^*.JS7OA34OB1\,Y' VV>D:TE_8*?ER2E]%/-T!P%F4 MT( 6@
MG1:,_'M?^"W=UH -QX7_ &4?V*O".K*P:+4[#X7J]S;$9*O'ON"JNK;7!((R
M@R"*_I*_X)-_%CQA\>/^";GP;\:^/9X[KQ9XK\-6^JWT\=G%9QS^=EXW6*)5
MC16B:,@*H&".*^&_A'_P9Y?L\>"O%EMJ'BKQI\4O'5C:S)*=)N+ZUT^SNU!R
MT<[6\"SE&X'[N6(@9YYX_5SPSX9TWP5X<T_1]'T^RTG2-)MH[.QL;.!8+:S@
MC4)'%%&H"HB* JJH      H)E)/8O4444$A1110 4444 %%%% 'P;_P<??\
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MXJUG2IK.QMK:[#G3[5[FX2 7%UL(80H7Z*5+NT:;EW;A_,/^P'\ %_X*3_\
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MS]I=S^RWX-^(&K^//@OX7\=ZSK6I>--?L9KB^OH91.?*@N1$H+P%\*J@%R
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M%;?C5JWBW['X!\$_!71]0U1-O]E>$_@WH+R7GE+)(6\O['+*Y5/,8\D*JL<
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M?\IKO^">W_7Y\0O_ %'5K[SKX,_X*&?\IKO^">W_ %^?$+_U'5K[SH ****
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M#XMB=]L,^CW4B).[_P#7!A'=+C&7M5!(5FH"4;G]B5% .:*#$**** "BBB@
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M -/MS7V%7Q[_ ,$7?^2*_&+_ ++EX]_]/MS0!]A4444 %%%% !1110 4444
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MQ>9(QB9E#>7(H/(J3P_X?O/%NOV.DZ;"USJ&I3+;V\0_C=C@9/8#J2>  2<
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M444 %%%% !1110 4444 %%%% !7Q[_P1=_Y(K\8O^RY>/?\ T^W-?85?'O\
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M]JO_ )3,?LA_]BI\0O\ T5H=?85?'O[5?_*9C]D/_L5/B%_Z*T.@#["HHHH
M**** "BBB@ HHHH **** "BBOSZ_X.0_VROBU^Q'^Q1X+\2?!GQ4_A'Q=KWQ
M"L/#[W:Z?8WOGV\]EJ#F$K>12Q+NEBA._ (V?> + @'Z"T5^2VG?\%O?&Q_X
M-[-2^+ESJ$/_  T/INIR?#%T6PB%P?%)NA;I(+7R_*^T"T=+TP^6(]P9/+V_
M+7H'_!!3_@HM\1?C=_P3L^+WQ-_:-\:_V]??"_QGK-CJ6J/IUE9C3].L-*L+
MJ5=EE%'')Y;R7+;@K,V[&X@* #Y6?I317XW_ /!%?_@L9\>?C[^W'I/A[X]:
ME:KX+_:,\-:GXO\ A78#3;:W;2/LFI7<9T]9888WD'V:WN&W3M*S);VSAP9V
M!]G^&G[>GQ<\0_\ !P=^TA\$+SQA)-\+O OPP'B+0=$_LNR4:=?_ &;07\X7
M"PBXD^:]N3LED=/WOW<*H4"Q^E-%? 7_  ;<?MI?$[]O3_@G4_CSXM>*6\7>
M*F\4WVGB].G6EAMMXXK9DC$=K%%'P7<Y*[CNY) &/OV@04444 %%%% !1110
M 4444 %%%% 'C'_!1[_E'E\>?^R=>(/_ $VW%<Y_P2#_ .44W[-G_9,?#O\
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M]U%!)[I16=XO\4V?@?PMJ.M:E+]GTW2;:2]O)=C/Y,,:%W?:H+-A5)PH)..
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MM:^('[0VKRGP_(GA^ZUBZ\4W;>7)-/OMHY L2K-&[SR%(E5MS.J@D UW,_\
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M^(D/Q4\>?%NR\1PZ')X=FAU+50]QH<L]S#;H@W1[HKAB8QL7RV P%X_61/\
M@AG^R 0-O[/7PRXZ8TH<?K[?I0?^"&/[(('_ ";S\,N!_P! H?XT#YC\[_V3
M_B;X?^!OACX8V]S_ ,$I?B%)X[\&VFDPR^+H_A[9PW3:E:I"#J0F^S^:LGG1
M^=YA._/S$YR:_;Q'WK^)%?CK\5OBS_P1Y^"7Q8\0> _%GACX7:-XL\+ZK<:)
MJED_@#6I%M+N"5H98_-2S,;!9$8;U<H<9#$<U^D_PR_;3^$?BSXY:?\ !WPC
MXLTW5O%B^#;?QK86.G03S6<WA^22*""]ANU0VLD;-+$%"2LQ#!@-N2 1[+12
M*X9=PZ4@D5DW?P\T"'44U9E9<AN,;L^U"2*YX_48H =1110!\&_\''W_ "C,
MN?\ L>/"O_IZM*^\J^#?^#C[_E&9<_\ 8\>%?_3U:5]Y4 %%%% !7Q[^U7_R
MF8_9#_[%3XA?^BM#K["KX]_:K_Y3,?LA_P#8J?$+_P!%:'0!]A4444 %%%>4
M? W]MKX9_M(^(OB-H_@OQ-#JVK?"769= \5VLEE=63Z/>1EPZ-Y\2;T_=28E
MCW1ML.UCB@#U>BO-?V3?VNO '[</P2T_XC?#'6I_$7@O5IYX+'4GTN\T];MH
M9&BD*)=112%5D5TW!=NY& )((&Q\;?VA? W[-GA6UUSQ_P"*]#\'Z/>7T.FP
M7FK7:VL,MS+GRX0S$#>VUL#O@T =E136F5#@_4\=*Y_XM_%/1_@C\,M=\8>(
M9KJWT#PU92ZEJ,]O93WTD%O$I>1Q#;I)+)M4$X1&. >* .BHKY]\1_\ !4SX
M#>$OV--'_: U#XB:7'\)O$$D4.FZW%9W<[7TLDS0"&.U2$W33"1)%:(1;T\J
M4L%$;D>[:-K<6M:3;WD:W$<=U$LR+/!)!*JLH8;XY%5T;GE74,IX(!!% %RO
MS?\ ^#G?X ^._P!HW]B7X<:/\/?!_B;QKK&F_%+2=3N;/1-/EO9[:U2SU!7G
M98P2(U9T!8\ NOJ*_2"O(?VG?V"/@W^VA?Z-<_%;X<^%_'LOAU)H],;5[3SS
M9+,4,H3GC<8TS_NB@%HS\KKC_@D[\53_ ,' LFBKH7B+_AE^Z^($7[0,M]Y;
M?V6NN1VLF$\[[IN#J3LIM\[OLYW8V#GQ3X??LU_M)>$O^",'Q'^!>@_!WXE6
M7C#X\?M 7=M=&YT"Z@33/#[VVF,]_,^S]W;230QQ%VPIC^T'/[LBOU!^-_\
MP2>_8=_9S^$'B+Q[XN^!?PQT?PKX1L)=3U:^.A23_9+>)2SR>7$KR-M&3A%+
M'L*^:OV9M;_X)%?M@?&73?A_X \,_!_5?%VL%DL;"\\(:CI7VQU_Y91R7=O%
M&TA_AC#%VP=H.#07S'DO[?G_  1S_:6_9%^&7P.^*'@7XJ:]^T)K7[,^L:;:
M^$O!^F_#ZSTN[T[2U:%72-[-FFND(MK:.190[&-Y7+ []WLW[/7P,^(6N?\
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MEI=^+A=5>.RBD']G-I9*I#/:K";;>'SPI'[;?!OX ^ _V=/#5SHOP]\$^$?
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MM0.K>)-,?PY9M9^(;TR+*;F\B,>RXF,B(_F2AFW(ISD UX%\#_\ @E.O@?\
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MP+H^H?"S2_#WC*;PO;1QS:;+-<ZRL<+1F]D@N/+A&=Z1BX,)4MMQ^J=Y\!?
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M>$/A+\-/"_\ PF%N]GK@TKPQ96?]KP.,/#<>7&/-B;)S&V4.YCC))(!^.G[
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M3KQ!_P"FVXKG/^"0?_**;]FS_LF/AW_TVV] 'T51110 4444 %%%% !1110
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MV?\ 9,?#O_IMMZ /HJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[L2,"P4\$@8R1],C/ID>M/DE6+[WH3T["@#Y5'_!%CX "'R_[.^*GEYW;/\
MA;_B_;GUQ_:E+_PY;^ .Q5_L_P"*FU#N4?\ "W_&&%/J/^)I7U.+M&/&X_13
M1#=QW,3/&PD56*DK\W()!'U!!!'8@T ?+)_X(M_ $W'G?V?\5/-SG?\ \+?\
M8;L_7^U*/^'+GP"".OV#XJ;9#N<?\+?\888^I_XFG-?5'G+\OWCNYX!J.WOH
M;N6:..2-Y+=@DJALM&Q 8!AV)4@X/8@]Z /EP?\ !&#X"!=OV'XK;=I7'_"X
M/&'0]1_R%.E)!_P1<^ 5LV8[#XJ1G&,K\7_& _\ <I7U(U]$DHC9MLC D*1@
ML!C) [XR.1ZT/J$,4L*/(L;7#%(@_P ID8 M@9ZG:K''HI/:@#Y9'_!%KX B
M7S/[/^*GF9W;O^%O^,,Y]<_VI4R?\$:/@1&#MM?BRN3DX^,7C'D_^#2OI^+4
MH)Y98XY!(\#B.4+\QC8@$*WH<,IP>S ]#4C3JIZ-TSPI- 'RS_PY@^ AF:3[
M#\5O,88+_P#"X/&&XCCJ?[4]A^5);_\ !%WX!VDF^&Q^*L3XV[D^,'C!3CTX
MU2OJ:2X6(9;( &3QTIMU?PV,9>:188U )=SM49.!DGCK0!\MK_P1<^ 23^8N
MG_%02$Y+CXO^,-WY_P!J4Z#_ ((Q_ 6V\SR[/XKQ^<29-OQA\8+OSZ_\33FO
MI[4-;M-(M'N+NXBM;>, O+.PC1,D 99L 9) ^IITVJ6]M:R3R2+'!$AD>1CA
M$4#)8GH!CG)XQ0!\M_\ #EGX ^3Y?]G_ !4\O.[;_P +?\8;<^N/[4J2;_@C
M#\!;F%8Y++XK21Q\JK?&#Q@57Z#^U*]F_:<_:6\/_LJ_L]>,OB3KT>H7VB^!
M]$N-?O;734CDO9[:!"[^2DCQJS$# W.JY(Y%>A4 ?*LG_!%_X!RVZPM8_%9H
M4^ZA^,'C JOT']J4H_X(O_ -95<6/Q6#QC:K?\+@\894>@/]J5].V&O6>K+(
MUK<0W2PR&&0PL)/+<8RC8Z,,C(/(JWO^;'/Y4 ?*\/\ P1@^ ENFV.Q^*T:\
M\+\8/& '/7_F*=Z2V_X(O? .S+&&Q^*L188)3XP>,%S^6J5[M\5_C7:_#;X1
M^)?%NGZ3KWCC_A&;66Y?1_"]JNI:KJ#QKN-O;P[U#SD$80LI.1TJI\-OVB]#
M^)OQ'^)GAFTAU"UO/A7K%MHFKS74:);S33Z79ZFKPLKL6C$%[$&+JA#JXP5
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MI7QA^QY_RFC_ &TO^Q?^'7_I'K%?9YZ5\8?L>?\ *:/]M+_L7_AU_P"D>L4
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M;;T ?15%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?'O\
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MK%:1E8HXXU+,Y"*%!9F+,?J6))/<DF@#\J?^"L_[4OPZ_:6U[6I/A[XR\/\
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M7\2:=<:MX?OK6SO9],N[F!XH;R!(WEM'92%E59%9&92=P#JRDCD$9% 'Y_\
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M889)+5S+"SH&,+E60LI[':S+D=F(Z$U-TH ^#/\ @H9_RFN_X)[?]?GQ"_\
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M?VNF^(IK7X\?"S3M \,^-;^XM387%Y:Z/>6,B7[Q'S8I))KB,MLM=K(9"N.
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M10M"96'DIN?&3]B[XI6VI^,M>T?3_'5VOA7XUZ)XRM_[!U/3_P#A(O$NEP>
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MV]='_P %'O\ E'E\>?\ LG7B#_TVW%<Y_P $@_\ E%-^S9_V3'P[_P"FVWH
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M^F^%_@9I>IV_@N_MM6>YU+7[W5;>UBGGN(/)1+:*UC2\A1#),96N1(#%M*,
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MPL6&<DY->0^ O^"5/PA^''B+X>ZMI\7CVXO_ (3W(E\'2:CXZUG45\.P^3+
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M(H[?PE=37_AK1+OQ/J5[H/A>YFCEBDET_3YIWMK8^5,\:+'&$@1G6%8A))O
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M],FN'M+4B*XEC01Q!84=EA6(,X8 ]\HHHH ^#/\ @H9_RFN_X)[?]?GQ"_\
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M^:NW'@'1;O3-0LI=)TV2SU=G>^@:UC:*]9U"N95(Q(64 $L#D  YQ0!\W_\
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M?Q/;0XSHGBKPA-<QZ)_9NDVFFK<Q265W;*[ND#L\/EQQMB!4: (YD .7O?\
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MJZ>\%K/G0M.D:)XH&N'D(3?</.4C*5Q/QV^*EI\5OCUXVO8/"OA_19I_B%\
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M^,O"JZ7X)TWP+;Z)IF@^*]^A1V[76N:I(Z7;30WI>)[>2:)6M((4ABNA)*I
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M'AJ[S)I]W=6RS0O:W#1*SQQSVUS<P^:L<AB,JR".0H%(!X1^V3_P4QUSP_\
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M%=-_X6/X4\*:2FEZ/JMQJ7V"[TPZNUT#-+:V^^$G4(1&^Q6;8Y9(\ $ J_\
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M%J=IK5Y)-K6DW3Z]*0UNUDHM[M'U6!/*$TL;".1O.4[4/0?#S_@G7XZ\,?\
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M"OQ.N?##'P=XTDG%OK-IIMA>07$4LWV69;&=;B>WG@G2.XS]G*$1%Q(G>?\
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M$FD^*K[2OBQ\-=6M/ T1F\0RV?BFPF31%R0#=,)L0 L-H,A49XSD&LOX*?\
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MG_!(/_E%-^S9_P!DQ\._^FVWKH_^"CW_ "CR^//_ &3KQ!_Z;;BN<_X)!_\
M**;]FS_LF/AW_P!-MO0!]%4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5^8W[!W_!0KP?^Q7I?QA\&>//"OQEM=:D^,/C35HCI_P -=<U*
MUN+6YUFXE@ECG@M7C=70A@58\&OTYHH ^._^'X/P:_Z 'QX_\-%XD_\ D.C_
M (?@_!K_ * 'QX_\-%XD_P#D.OL2B@#X[_X?@_!K_H ?'C_PT7B3_P"0Z/\
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M * 'QX_\-%XD_P#D.OL2B@#X[_X?@_!K_H ?'C_PT7B3_P"0Z/\ A^#\&O\
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M10!\=_\ #\'X-?\ 0 ^/'_AHO$G_ ,AT?\/P?@U_T /CQ_X:+Q)_\AU]B44
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M #X\?^&B\2?_ "'1_P /P?@U_P! #X\?^&B\2?\ R'7V)10!\=_\/P?@U_T
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M .0Z/^'X/P:_Z 'QX_\ #1>)/_D.OL2B@#X[_P"'X/P:_P"@!\>/_#1>)/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
